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Background: Research in humans demonstrates a link between an adverse environment during 
development and unfavourable health outcomes in adulthood. Animal research used to 
understand this phenomenon reveals that exposure to prenatal stress and to glucocorticoids may 
programme offspring hypothalamic-pituitary-adrenal (HPA) axis, which is in turn hypothesised to 
mediate disease risk. Extension of these findings in human research is at a less advanced stage, 
although synthesis of a number of lines of evidence suggests that similar HPA axis programming 
exists. Glucocorticoids are hypothesised as the final mediator in the pathway from adverse 
antenatal environment to programming effects, including altered offspring HPA axis activity, 
although molecular mechanisms underlying this hypothesis are yet to be elucidated. Depression 
in pregnancy is a paradigm by which mechanisms for developmental programming may be further 
studied.  
 
Methodology: A prospective longitudinal observational study of 82 pregnant women from the 
second trimester of pregnancy, and their offspring to 1 year postnatal is described.  A cases 
group with DSM-IV major depressive disorder (MDD) was compared with a non-depressed control 
group. Maternal mood, antenatal HPA axis, obstetric outcomes and infant basal HPA axis activity 
and cortisol response to pain stress were assessed.  
 
Results: Compared with the control group, women with MDD in pregnancy had overactivity of the 
HPA axis in the third trimester of pregnancy, a shorter length of gestation, infants with larger 
cortisol response to pain stress at 8 weeks and 1 year postnatal and higher evening cortisol at 1 
year of age. Furthermore, associations were found between antenatal depression, maternal 
antenatal HPA axis and infant HPA axis. The findings were independent of socio-demographic 
and obstetric factors and maternal postnatal mood. 
 
Conclusions: The associations between maternal antenatal depression and altered maternal and 
infant HPA axis activity suggest programming effects and add to the important literature on 
developmental programming in humans. Furthermore, the findings have clinical relevance in the 
fields of obstetrics, psychiatry and paediatrics. 
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The broad theme of this thesis is developmental programming, the concept that the environment 
of the developing organism shapes its development. In this context I describe a study of major 
depressive disorder in pregnancy, the associated biology in the principal endocrine system 
regulating the body’s response to stress, the hypothalamic-pituitary adrenal (HPA) axis, the 
obstetric outcomes and the offspring HPA axis. An understanding of these discrete topics 
provides the necessary background for their synthesis into the single overall framework of this 
study and is key to the complex theme of developmental programming, as it pertains to antenatal 
depression in particular. 
 
Accordingly, the introduction provides a description of each of these areas in turn. I start by 
reviewing the clinical, epidemiological and biological features of major depression in section 1.2.2 
before focusing on depression in pregnancy in section 1.2.4. Next I have reviewed normal 
pregnancy and it’s biology in section 1.3.2 before describing the epidemiology, biological features 
and consequences of the major adverse obstetric outcomes in sections 1.3.3 to 1.3.5. 
Subsequently, since I have assessed the HPA axis in pregnancy and in the infant, I first review 
the HPA axis in general in section 1.4.2; next I focus on the HPA axis in major depression in 
section 1.4.3, then the HPA axis in pregnancy in section 1.4.4 and lastly the HPA axis in antenatal 
depression in section 1.4.5. In the final section I have reviewed developmental programming, 
firstly focusing on studies in animals including research paradigms, outcomes and mechanisms in 
section 1.5.2. Next I have reviewed developmental programming studies in humans in section 
1.5.3, beginning with the effects of prenatal stress in general, next the specific effects of antenatal 
depression and finally a review of proposed mechanisms. Lastly, in section 1.6, I present my 











The lifetime prevalence of major depressive disorder is highest in women, particularly during the 
childbearing years (Kessler et al., 2010); accordingly, its occurrence during the perinatal period 
(pregnancy and the first postnatal year) is not unexpected. Historically, there has been much 
focus on postnatal depression, both in the medical literature and the broader media; 
correspondingly much research effort has been directed towards postnatal depression. Despite its 
recognition as early as the 19th century, as indicated by the recording in the psychiatric literature 
of several series of case reports of ‘prepartum melancholia’ (Brockington, 1996), the relatively 
recent recognition of the importance of major depression occurring during pregnancy is now 
reflected by an increase in the volume of research pertinent to the antenatal period. The absence 
of ‘antenatal depression’ in the scientific and public consciousness may have been related to 
unsupported cultural beliefs that pregnancy is a period of happiness and fulfilment for women, 
which thus protects against depression.  
 
The effect of antenatal depression on pregnancy and on the maternal and offspring biological 
stress system is the principal focus of this thesis. Thus, depression, and particularly its 
occurrence in relation to pregnancy, is described in sections 1.2.2 to 1.2.4 below. I start by 
reviewing the clinical, epidemiological and biological features of major depression in section 1.2.2. 
Next I include a section on postnatal depression, its pertinence relates to the fact that antenatal 
depression is likely to have been an unmeasured confounding factor in much research of 
postnatal depression (see section 1.2.3 below), thus an understanding of postnatal depression 
will inform that of antenatal depression which is discussed in section 1.2.4. In addition to 
reviewing clinical, epidemiological and biological features of perinatal depression, within the 
respective sections I have included a review of the consequences of perinatal depression in order 
to emphasize the importance and potential impact of depression in the perinatal period. 
 
1.2.2 Major Depressive Disorder  
Depression is a common mental disorder; the World Health Organisation has ranked it as the 4th 
leading cause of disability worldwide, and predicted it to be the leading cause by 2030, 
demonstrating that it is a significant public health issue (Mathers et al., 2008). Major depression is 
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associated with burden in many domains including disruption in personal and family relationships 
(Breslau et al., 2011, Lovejoy et al., 2000), unemployment (Kawakami et al., 2012) and increased 
morbidity and mortality, reviewed by Kessler (Kessler, 2012); the associated financial costs are 
high therefore. Depression has been given a variety of apposite epithets by some well-known 
sufferers. The following examples convey the negative and pervasive nature of this disorder: 
‘Black Dog’, used by the 18th century literary figure, Samuel Johnson, and later by the British 
Prime Minister Sir Winston Churchill, ‘a dark destroyer’ by developmental biologist Professor 
Lewis Wolpert and ‘Darkness Visible’ by novelist William Styron. 
 
1.2.2.1 Classification and clinical features 
Depression is characterised by the core symptoms of low mood and/or anhedonia and a 
combination of other symptoms including the biological symptoms (fatigue or lack of energy, 
psychomotor agitation or retardation, sleep disturbance, appetite disturbance) and the cognitive 
symptoms (poor concentration, worthlessness, guilt and suicidal thoughts or actions). The two 
major systems of disease classification are broadly similar for depression, which is listed within 
mood disorders; the term ‘major depressive disorder’ is used in Diagnostic and Statistical Manual 
(DSM-5) (APA, 2013) and ‘depressive episode’ in the International Classification of Disease (ICD-
10) (World Health Organization., 1992). Operationally defined criteria of the symptoms listed 
above must be met in order to make a diagnosis; in DSM-5, duration of symptoms is at least 2 
weeks with at least 5 symptoms that must cause clinically significant distress or impairment. 
Depression may be further classified by severity into mild, moderate or severe with or without 
psychotic symptoms. The pattern of unipolar depression ranges from a single episode, a remitting 
and relapsing course to chronic depression.  
 
1.2.2.2 Epidemiology 
A recent large-scale epidemiological study of major depression in over nine thousand adults in the 
USA, The National Comorbidity Surveys Replication (NCS-R), estimated a lifetime prevalence of 
a major depressive episode of 19.2% and a 12-month prevalence of 8.3% (Kessler et al., 2010). 
Another well-designed retrospective study has provided similar prevalence data (Wells et al., 
2006).  However, when studied prospectively, prevalence is much higher: lifetime prevalence in 
the age group 18-32 years was approximately double, at 41% (Moffitt et al., 2010). Depression is 
more prevalent in women of all age groups; findings from the NCS-R estimated that the lifetime 
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prevalence in women of childbearing age was 25.2% compared to 16.8% in men of the same age 
range (Kessler et al., 2010). Major depression is additionally associated with a number of socio-
demographic factors including unemployment, the divorced or never married, less than 12 years 
of education and poverty (Kessler et al., 2003). Prevalence is higher in high-income countries 
(Weissman et al., 1996, Andrade et al., 2003, Bromet et al., 2011). Psychiatric comorbidity is 
common, particularly anxiety and substance use disorders (Kessler et al., 2003). The mean age 
of onset falls between 24.8 and 34.8 years across 10 countries worldwide (Weissman et al., 
1996). Major depression is commonly recurrent over the lifetime; results of a prospective study in 
the USA suggested that 54% of those with an episode of major depression were likely to recover 
within 6 months, 70% by 1 year and 81% by 2 years; the remaining 19% continued to be 
symptomatic for at least 5 years. At fifteen-year follow-up of the same cohort, relapse had 
occurred in 85% of those who had remitted following the initial episode. Only 11% never 
experienced a further episode following remission (Keller et al., 1992, Mueller et al., 1999). 
 
1.2.2.3 Aetiology 
The aetiology of depression is complex and is not fully understood, although evidence indicates 
that both genetics and stress play important roles. However, despite the fact that the heritability of 
unipolar depression is in the region of 40% (Sullivan et al., 2000), in the main, genome-wide 
association studies have not identified genes for depression (Wray et al., 2012), although one 
study of a phenotypically homogeneous sample has identified two loci on chromosome 10 which 
contribute to risk of MDD (Cai et al., 2015). Stress, both early-life and recent, has an aetiological 
role (Mazure, 1998); however there is inter-individual vulnerability to its propensity to culminate in 
depression.  An expanding body of research since 2003, reviewed by Keers et al., suggests that 
the effects of environment on the individual may vary according to that individual’s genotype 
(Keers and Uher, 2012). A number of pathophysiological mechanisms for the development of 
depression have been suggested, including over activity of the hypothalamic-pituitary-adrenal 
(HPA) axis (Nemeroff, 1996) and of inflammatory responses (Howren et al., 2009), reduced brain 
neurotrophins (Autry and Monteggia, 2012) and reduced noradrenergic and serotonergic 
neurotransmission. There are also associated structural (Videbech and Ravnkilde, 2004, 




The mainstay of treatment of major depression is pharmacological. The main classes of 
antidepressant drugs, developed since the 1950s, are tricyclic, monoamine oxidase inhibitor, 
selective serotonin reuptake inhibitor and serotonin noradrenalin reuptake inhibitor. Mood 
stabilizing drugs are used in recurrent or resistant depression (e.g. lithium or sodium valproate). 
Other examples of physical treatments are electroconvulsive therapy (ECT) and transcranial 
magnetic stimulation. Psychological therapies, particularly cognitive behavioural therapy are also 
used; good practice dictates that attention is paid to psychological and social factors in the 
management of depression (Taylor et al., 2012). 
 
1.2.3 Postnatal depression  
1.2.3.1 Introduction  
Major depressive disorder (MDD) occurring in the postnatal period is common and can have 
serious and long lasting consequences for the mother, her infant and family. It seems that 
postnatal depression (PND) is simply an episode of MDD that occurs post-natally, and as 
discussed in section 1.2.1 above, this is not unexpected since the prevalence of MDD is highest 
in women during their childbearing years. Brockington, a pre-eminent figure in perinatal psychiatry 
research, suggested that the main strengths of the construct of PND are to highlight it as a public 
health issue, reduce stigma and enable women to present to services and obtain treatment 
(Brockington, 1996). As the majority of research in perinatal mental health has, historically, 
tended to focus on postnatal rather than antenatal depression, it is worthy of comment that in one 
prospective study of 360 women, 50% of cases of “postnatal depression” began in the antenatal 
period and approximately one third of the cases of antenatal depression continued to be 
depressed in the postpartum period (Gotlib et al., 1989). Thus antenatal depression is likely to 
have been an unmeasured confounding factor that may account for some findings from research 
of postnatal depression; it therefore warrants more detailed description in sections 1.2.3.2 to 
1.2.3.6 below. 
 
1.2.3.2 Classification and clinical features 
The clinical symptoms of PND are indistinguishable from MDD outside of the perinatal period 
(O'Hara and McCabe, 2013). ICD-10 does not specify PND, although it is possible to code for 
disorders associated with the puerperium with an onset within 6 weeks of delivery. DSM-IV 
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includes a specifier for MDD ‘with postpartum onset’ occurring within 4 weeks of parturition. In the 
preparation of DSM-5 it was initially proposed to increase this window to within 6 months of 
parturition, however, the final decision, leading to a degree of controversy, was instead a 
‘peripartum onset’ specifier which includes pregnancy and the first 4 postnatal weeks (APA, 
2013). These differences and deliberations illustrate the artificial time frame assigned to the 
construct of PND.  
 
1.2.3.3 Epidemiology 
Epidemiological studies of PND provide a range of results, due to differences in the time frame 
measured (as discussed in section 1.2.3.2 above), whether diagnostic interviews or self-report 
questionnaires were used, and the population studied. A systematic review of 109 studies 
performed in developed countries using a diagnostic interview, suggested a period prevalence of 
depression in the first 3 months postpartum was 7.1% and the incidence of a new episode of 
depression during the same period was 6.5%. One conclusion of this paper was that a significant 
amount of uncertainty persists (Gavin et al., 2005). The prevalence of PND in developing 
countries is likely higher, in the region of 20% (Fisher et al., 2012).  Risk factors for PND, 
reviewed by O’Hara et al., include past history of depression, depression and anxiety during the 
index pregnancy, neuroticism, low self-esteem, postpartum blues, stressful life-events, poor 
marital relationship, poor social support, low socioeconomic status, being single, an unwanted 
pregnancy and difficult infant temperament (O'Hara and McCabe, 2013).  
 
1.2.3.4 Aetiology 
Since there is little evidence to support PND as a distinct clinical entity, the aetiology should not 
differ from MDD in general. None-the-less, there may be a subset of women whose depression is 
specifically linked to childbirth (Cooper and Murray, 1995), whereas in others with PND, childbirth 
probably represents a general stressor in women already predisposed to depression. Some 
studies have shown that certain women may be vulnerable to PND by their sensitivity to changes 
in the levels of the gonadotrophic hormones, oestradiol and progesterone, as occurs at the time of 
childbirth or that gonadotrophins produce down-stream effects by their modulation of serotonin 
and dopamine neurotransmitter systems (Bloch et al., 2000, Bloch et al., 2003, Bloch et al., 
2005). Dysregulation of the HPA axis is another postulated mechanism in a subgroup of women 
with PND (Workman et al., 2012, Meltzer-Brody, 2011, Magiakou et al., 1996b), furthermore there 
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is complex interaction between the HPA axis and gonadotrophins. Although there appears to be 
some familial element to PND (Forty et al., 2006), the role of genes in the aetiology of PND 
remains to be elucidated. 
 
1.2.3.5 Treatment 
The treatment of PND is as for MDD occurring outside of the postnatal period, however it is 
complicated by exposure of the infant to psychotropic medications that are excreted in breast 
milk. Furthermore, the practicalities of childcare and breastfeeding may be a barrier to treatment 
with psychological therapies in the postpartum. Overall, the infant and wider family are important 




The outcome of PND differs from MDD occurring at other times because the sufferer is generally 
the main caregiver for the new infant, thus it impacts not just on the mother, but also the infant. 
 
1.2.3.6.1 The sufferer 
An episode of PND may be of long duration; furthermore the majority of women who experience 
an episode of PND are likely to experience subsequent episodes of MDD during their child’s 
lifetime (Hay et al., 2008); this potentially results in cumulative exposure of the infant to maternal 
negative affect over childhood. Moreover, one grave outcome of PND, maternal suicide, was the 
leading cause, accounting for 28%, of indirect maternal deaths in the UK 1997-1999 (Oates, 
2003). 
 
1.2.3.6.2 The offspring 
Much research has focussed on the effect of maternal depression, and more specifically PND, on 
the offspring. There is a clear association with behavioural and emotional problems during 
childhood (Murray et al., 2011, Avan et al., 2010). Cognitive development is adversely effected, 
with exposure to PND predicting poorer IQ and language development (Grace et al., 2003, Sohr-
Preston and Scaramella, 2006, Brand and Brennan, 2009); the effect being stronger in boys 
(Brand and Brennan, 2009, Grace et al., 2003). The poor childcare practices discussed below 
may affect offspring physical health. Furthermore, It is likely that the severity and chronicity of 
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maternal depression also affects these outcomes (Brennan et al., 2000, Sohr-Preston and 
Scaramella, 2006). Although research on mediating factors is needed, it is clear that PND is 
associated with poor childcare practices, for example, poor attendance at child health visits, 
decreased immunization uptake, poor adherence to safe infant sleeping positions, general safety 
precautions (Field, 2010, Conroy et al., 2010), an increased potential for child abuse and neglect 
(Cadzow et al., 1999, Pawlby et al., 2011) and impaired or negative mother-infant interactions 
(Field, 2010). 
 
1.2.4 Antenatal depression  
1.2.4.1 Introduction 
Just as at other times in women’s lives, MDD may occur during pregnancy, either as a 
continuation of an episode during which conception occurred, a discrete episode beginning in 
pregnancy in a woman with a history of recurrent MDD, or a first episode of depressive illness. 
Significantly, in addition to those of MDD occurring outside of pregnancy, the consequences of 
antenatal depression (AND) include the effect on the pregnancy, foetus and offspring; since this is 
a principal focus of the thesis, antenatal depression is described in detail in sections 1.2.4.2 to 
1.2.4.6 below. 
 
1.2.4.2 Classification and clinical features 
ICD-10 and DSM-IV do not specify antenatal depression, although, as described in section 
1.2.3.2 above, the recently adopted DSM-5 now includes a ‘with peripartum onset’ specifier. The 
clinical features of antenatal depression do not differ from MDD at other times (Nylen et al., 2013). 
It has been suggested that some symptoms of depression might be confused with ‘symptoms’ of 
pregnancy, for example, tiredness and fatigability, sleep and appetite disturbance (Yonkers et al., 
2011, Bloch et al., 2000); however O’Hara reported that these symptoms remain good indicators 
of mood disorder in the post partum despite their common occurrence in women without mood 
disorder (O'Hara and McCabe, 2013); it would seem likely, therefore, that the same would apply 





A systematic review of prevalence and incidence of perinatal depression in developed countries 
identified 12 studies that used diagnostic interviews in pregnancy; the incidence of a new episode 
of MDD occurring during pregnancy was 7.5%. There were few studies of period prevalence; 
however, the best estimate of MDD occurring during pregnancy was 12.7% (Gavin et al., 2005). 
Higher prevalence rates, between 18 and 39%, are reported in epidemiological studies in 
developing countries (Rahman et al., 2003, Karmaliani et al., 2009, Kazi et al., 2006). A 
systematic review of risk factors for depressive symptoms during pregnancy identified maternal 
anxiety, life stress, personal history of depression, lack of social support, domestic violence, 
unintended pregnancy, low income, lower education, smoking and relationship factors (Lancaster 
et al., 2010). Compared with women who have not experienced childhood maltreatment, those 
who have, are ten times more likely to experience depression in pregnancy (Plant et al., 2013).  
 
1.2.4.4 Aetiology 
Although the aetiology of antenatal depression has received little research attention, one would 
expect it to mirror that of MDD at any other time (see section 1.2.2.3 above); however, pregnancy 
presents a unique period of altered biology, which may also play a role in the aetiology of MDD 
occurring at this particular time.  
 
1.2.4.4.1 HPA axis 
Section 1.2.2.3 above describes overactivity of the HPA axis as a proposed pathophysiological 
mechanism in MDD outside of pregnancy. This is one of the most consistent biological findings in 
psychiatry (Pariante and Lightman, 2008). Furthermore, normal pregnancy heralds a profound 
change in the HPA axis as the placenta takes over secretion of corticotrophin-releasing hormone 
(CRH), which is produced in exponentially increasing amounts to term (McLean et al., 1995). 
Taken together, these facts point to the HPA axis as a potential candidate in understanding the 
aetiology of antenatal depression, although this line of research is still in its infancy. The HPA axis 
and MDD in pregnancy are one focus of this thesis therefore this topic is described in detail in 
section 1.4.5 below. The HPA axis as a proposed aetiological factor in antenatal depression has 
been most studied; however, other systems are described below for completeness. 
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1.2.4.4.2 Immune system 
Inflammatory responses are a proposed pathophysiological mechanism in MDD outside of 
pregnancy (see section 1.2.2.3 above). Intriguingly, pregnancy is a period of altered inflammatory 
and immune system responses (Sykes et al., 2012); furthermore, inflammation is associated with 
some pregnancy-related disorders such as preeclampsia and preterm birth, which are, in turn, 
associated with antenatal depression (Osborne and Monk, 2013). There are few studies of 
inflammation and depression in pregnancy but they suggest a possible role of the immune 
system. Although research in this field is in its infancy, antenatal depression has been associated 
with interleukins 1β and 6 (IL-1β, IL-6) (Cassidy-Bushrow et al., 2012, Christian et al., 2009), C-
reactive protein (CRP) (Scrandis et al., 2008), macrophage migration inhibitory factor (MIF) 
(Christian et al., 2010) and tumour necrosis factor alpha (TNFα) (Haeri et al., 2013). 
 
1.2.4.4.3 Sex hormones 
The levels of oestrogen and progesterone increase throughout gestation, however little data is 
available for any role in antenatal depression. O’Keane et al. found no statistically significant 
difference in progesterone between depressed and healthy pregnant women at 25 or 36 weeks 
gestation (O'Keane et al., 2011). None-the-less, the research cited in section 1.2.3.4 above 
suggests that changes in levels of sex hormones may play an aetiological role in the development 
of PND (Bloch et al., 2003), thus the same potentially applies to antenatal depression.  
 
1.2.4.4.4 Neurotransmitter systems 
As described in section 1.2.3.4 there is interplay between gonadotrophic hormones and 
serotonergic and other neurotransmitter systems implicated in the aetiology of MDD (see section 
1.2.2.3), which again may be relevant to antenatal depression. 
 
1.2.4.4.5 Thyroid function 
There is a well-established association between abnormality of thyroid function and depression. 
Furthermore, physiological changes to the thyroid gland occur in normal pregnancy, thyroid 
disorders are common in pregnancy and are associated with both maternal and foetal 
complications (Cignini et al., 2012). Although more research has been performed for PND, an 
association has been reported between depressive symptoms during pregnancy and total and 




Disruption of circadian rhythms is found in MDD and is hypothesized in the aetiology of mood 
disorders (reviewed by (Germain and Kupfer, 2008). Melatonin is a measure of circadian 
rhythmicity in humans (Lanfumey et al., 2013), however, little research exists on the role of 
melatonin in antenatal depression. One small study found lower melatonin levels, and a lack of 
the normal increase in melatonin secretion over the duration of the pregnancy in women with 
antenatal depression compared with healthy controls (Parry et al., 2008).  
 
1.2.4.4.7 Genetics 
A family study has demonstrated a familial element to perinatal depression (MDD in pregnancy 
and/or postpartum), although the study does not specifically explore antenatal depression. 
However, the odds ratio for prediction of sibling status for perinatal depression was 2.28 (Murphy-
Eberenz et al., 2006). In a small genetic study of 89 pregnant women, symptoms of depression 
were correlated with the low-activity variants of the genes coding for mono-amine-oxidase type A 
and catechol-o-methyl-transferase (COMT) and the high-activity variant of the serotonin 
transporter (5-HTT) (Doornbos et al., 2009), providing preliminary evidence for the role of genes 
in the aetiology of antenatal depression. 
 
1.2.4.5 Treatment 
The management of antenatal depression differs from that for MDD, described in section 1.2.2.4 
above, only because consideration must be given to the unborn child, and looking ahead to 
breastfeeding and the health and wellbeing of the infant in the longer term. The use of 
antidepressant drugs in pregnancy should be based on a careful risk-benefit analysis and shared 
decision-making between the doctor and pregnant woman. Electroconvulsive therapy may be 
used and there is no evidence of harm to the mother or foetus (Miller, 1994). In the UK, the 
National Institute for Health and Care Excellence has issued guidelines for clinical management 
of antenatal and postnatal mental health (NICE, 2014). 
 
1.2.4.6 Outcome 
The outcome of antenatal depression differs from MDD occurring at other times in that it impacts 
not just on the mother, but also the pregnancy and unborn child. 
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1.2.4.6.1 The sufferer 
As described for PND (section 1.2.3.6.1 above) and MDD in general, since depression is often a 
chronic and relapsing disorder, further episodes are likely to be experienced throughout the 
lifetime. Moreover, one notable outcome is suicide which was the leading cause, accounting for 
28%, of all indirect maternal deaths in the UK 1997-1999 (Oates, 2003). Despite this fact, there is 
a dearth of research into antenatal depression and suicide in pregnancy. Suicidal ideation in the 
perinatal period has been assessed using the suicidality item of self-report depression rating 
scales, for example the Edinburgh Postnatal Depression Scale (EPDS (Cox et al., 1987)).  
Accordingly, suicidal ideation in pregnancy has been found to be relatively prevalent, ranging from 
5% and 14% (Lindahl et al., 2005). In women with a diagnosis of major or minor depression in 
pregnancy the range was much higher at 26%-34% (Mauri et al., 2012). However, the act of 
suicide in pregnancy is less common than in non-pregnant women of childbearing age. One study 
found lower rates of suicidality (rated by the Hamilton Depression Rating Scale, (Hamilton, 1960)) 
in depressed women who were pregnant compared with depressed non-pregnant women 
(Manber et al., 2008). Furthermore, Appleby found that suicide in pregnancy (all women) was rare 
(standardized mortality ratio, 0.05) and postulated a protective effect of pregnancy and 
motherhood (Appleby, 1991).  
 
1.2.4.6.2 The pregnancy 
Antenatal depression has been associated with the adverse obstetric outcomes of preterm birth 
(PTB) (<37 weeks gestation), low birth weight (LBW) (<2500g) and intrauterine growth restriction 
(IUGR) (<10th percentile for gestational age). Worldwide, these birth outcomes are the leading 
causes of neurodevelopmental impairments and disabilities and of neonatal and childhood 
morbidity and mortality (WHO, 1995, Swamy et al., 2008, Allen and Jones, 1986, Wilson-Costello 
et al., 2005). Two meta-analyses (sharing some of the same data) have examined the relationship 
between antenatal depression, PTB and LBW (Grigoriadis et al., 2013, Grote et al., 2010); both 
describe modest but statistically significant risks between antenatal depression and both 
outcomes, for example, PTB: RR = 1.39; 95% CI, 1.19 to 1.61, and LBW: RR = 1.49; 95% CI, 
1.25 to 1.77. One of these meta-analyses also examined IUGR and likewise describes an 
association with antenatal depression: RR = 1.45; 95% CI, 1.05 to 2.02 (Grote et al., 2010).  The 
associations were strongest in studies of categorically defined depression. The public health 
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significance was highlighted, as whilst the sizes of the relative risks are modest, antenatal 
depression is common; the magnitude of the risk of PTB associated with antenatal depression 
was likened to that of smoking 10 cigarettes per day in pregnancy (Grote et al., 2010). 
Methodological weaknesses of the studies included in these 2 meta-analyses were noted as 
important limitations. For example, a number of studies did not control for potential confounding 
factors such as smoking or antidepressant use; the authors concluded that more research with 
improved methodologies is required. Indeed only a minority of the studies included in these meta-
analyses were of operationally defined MDD as opposed to self-rated symptom levels (Diego et 
al., 2009, Field et al., 2010, Field et al., 2006a, Suri et al., 2007, Wisner et al., 2009, Rahman et 
al., 2004). The findings of the two meta-analyses are corroborated by a more recent population-
based cross-sectional study in Finland of over 500,000 pregnant women which found that women 
with physician-diagnosed ICD-10 depression, identified through specialised healthcare units (n = 
4120), had increased odds of preterm birth, LBW and SGA babies (Raisanen et al., 2014). 
 
Two other obstetric outcomes, gestational age at birth and birth weight as continua were included 
in one of the above meta-analyses but no association between antenatal depression and either of 
these outcomes was found (Grigoriadis et al., 2013). However, contemporaneous publications not 
included in the meta-analysis have found shorter length of gestation in antenatal depression. In a 
large (>4000 subjects) birth cohort study an association of shorter length of gestation (albeit in 
days) and high levels of depressive symptoms in pregnancy is reported (Van Dijk et al., 2010) and 
a smaller study (n=54) of operationally defined MDD also found a shorter length of gestation in 
the depressed group (O'Keane et al., 2011).  As discussed in section 1.3.4.3 below, shorter length 
of gestation even within the ‘at-term’ range is associated with a variety of sub-optimal outcomes; 
its association with antenatal depression is therefore noteworthy.  
 
Antenatal depression is further likely to have indirect adverse effects on obstetric outcome since it 
is associated with other risk factors for adverse pregnancy outcomes including health-related 
behaviours such as smoking (Kyrklund-Blomberg and Cnattingius, 1998, Ellard et al., 1996), 
substance misuse (Kelly et al., 2002), alcohol, poor weight gain, poor attendance for antenatal 
care (Zuckerman et al., 1989), and medical problems such as hypertension (Haelterman et al., 
1997, Sibai et al., 2000), pre-eclampsia (Kharaghani et al., 2012, Kurki et al., 2000, Xiong et al., 
1999) and diabetes (Kozhimannil et al., 2009, Evers et al., 2004). 
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Lastly, since women with antenatal depression may require treatment with antidepressants during 
their pregnancy, the effect of these drugs should also be considered. A recent meta-analysis 
provided data for pregnant women who received antidepressants during pregnancy and those 
who did not (either with or without current depression). Antidepressant exposure was associated 
with lower gestational age (mean difference of 0.45 weeks; 95% CI, 0.25 to 0.64) and with PTB 
(OR = 1.55, 95% CI, 1.38 to 1.74), including when the comparison group was solely women who 
were depressed during pregnancy. Antidepressant exposure was not associated with reduced 
birth weight when the comparison group was solely women depressed during pregnancy; in 
contrast Apgar scores were lower at 1 and 5 minutes, although still within the accepted normal 
range. Notably, the authors concluded that all the effect sizes were small thus the clinical 
significance was questioned. Moreover, the amount of available data for the meta-analysis was 
small and of variable quality, with relatively few studies including data on important confounding 
factors such as smoking (Ross et al., 2013). 
 
1.2.4.6.3 The offspring  
1.2.4.6.3.1 Foetus 
The effect of antenatal depression on the foetus was investigated in 2 small studies of women 
with high or low levels of depressive symptoms; the findings included higher basal heart rate and 
slower heart rate response to a vibro-acoustic stimulus, which took longer to return to basal levels 




Effects of antenatal depression on neonates include higher urine cortisol and lower urine 
dopamine and serotonin levels and frontal EEG asymmetry in 2 studies from the same research 
group of >70 women with high levels of depressive symptoms in pregnancy (Field et al., 2004a, 
Diego et al., 2004). In the same study (Field et al., 2004a) and one other from that research group 
(Diego et al., 2005), neonates exposed to symptoms of depression were examined using the 
Neonatal Behavioural Assessment Scale (NBAS) (Brazelton, 1995) and showed poorer scores in 
habituation, orientation and motor items. Another study of 39 women with DSM-IV MDD in 
pregnancy found that male, but not female, neonates had poorer motor scores and regulation of 
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states according to the NBAS (Gerardin et al., 2010). Examination of >1000 neonates, by a 
paediatrician, using the Neurologic and Adaptive Capacity Scale (NACS) (Amiel-Tison et al., 
1982), showed that symptoms of depression in pregnancy predicted infants who were difficult to 
console or cried excessively (Zuckerman et al., 1990). Compared with healthy women, in those 
with high levels of depressive symptoms in pregnancy, initiation of breast feeding was reduced 
(OR = 0.68; 95% CI, 0.61-0.76; p < .001) (Grigoriadis et al., 2013), therefore their infants were not 
advantaged by the benefits of breastfeeding (Salone et al., 2013). 
 
1.2.4.6.3.3 Infants and older children 
In a study of 247 women, depression symptoms in pregnancy predicted negative reactivity in 2-
month-old infants (Davis et al., 2007). Compared with 1-year-old infants of a control group of 
mothers without antenatal depression or PND (n=79), the infants of 39 women with DSM-IV MDD 
in pregnancy had higher scores on anxiety, activity/impulsiveness and sleep problems (Carter et 
al., 2003) measured with the Infant-Toddler Social and Emotional Assessment (ITSEA) (Gerardin 
et al., 2010). Using the prospectively ascertained cohort of the Avon Longitudinal Study of 
Parents and Children (ALSPAC) (Golding et al., 2001), the development of the 18-month-old 
children of >9000 women, with either low or high levels of depressive symptoms in pregnancy 
were compared; a modified version of the Denver Developmental Screening Test (Frankenburg et 
al., 1992) was used. A high level of symptoms of depression throughout pregnancy was 
associated with developmental delay in the children (OR 1.34, 95% CI 1.1-1.6) (Deave et al., 
2008). In the same cohort, there was increased risk of child attention problems, measured with 
the strengths and difficulties questionnaire (SDQ) (Goodman, 1999) (OR 1.33, 95% CI 1.19-1.48) 
(Van Batenburg-Eddes et al., 2012). Compared with three-year-old children not exposed (n=769), 
children exposed to a high level of symptoms of depression in pregnancy (n=69) were found to 
have lower body mass index (BMI) and higher central adiposity (Ertel et al., 2010). Regarding 
older children, a prospective longitudinal study of 120 pregnant women showed a twofold 
increase in risk for antisocial outcomes, fourfold risk for violent behaviour (Hay et al., 2010) and 
almost fivefold risk for depression (Pawlby et al., 2009) in the 16-year-old offspring of women 
diagnosed with MDD in pregnancy. In the same prospective study, the offspring of women who 
had themselves experienced childhood maltreatment and subsequently had depression in 
pregnancy, experienced greater levels of maltreatment by age 11 years (Plant et al., 2013). The 
ALSPAC study, described above, found that 15-year-old adolescents exposed to high levels of 
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maternal symptoms of depression (and anxiety) in pregnancy had a blunted cortisol awakening 
response (CAR), suggesting that prenatal mood has a persisting effect on offspring HPA axis; this 
finding was independent of potential antenatal and postnatal confounding factors and lends 
support to the developmental programming hypothesis (O'Donnell et al., 2013) (see section 
1.5.3.2.1 below). Further findings from the ALSPAC cohort demonstrated that symptoms of 
antenatal depression were an independent risk factor for offspring MDD aged 18, with a dose-
related effect (Pearson et al., 2013). 
In summary, the effects of antenatal depression on the offspring are wide-ranging and significant 
and include adverse effects on health physiology, neurodevelopment, mental health and 
behaviour. 
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1.3 Pregnancy and adverse obstetric outcomes  
 
1.3.1 Introduction 
As described in section 1.2.4.6.2 above, there is a clear association between MDD in pregnancy 
and several adverse pregnancy outcomes. Since obstetric outcome is one focus of this thesis, the 
following section describes these factors and highlights their pertinence to antenatal depression. 
First I have reviewed normal pregnancy and it’s biology in section 1.3.2 before describing the 
epidemiology, aetiology and consequences of the adverse obstetric outcomes of preterm birth, 
shortened length of gestation, small for gestational age and low birth weight babies in sections 
1.3.3 to 1.3.5. 
 
1.3.2 Normal pregnancy  
A normal singleton pregnancy lasts 40 weeks from the first day of the last menstrual period. Term 
gestation is widely accepted to be that occurring between 37 and 42 weeks from the first day of 
the last menstrual period. These cut-offs have been devised somewhat arbitrarily by dint of the 
complications that occur in shorter or longer pregnancies. The designated duration of term 
pregnancy has been adjusted over the years to the most recent cut-off for PTB (<37 weeks) in the 
1970s, and for post-term (>42 weeks), in the 1950s (Fleischman et al., 2010).  
A normal weight baby falls between the 10th and 90th centiles of a standard growth chart. Birth 
weight is determined by length of gestation and foetal growth rate. Low birth weight (<2500g) 
regardless of gestational age occurs either because of preterm delivery or slow foetal growth rate 
(IUGR) or a combination of both. Babies with weight falling below the 10th centile for their 
gestational age are termed ‘small for gestational age’ and those above the 90th centile are termed 
‘large for gestational age;’ this usually occurs due to a high foetal growth-rate (Dunn, 1985). 
Pregnancy is traditionally broken down into 3 stages or ‘trimesters’ of approximately 3 months 
each. The 1st trimester includes implantation of the embryo to the endometrial lining of the uterus, 
formation of the placenta and a period of rapid foetal growth and development; the brain, other 
organs and limbs begin to form. The first trimester is the period of greatest risk for miscarriage 
and birth defects. Growth and major organ development continue in the 2nd trimester; of relevance 
to this thesis, foetal HPA axis activity begins in mid-gestation (Mastorakos and Ilias, 2003). The 
period of highest foetal weight gain occurs in the 3rd trimester.  
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Many metabolic and physiological changes occur in the pregnant woman’s body in order to 
support the growth and development of the foetus and to prepare for parturition and lactation. The 
placenta develops both from foetal cells and maternal uterine tissue and forms a barrier between 
maternal and foetal blood (which do not mix). The placenta has several functions:  (i) it allows 
delivery of nutrients to, and elimination of waste products from the foetus, and gas exchange 
between mother and foetus; (ii) it allows the development of passive immunity by the transport 
across the placenta of maternal immunoglobulin G (IgG) antibodies; (iii) by term, the placenta has 
become the largest endocrine organ in the body; it secretes oestrogens, progesterone, human 
chorionic gonadotrophin (hCG), human placental lactogen (hPL), and CRH. Progesterone levels 
rise throughout pregnancy, and decline towards the end; progesterone facilitates implantation, 
inhibits uterine smooth muscle contraction and inhibits lactation (Feldt-Rasmussen and 
Mathiesen, 2011). Levels of oestrogens rise steadily from week 10 to term; oestrogens are 
involved in controlling other pregnancy hormones and in foetal development. Levels of hCG rise 
exponentially from implantation, peak at 10 weeks gestation, then decline and plateau for the 
remainder of the pregnancy. hCG has many key roles in pregnancy including embryo 
implantation, placental development and uterine and foetal growth (Cole, 2012). Levels of hPL 
rise linearly throughout gestation to peak at 32-35 weeks gestation; hPL appears to modify 
maternal metabolism to ensure adequate foetal nutrition (Newbern and Freemark, 2011) (see 
Figure 1). Levels of CRH rise exponentially throughout pregnancy, peaking at delivery (Sasaki et 
al., 1987, Frim et al., 1988). Of particular relevance to this thesis, CRH is essential for foetal 
development and maturation, the maintenance of pregnancy and the timing of delivery (McLean 
et al., 1995, Zoumakis et al., 2009).  
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Figure 1: Maternal hormones in pregnancy (Gwatkin, 1989) 
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1.3.3 Preterm birth   
Preterm birth is a major public health concern worldwide; it is associated with significant morbidity 
and mortality and high costs in health and social care. PTB may be either medically indicated or 
spontaneous (either spontaneous onset of labour or spontaneous rupture of membranes). The 
pathways to PTB are complex, and are not yet fully understood.  
 
1.3.3.1 Definition 
The World Health Organisation (WHO) defines PTB as less that 37 completed weeks of gestation. 
Birth weight was originally used as a proxy for prematurity, however this is now considered 
unsatisfactory as it may miss many preterm babies (Behrman, 2007). Gestational age can be 
determined using the first day of the last menstrual period but it is commonly confirmed by 




The worldwide estimate for PTB in 2010 was between 12.3 and 18.1 million; equivalent to 11.1% 
of all live births. However, there are marked differences by country, for example rates were 5% in 
several European countries and 18% in some African countries. PTB also occurs in wealthy 
countries, for example the USA is one of ten countries worldwide with the highest rates of PTB 
(Blencowe et al., 2012). Furthermore differences exist within countries, for example in the USA, 
rates of PTB are 10.9% in white Americans and 17.5% in African–Americans. Worldwide, the 
majority (82%) are moderate or late PTBs (>32 weeks gestation) where chances of survival and 
adverse consequences are better than early PTB. PTB is more common with male (55%) than 
female offspring (Zeitlin et al., 2002). Despite advances in science and healthcare, rates of PTB 
have been rising over the past 20 years (Blencowe et al., 2012, Goldenberg et al., 2008).  
 
1.3.3.3 Aetiology  
The aetiology of PTB is explored in detail in this section since depression and PTB have a 
number of aetiological factors in common, for example, anxiety, stressful life events, substance 
misuse, marital status, socio-economic status.  
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1.3.3.3.1 Psychosocial and stress 
Much research has focussed on the relationship between stress and PTB. Historically, research 
on stress and PTB has been somewhat hampered as depression, anxiety and general distress 
have not been distinguished. A review in 1999 found that only half of the 20 studies on the theme 
reported a significant association of stress (including life events, anxiety, depression or emotional 
distress) with PTB (Savitz and Pastore, 1999). However, in this new century the body of research 
on stress and PTB has burgeoned, and is strengthened by a number of improvements in 
methodology. The majority of these more recent investigations have shown significant 
associations of stress with PTB; it appears that more methodologically rigorous research is 
providing clearer results (Behrman, 2007). Mechanisms linking stress in pregnancy and PTB are 




Depression can be conceptualised as a form of chronic stress and as described in detail in 
section 1.2.4.6.2 above, two recent meta-analyses have supported the finding of increased risk of 
PTB in antenatal depression (Grote et al., 2010, Grigoriadis et al., 2013).  
1.3.3.3.1.2 Anxiety and other types of stress 
Although anxiety and depression are often co-morbid they are distinguishable conditions and it is 
important to disentangle their individual influence on the risk of PTB. The evidence for an effect of 
general anxiety on PTB is mixed and a meta-analysis of anxiety symptoms in pregnancy showed 
no significant association with PTB (Littleton et al., 2007). However, it appears that pregnancy-
specific anxiety in particular predicts PTB but not an individual’s anxiety resulting from knowledge 
about their own medical risk (Dole et al., 2003, Mancuso et al., 2004, Rini et al., 1999).  
Life event and PTB research has provided mixed results, although in general, studies with more 
rigorous methodology have shown significant results (Behrman, 2007). There are also mixed 
results for an effect of catastrophic stress occurring during pregnancy on PTB, however, a recent 
systematic review concluded that there does not seem to be an effect on length of gestation 
(Harville et al., 2010). Chronic stress in pregnancy, for example, financial, family and work, has 
been associated with PTB (Misra et al., 2001). A meta-analysis of domestic violence showed an 
increased risk of PTB (adjusted OR = 1.46; 95% CI, 1.27-1.67) (Shah and Shah, 2010).  
39 
1.3.3.3.2 Behavioural  
Within this category, cocaine use is the most consistently associated with risk of PTB with an 
approximate two-fold increase and there is probably a modest association with cigarette smoking, 
(Berkowitz and Papiernik, 1993). 
 
1.3.3.3.3 Social and demographic 
Both young maternal age (Hediger et al., 1997) and maternal age over 35 (Cnattingius et al., 
1992) are risk factors for PTB. Single women appear at higher risk for PTB than married women 
(Raatikainen et al., 2005). Compared with white women, black, but not Asian and Hispanic 
women are at increased risk of PTB (Schaaf et al., 2012). Several studies in developed countries 
demonstrate an association between lower socioeconomic status and PTB (Behrman, 2007).  
 
1.3.3.3.4 Medical conditions and pregnancy problems 
Chronic and acute medical conditions, previous indicated or spontaneous PTB and family history 
of PTB all constitute risks. Birth defects and PTB are associated (Rasmussen et al., 2001). A 
short inter-pregnancy interval (<6 months between the termination of one and conception of 
another) has been linked to PTB (Smith et al., 2003a). Multiple gestation is associated with PTB, 
furthermore, assisted reproductive techniques, for example in vitro fertilization (IVF), even for 
singletons have around a two-fold increased risk for PTB (McGovern et al., 2004). 
 
1.3.3.3.5 Genetics 
Genetics are thought to play a role in the predisposition to PTB (Dolan, 2010). Twin studies 
indicate that heritability lies between 20-40% (Treloar et al., 2000, Clausson et al., 2000). The 
results of a large genome-wide association study (GWAS) are due to be published soon (Dolan 
and Christiaens, 2013). 
 
1.3.3.3.6 Environmental toxins 
Lead, tobacco smoke and air pollution likely contribute to the risk of PTB, but investigation of 
other environmental toxins is lacking (Behrman, 2007). 
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1.3.3.3.7 Common biological pathways 
As described in the sections above, the causes of PTB are multifactorial and complex and vary 
according to gestational age; however, there is a common biological pathway to the process of 
parturition, reviewed by Challis et al., 2000. The HPA axis, a key focus of this thesis, is central to 
this pathway, which is initiated by HPA axis activation and increased placental CRH expression. 
This, in turn, leads to a biological cascade including a functional progesterone withdrawal and 
oestrogen activation, expression and activation of contraction-associated proteins, oxytocin and 
prostaglandins. This cascade culminates in cervical ripening, uterine contractility and decidual 
and foetal membrane activation (Challis et al., 2000). PTB occurs when pathological processes 
activate one or more elements of this pathway before full term. These processes include stress, 
systemic or genital tract infection, placental ischaemia or vascular lesions and uterine over-
distension (Behrman, 2007). PTB is preceded by preterm premature rupture of membranes 
(PPROM) in 40% of cases; again this is part of the final common pathway to PTB. With regards to 
HPA axis involvement in PTB, compared with women delivering at term, 2nd trimester plasma 
CRH has been shown to be significantly higher in those who go on to deliver preterm, and lower 
in those delivering post-term (McLean et al., 1995). The term ‘CRH placental clock’ has been 
used, active from early pregnancy, length of gestation and timing of delivery is thus determined 
(McLean et al., 1995) and CRH in early third trimester has been shown to predict length of 
gestation (Wadhwa et al., 1998). Furthermore levels of the binding protein (CRHBP) have been 
shown to be lower in the second and third trimesters in pregnancies ending in PTB (Hobel et al., 
1999) (see section 1.4.4 below).  
 
1.3.3.4 Outcomes 
1.3.3.4.1 Short-term outcomes 
Those born at the lower limits of viability have the highest mortality rates and levels of 
prematurity-related morbidity. Prematurity is one of the leading causes of infant mortality 
worldwide (Liu et al., 2012) and mortality rates increase with decreasing gestational age (CDC, 
2003). In 2010 the infant mortality rate for preterm babies was 2.4% of live births in the UK (ONS, 
2012). The more premature the infant, the more immature are the organ systems and the less 
prepared to support extra-uterine life. Morbidity includes lung disease including respiratory 
distress syndrome, gastrointestinal disorder, compromised immune system, morphological and 
functional cardiovascular disease, auditory and ophthalmic problems and neurological insult. 
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Moreover, the aetiology of the PTB and the biological mechanisms of the common pathway to 
PTB, for example inflammation and cytokine injury, may also influence infant health outcomes 
(Behrman, 2007). 
1.3.3.4.2 Long-term outcomes 
1.3.3.4.2.1 The preterm individual and their family 
Prematurity may lead to a wide range of neurodevelopmental disabilities, some with long-term 
effects into adulthood. These disabilities include cerebral palsy, mental retardation, hearing, sight 
and language impairments, learning disability, attention deficit-hyperactivity disorder (ADHD), 
minor neuro-motor dysfunction or developmental coordination disorders, behavioural problems 
and social-emotional difficulties (Behrman, 2007). The majority of studies on foetal origins of adult 
disease have used birth weight as the marker of early adversity, however more recent research 
has used PTB. Insulin resistance (Fewtrell et al., 2000, Hofman et al., 2004b) and metabolic 
abnormalities (Hofman et al., 2004a) have been reported in pre-teen children who were born 
preterm. The impact on families of having a child born preterm may be multi-faceted and long-
term. Reduced psychological wellbeing, family breakdown, reduced employment opportunities 
and financial impacts are possible negative factors. Conversely, the impact may be positive, for 
example, bringing families closer together. 
 
1.3.3.4.2.2 Society 
In the USA in 2005, the financial burden to society for each child born preterm, over and above 
costs associated with a child born at full term, were quoted as 51,600 USD (approximately 34,000 
GBP) per year. Costs include the infant’s medical care, maternal delivery costs, early intervention 
services, special education and lost household and labour market productivity (Behrman, 2007). 
 
1.3.4 Shortened length of gestation  
1.3.4.1 Introduction 
As detailed in section 1.3.2 above, the consensus length of gestation for a full term pregnancy is 
somewhat arbitrary but is based on the increased risk of complications seen in infants born at <37 
or >42 weeks gestation. There has been increasing research interest in the complications that 
attend infants born early within the at-term range as it has become apparent that infants born at 
37 and 38 weeks gestation have significantly higher risks of morbidity and mortality (Kramer et al., 
2013, Zhang and Kramer, 2009, Fleischman et al., 2010). Evidence is emerging of correlations 
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between the severity of some sub-optimal outcomes and shorter length of gestation even within 
the ‘at-term’ range (see section 1.3.4.3 below). Thus, for certain outcomes, it appears that it may 
be more appropriate to consider the effect of gestational age as a continuum rather than PTB as 
‘all or none’ (Fleischman et al., 2010).  
 
1.3.4.2 Depression and shortened length of gestation 
Since depression during pregnancy may be associated with shorter length of gestation (the 
evidence is described in section 1.2.4.6.2 above) an outline of the effects of this particular 
outcome is warranted. Several large studies on outcomes associated with shortened length of 




1.3.4.3.1 Respiratory system 
Gestational age is a determinant of the degree of pulmonary maturation and the adequacy of 
surfactant production, which are critical factors in determining respiratory function at birth. A 
retrospective study of >180,000 live births in one region of the UK from 1988 – 1992 showed that 
compared with infants born at 39-31 weeks, infants born at 37-38 weeks gestation were at 
increased risk of respiratory distress and its associated mortality, particularly when labour was not 
spontaneous. This increased risk was in the order of a 200-fold increase at 37 weeks. 
Furthermore, the requirement for ventilator support for respiratory distress was 78 times more 
likely at 38 than at 39-41 weeks gestation (Madar et al., 1999).  
 
1.3.4.3.2 Sudden Infant Death Syndrome (SIDS) 
A study in Scotland of >200,000 live births following spontaneous onset of labour at full term, 
between 1992-1995, showed the risk of SIDS decreased significantly with each additional week of 
gestation (OR = 0.72; 95% CI, .60-.86). Compared with infants born at 40 weeks, those born at 37 
weeks gestation had an increased risk of sudden infant death (adjusted OR = 2.5, 95% CI, 1.2-
5.2) (Smith et al., 2003b). 
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1.3.4.3.3 Brain development  
An MRI study of 67 healthy American children aged 6-10 years who had been born at full term 
and had a stable neonatal course found that longer gestation was associated with 
neurodevelopmental benefit i.e. increases in grey matter density in some temporal regions (Davis 
et al., 2011a). This finding demonstrates that even at full term, shorter length of gestation has 
lasting effects on neurodevelopment. Disruptions to brain development may increase risk, in the 
longer term, for the development of behavioural (Gozzo et al., 2009), cognitive (Yang et al., 2010) 
or psychopathological (Janssens et al., 2009, Wright et al., 2000, Raikkonen et al., 2007) 
problems. 
 
1.3.4.3.4 Cognitive ability 
A study of >13,000 6 year old children born at full term and of normal weight in the 1990’s in 
Belarus compared the IQ (using the Wechsler Abbreviated Scales of Intelligence) of children born 
at 39-41 weeks with those born at 37 and 38 weeks gestation. The full-scale IQ was 1.7 (95% CI -
2.7, -0.7) and 0.4 (95% CI -1.1, 0.02) points lower in children born at 37 and 38 weeks gestation 
respectively (Yang et al., 2010). A retrospective population-based study, in Scotland, of >17,000 
school-aged children showed an increasing risk of special educational need (SEN) with 
decreasing gestational age at birth which held true both for preterm and full term births. There 
was increased risk of special educational need for children born at 33-36 weeks (adjusted OR = 
1.53; 95% CI, 1.43-1.63) and at 37-39 weeks (OR = 1.16; 95% CI, 1.12-1.20) (MacKay et al., 
2010). Academic achievement, by 3rd grade reading and maths tests, was investigated in 
>128,000 8-year-old American children who had been born at full term. Gestational age was 
significantly and positively related to reading and maths scores, and children born at 37-38 weeks 
achieved significantly lower scores than those born between 39-41 weeks (Noble et al., 2012). 
 
1.3.5 Intra-uterine growth restriction and low birth weight  
 
1.3.5.1 Introduction 
Since antenatal depression has been associated with the adverse obstetric outcomes of IUGR 
and LBW (described in section 1.2.4.6.2 above) this topic will be described in more detail. A LBW 
infant may have been born preterm but be normal weight for their gestational age (as detailed in 
PTB in section 1.3.3 above); alternatively they may have IUGR, whether full-term or preterm, 
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indicating poor growth. Prior to the 1960s LBW and/or gestational age formed the definition of 
prematurity; it was not until after this time that the two measures were distinguished by WHO 
(Fleischman et al., 2010). Consequently, historically there has been lack of clarity in definitions, 
and terms have been used interchangeably for research on prematurity. This has hindered the 
understanding of causes, consequences and treatments for adverse obstetric outcomes 
(Behrman, 2007, Bamberg and Kalache, 2004). The following sections principally concern IUGR. 
 
1.3.5.2 Definitions 
IUGR refers to the poor growth of the foetus in utero i.e. a pattern of growth deviating from the 
expected norms. IUGR may be asymmetric (the most common), generally with head sparing, or 
symmetric. An infant small for gestational age (SGA) has a birth weight below the 10th percentile 
for gestational age; they may be constitutionally small (non-pathological) or have had IUGR. Low 
birth weight is defined as <2500g, and is further subdivided into very low birth weight (VLBW) 
(<1500g) and extremely low birth weight (ELBW) (<1000g). 
 
1.3.5.3 Epidemiology 
The prevalence of IUGR is in the region of 8%. IUGR is present in about 50% of stillbirths, 
additionally IUGR accounts for 10% of perinatal mortality (Mandruzzato et al., 2008).  
 
1.3.5.4 Aetiology 
The aetiology may be divided into placental (abnormalities of placental structure or function e.g. 
chorioangioma, infarction), the most common cause of IUGR; foetal (e.g. chromosomal disorders) 
or maternal (see below) (Resnik, 2002, Mandruzzato et al., 2008). As for PTB, depression and 




There is a modest association between antenatal depression, IUGR and LBW, the best overall 
evidence available, and its limitations, has been described for PTB in section1.2.4.6.2 above. 




IUGR is also associated with (i) behavioural conditions, for example smoking, alcohol and illicit 
substance use or abuse, (ii) maternal medical conditions, for example vascular disease and 
hypertension, renal insufficiency, SLE, diabetes and infection, (iii) extremes of reproductive age 
i.e. <16 years and >35 years, (iv) poor maternal weight gain, (v) malnutrition, (vi) low pre-
pregnancy weight, (vii) lower social-economic status, (viii) drugs such as anticonvulsants. Some 
of these associations are particularly strong, for example IUGR occurs in 50% of pregnant women 
with heroin addiction and smokers have a 3.5 fold risk of IUGR (ACOG, 2001). Furthermore, 
many of these maternal factors are independently associated with MDD and antenatal depression 
(see sections 1.2.2.2 and 1.2.4.3 above). 
 
1.3.5.4.2 Pathophysiology 
The mechanisms underlying poor foetal growth are not fully understood but likely include 
inflammatory response, hormones, growth factors, vasculopathy, vasoactive agents, maternal and 
foetal blood and foetal central nervous system (Sankaran and Kyle, 2009). 
 
1.3.5.5 Outcome 
The outcome depends on the specific cause for IUGR but the risk of morbidity and mortality 
increases with decreasing birth weight (Pallotto and Kilbride, 2006). 
 
1.3.5.5.1 Foetus 
The IUGR foetus is at increased risk of hypoxia (Marsal, 2002) and there is increased risk for 
sudden unexplained intrauterine death (OR = 7.0; 95% CI, 3.3.15.1); this risk increases with 
increasing severity of growth restriction (Pallotto and Kilbride, 2006). 
 
1.3.5.5.2 Offspring  
In the short-term there is around a 2- to 5-fold increase in risk for perinatal mortality both for full 
term and preterm IUGR births (Pallotto and Kilbride, 2006). There is also an increased risk of 
morbidity, including peri- and neonatal hypoxia, hypothermia, hypoglycaemia and other metabolic 
abnormalities, compromised immune system, infection and cerebral palsy (Marsal, 2002). In the 
long-term, IUGR offspring with chromosomal disorders, congenital malformation or infection may 
well have developmental retardation, neurosensory deficits and poor academic achievement. 
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Offspring with other causes of IUGR have been followed longitudinally; there is increased risk of 
shorter height and lower weight in childhood and shortness of stature as adults. There is 
increased rick of cerebral palsy and subtle neurological findings, developmental delay, a modest 
association with decreased IQ and with childhood behavioural and emotional problems (Pallotto 
and Kilbride, 2006). In recent years, a growing literature links IUGR with adult disorders such as 
cardiovascular disease, metabolic disorders and obesity (Barker et al., 1993) (see section 1.5 
below). 
 
1.3.5.5.3 Family and society 
Having an IUGR child may create considerable emotional and financial stress for families and 
economic burden for society, much as described for PTB described in section 1.3.3.4.2 above.
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1.4 The hypothalamic-pituitary-adrenal axis  
 
1.4.1 Introduction  
The HPA axis is a key theme in this thesis; I have assessed the maternal HPA axis in pregnancy 
and the infant HPA axis in the first year of life, and thus it is described here in more detail. I first 
review the HPA axis in general (including adult and infant HPA axis) in section 1.4.2; next I focus 
on the HPA axis in major depression in section 1.4.3, then the HPA axis in pregnancy (including 
maternal and foetal HPA axis) in section 1.4.4 and lastly the HPA axis in antenatal depression in 
section 1.4.5. In particular, I have reviewed aspects of the HPA axis such as diurnal variation in 
cortisol and the cortisol awakening response, since these are measures I have made in this study.  
 
1.4.2 The hypothalamic-pituitary adrenal (HPA) axis 
The HPA axis is the principal endocrine system regulating the body’s response to stress (see 
Figure 2). The HPA axis is headed by the peptides corticotrophin-releasing hormone (CRH), and 
arginine vasopressin (AVP), which are produced in the paraventricular nucleus of the 
hypothalamus. CRH enters the pituitary portal blood and, at the anterior pituitary, triggers 
secretion of the polypeptide, adrenocorticotropic hormone (ACTH). In turn, ACTH enters the 
peripheral circulation and at the adrenal cortex, stimulates release of the glucocorticoid, cortisol 
(Dinan and Scott, 2005). HPA axis activity is then regulated by cortisol, which exerts a direct 
negative feedback, via glucocorticoid (GR) and mineralocorticoid (MR) receptors, at the 
hypothalamus and pituitary. Furthermore, the HPA axis is regulated by other factors: It responds 
to psychological, physical and immunological stressors via excitatory and inhibitory inputs at the 
paraventricular nucleus of the hypothalamus that arise in other brain regions, for example, 
hippocampus, amygdala, bed nucleus of the stria terminalis, dorsomedial nucleus of the 
hypothalamus and brainstem nuclei. Lastly, HPA axis activity has an endogenous circadian 
rhythm, which is regulated by the suprachiasmatic nucleus of the hypothalamus and results in 
peak HPA axis activity in the morning (Lightman et al., 2002).  
Cortisol has many actions that prepare the body to deal with a stressor, for example, 
gluconeogenesis, peripheral insulin resistance, anti-inflammatory action and elevated blood 
pressure. Its central actions include regulation of neurogenesis, neuronal survival, neuronal 





Figure 2: Diagram of the HPA axis 
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1.4.2.1 Diurnal variation in cortisol secretion 
The cells of the suprachiasmatic nucleus (SCN) of the hypothalamus form a biological clock 
known as the ‘master circadian pacemaker,’ which creates and maintains circadian rhythms. 
Creation of these rhythms is endogenous i.e. they are not dependent on, but can be moderated 
by, external factors such as light. It is hypothesized that circadian rhythms have evolved as an 
adaptation to the rhythmic environment of the Earth, allowing our physiology and behaviour to 
align with its daily cycle (Albrecht, 2011, Vaze and Sharma, 2013). One such circadian rhythm is 
in the diurnal secretion of cortisol; levels are lowest around midnight and rise gradually from 2 to 
3am to peak within 30 minutes of waking, levels subsequently decline throughout the day to 
midnight (see diagram in Figure 3). Only more recently it emerges that this diurnal pattern closely 
tracks an underlying ultradian rhythm whereby cortisol is released in pulses at approximately 
hourly intervals. The amplitude of these pulses of cortisol dictates the pattern of its diurnal 
variation (Lightman and Conway-Campbell, 2010). Clearly the circadian rhythm of cortisol has 









1.4.2.2 The cortisol awakening response and post-awakening cortisol 
1.4.2.2.1 Introduction 
First described in the 1990s, one distinct and separate characteristic of the circadian rhythm of 
cortisol secretion is the cortisol awakening response (CAR) (Pruessner et al., 1997); a surge of 
cortisol secretion (a 50-160% increase (Clow et al., 2004)) that occurs on awakening and peaks 
within about 30 to 45 minutes (see Figure 4). The CAR is thought to be a physiological response 
to awakening (Clow et al., 2010) and the hippocampus is central to its regulation (Fries et al., 
2009). Furthermore, in addition to the negative feedback of glucocorticoids on the HPA axis, 
another regulator of the CAR is the suprachiasmatic nucleus, both directly via the HPA axis at the 
hypothalamus and indirectly via extra-pituitary neural pathways to the adrenals that appear to 
alter the sensitivity of the adrenal to ACTH prior to and after awakening (Clow et al., 2010). 
 
1.4.2.2.2 Function and characteristics of the CAR 
The function of the CAR is yet to be understood, but is likely to be manifold. It has been 
hypothesized to have a role in recovery from sleep inertia, the 15 to 60-minute period between 
awakening and regaining full alertness, providing a boost of energy (Clow et al., 2010), in 
cognitive function, regulation of the immune system and anticipation of the up-coming day (Fries 
et al., 2009). Although previous research suggests that there is high intra-individual stability of 
cortisol response (Fries et al., 2009) it is now being recognized as an inter-individual state marker, 
for example, prior day experiences, ovulation, and alcohol consumption (Law et al., 2013). The 
CAR is seen in 75% of healthy adults and it is about 40% heritable (Wust et al., 2000). 
 
1.4.2.2.3 Factors influencing the CAR 
Studies of factors influencing the CAR have provided inconsistent results for depression (Clow et 
al., 2010) (see section 1.4.3.2 below). Stress appears to be associated with the CAR, although 
the effect may differ for acute versus chronic stress (Fries et al., 2009); a recent meta-analysis 
showed that the most robust psychosocial associations with the CAR were job and general life 
stresses (increased CAR), and fatigue, burnout and exhaustion and possibly post traumatic stress 
disorder (PTSD) (reduced CAR) (Chida and Steptoe, 2009). Physical diseases, for example 
cardiovascular and autoimmune disorders, have been associated with a high waking cortisol and 
blunted CAR (Clow et al., 2010). It seems that age, gender, gonadal hormones and smoking have 
little, if any, effect on the CAR (Fries et al., 2009). Sleep and waking characteristics may have an 
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effect, for example, early awakening has been associated with a larger CAR, although duration of 
sleep and nocturnal awakening has not (Fries et al., 2009). 
 
1.4.2.2.4 Measurement of the CAR and post-awakening cortisol 
A number of approaches are used to measure the CAR; serial saliva samples are acquired after 
awakening and free cortisol is subsequently quantified. Using these methods, the CAR is 
variously described as repeated measures analysis of cortisol levels from the serial samples, 
change scores between awakening and peak value, or by calculating the area under the curve 
(AUC) (Clow et al., 2004). Historically, CAR has been used to describe various aspects of post-
awakening cortisol, however, recent expert consensus guidelines propose a clear division. These 
guidelines suggest that the term CAR should be restricted to measures of the dynamic of post-
awakening cortisol changes (for example AUCi or mean increase in cortisol from awakening). 
Total post-awakening cortisol (for example AUCg) may be reported as additional information but 
is not an estimate of the dynamic of the awakening ‘response’ (Stalder et al., 2016). Accordingly, 
this thesis adopts the newly recommended terminology. When the sampling procedure is 
undertaken in subjects’ homes, sample timings may be unreliable (Clow et al., 2004). Although 
not much implemented in past research, optimal CAR measurement protocols, based on 
comparative research, have now been proposed. Awakening time can be recorded in the home 
accurately by electronic means (e.g. the wrist-watch-style actigraph) and sample timings by using 
an electronic medication event monitoring (MEM) system for saliva collection tubes.(Smyth et al., 




Figure 4: Cortisol awakening response (Pruessner et al., 1997) 
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1.4.2.3 Neonate and infant HPA axis and infant cortisol response to stress 
Since infant HPA axis, including cortisol response to the pain of immunization, is measured in this 
research, it is now described in more detail. The HPA axis is already functional and stress-
responsive in new-borns, although diurnal variation in cortisol is not seen until about 3 months 
postnatal (Moustogiannis and Vagenakis, 1998). The adult diurnal pattern of cortisol secretion 
only develops after cessation of daytime naps; prior to this, cortisol levels remain stable from mid-
morning to mid-afternoon (Watamura et al., 2004). Measures of HPA axis response to stress in 
children has received increasing research interest, particularly with emerging evidence that future 
health and development may be affected by stress during phases of rapid neurological 
development such as childhood (Gunnar and Quevedo, 2007). Infants are thought to mount a 
cortisol response to stresses such as pain until around 6 to 12 months-of-age, following this it 
disappears although a behavioural response persists. Children then develop a period of relative 
cortisol hypo-responsiveness to stress that diminishes by adolescence (Gunnar and Quevedo, 
2007). In their systematic review of cortisol reactivity in children to the age of 2 years, Jansen et 
al. reported on 48 studies of cortisol response to a range of physical and emotional stressors in 
children between birth and 2 years of age. There were 35 studies of cortisol response to pain 
(heel-stick or vaccination); this type of stressor was found to have a large effect size (mean 
Cohen’s d 1.10); only 5 of these studies were in infants older than 6 months and these results 
were mixed, ranging from no effect to a moderate effect size (Jansen et al., 2010).  
 
1.4.2.4 Measures of the HPA axis 
The level of hormones of the HPA axis can be measured. Cortisol is measured in tissues such as 
blood, urine and saliva; either dynamic measures, by stimulation or suppression tests (e.g. 
dexamethasone suppression test), or by static levels. Corticosteroid binding globulin (CBG) is 
present in blood, accordingly total cortisol is measured in this tissue; conversely, only the 
biologically active, unbound or ‘free’ cortisol is measured in saliva and urine. ACTH can be 
measured in blood. Other than during pregnancy, when levels are high enough to measure in 
blood, CRH is measured in cerebral spinal fluid (CSF). Other indices of the HPA axis may be 
evaluated, for example, the volume of pituitary or adrenal glands on MRI scans.  
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1.4.3 The hypothalamic-pituitary-adrenal axis in depression  
Hyperactivity and impaired feedback regulation of the HPA axis are consistent biological findings 
in major depression. An analysis of studies testing HPA axis function (by dexamethasone 
suppression test) in thousands of depressed patients suggests evidence of impaired negative 
feedback regulation in 44%; with a higher proportion, around three quarters, in the more severely 
ill (Arana et al., 1985). HPA axis hyperactivity ensues, as evidenced by increased levels of cortisol 
in urine and plasma (Sachar et al., 1970), increased levels of CRH in cerebrospinal fluid 
(Nemeroff et al., 1984) and increased volume of pituitary (Krishnan et al., 1991) and adrenal 
(Rubin et al., 1995, Nemeroff et al., 1992) glands. The impaired negative feedback regulation of 
the HPA axis found in MDD has been termed glucocorticoid resistance. Impaired function of the 
glucocorticoid receptor is hypothesized to contribute to this phenomenon and is thought to be key 
in understanding the pathophysiology of depression (Anacker et al., 2011). Furthermore, MR, or 
an imbalance between MR and GR, is also implicated, as reviewed by Berardelli (Berardelli et al., 
2013) and Pariante (Pariante, 2009). Whether these abnormalities of the HPA axis are simply a 
consequence or epiphenomenon, or form part of the pathophysiology of depression remains to be 
clarified. However, it is hypothesized that in MDD, impaired GR function is central, and the high 
cortisol levels are consequent (Pariante, 2009).  
 
1.4.3.1 Diurnal variation in cortisol secretion in depression 
The normal pattern of diurnal secretion of cortisol (described in section 1.4.2.1 above) appears to 
be disrupted in MDD although debate on the nature of this disruption continues. Depressed 
inpatients have been found to have higher morning cortisol and a higher flat pattern of cortisol 
secretion across the day (Holsboer, 2000, Plotsky et al., 1998); although these findings do not 
seem to hold for the less unwell (Dienes et al., 2013). However a large community study did show 
a pattern of cortisol secretion similar to the depressed inpatients described above (Vreeburg et 
al., 2009). Others variously suggest elevated evening cortisol levels in about 50% (Claustrat et al., 
1984, O'Brien et al., 2004), a different pattern of cortisol hypersecretion, or no change in the 
normal diurnal pattern (reviewed by (Herbert, 2013)). Methodological differences, type and 
severity of depression, are likely to account for some of these differences.  
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1.4.3.2 The cortisol awakening response and post-awakening cortisol in depression 
Studies of cortisol awakening response in depression have provided inconsistent results (Clow et 
al., 2010, Dedovic and Ngiam, 2015).  Depression has been associated with a higher CAR 
(indexed by a variety of measures, for example AUCi, change in cortisol between awakening and 
30 minutes post-awakening, or repeated measures ANOVA) (Aubry et al., 2010, Bhagwagar et 
al., 2003, Dienes et al., 2013, Ulrike et al., 2013, Vreeburg et al., 2009) and a greater post-
awakening total cortisol (AUCg) (Vreeburg et al., 2009); and a blunted CAR (for example indexed 
by change in cortisol between awakening and 30 minutes post-awakening or the mean of three 
values of cortisol at awakening, 15 and 30 minutes post-awakening) (Huber et al., 2006, Stetler 
and Miller, 2005); these inconsistencies have been attributed to the heterogeneous nature of 
depression and methodologically diverse studies. It appears that in methodologically more 
rigorous studies, that is, large studies, controlling for confounding factors or where MDD is 
operationally defined, MDD is associated with a larger CAR and greater post-awakening total 
cortisol.  
 
1.4.4 The hypothalamic-pituitary-adrenal axis in human pregnancy  
The HPA axis plays a pivotal role in the mechanisms maintaining pregnancy, foetal development 
and in parturition, although additional hormonal, neuronal and immune pathways, both maternal 
and foetal, participate in these complex functions. In contrast to very low or undetectable levels in 
the non-pregnant state, CRH in pregnancy is detectable in plasma from the 8th to 10th week of 
gestation onwards. CRH is produced by the placenta in exponentially increasing amounts, 
reaching up to 1000 times that of non-pregnant levels (Goland et al., 1988), to about 800 pg/ml in 
late pregnancy (Figure 5) and peaking at 2000-3000 pg/ml during labour (Kalantaridou et al., 
2010); CRH is undetectable in plasma within 24 hours of delivery (Goland et al., 1986).  In 
contrast to the negative feedback regulation of CRH by cortisol at the hypothalamus, placental 















CRH exerts its actions by binding to CRH receptors (CRHR1 and CRHR2); it is made inactive by 
binding to CRH binding protein (CRHBP) which is synthesised in liver and placenta (Petraglia et 
al., 1993). The level of CRHBP changes little throughout much of gestation until in the 3rd 
trimester when levels fall, reaching about one third of previous levels within the last 6 weeks, and 
more-so during labour (Perkins et al., 1993). Within 48 hours of delivery, CRHBP has returned to 
non-pregnant levels (Campbell et al., 1987). 
In pregnancy CRH has multiple targets including placenta, myometrial smooth muscle, foetal 
membranes and foetal adrenal glands. The role of CRH includes facilitation of embryo 
implantation (Makrigiannakis et al., 2004), myometrial relaxation and contractility 
(Grammatopoulos, 2007), control of placental vascular tone (Clifton et al., 1994) and modulation 
of immune function (Zoumakis et al., 2000) and endocrine function, for example, ACTH (Petraglia 
et al., 1987), prostaglandins (Jones and Challis, 1989), oestrogen and progesterone (Kalantaridou 
et al., 2010).  
In contrast to unbound CRH, plasma ACTH levels rise throughout pregnancy but stay within 
normal limits; ACTH levels parallel cortisol levels (Laatikainen et al., 1987). The pituitary gland 
becomes about 1/3rd larger in pregnancy due to prolactin cell, rather than corticotrophe, 
hyperplasia. In contrast the adrenal glands enlarge as increasing amounts of cortisol are 
produced. Cortisol levels peak in the 3rd trimester, total cortisol levels double, and free cortisol 
levels triple the non-pregnant values; levels are comparable to those found in Cushing’s disease 
or severe depression (Mastorakos and Ilias, 2003). 
 
1.4.4.1 Diurnal variation in cortisol secretion in pregnancy 
Diurnal variation of ACTH and cortisol secretion is present in pregnancy (Nolten, 1980, Lindholm 
and Schultz-Moller, 1973, Kivlighan et al., 2008, Allolio et al., 1990), however CRH does not show 
a circadian rhythm (Magiakou et al., 1996a, Allolio et al., 1990). Some studies have shown 
correlations between CRH, cortisol and ACTH in pregnancy, whereas others have not 
(Mastorakos and Ilias, 2003, Wadhwa et al., 1997). Since ACTH and cortisol both show continued 
circadian rhythmicity in pregnancy, it is proposed that the ACTH secretogogue, arginine 
vasopressin, drives these circadian rhythms (Magiakou et al., 1996a). 
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1.4.4.2 The cortisol awakening response and post-awakening cortisol in pregnancy 
The cortisol awakening response is present in pregnancy. In a study of 119 pregnant women, the 
CAR was present and robust at 32 weeks gestation, with greater mean difference between 
awakening and 30 minutes post-awakening compared to the non-pregnant state in the same 
women (de Weerth and Buitelaar, 2005). In three reports all from the same group, one study of 
148 pregnant women showed the CAR (measured at weeks 17 and 31 gestation) to decline over 
pregnancy (Entringer et al., 2010). The second reported a study of 101 pregnant women 
demonstrating the same attenuation of CAR from 17 to 31 weeks gestation together with the 
finding of associations between shorter length of gestation and both a reduced attenuation of the 
CAR over pregnancy and a larger CAR in late pregnancy (Buss et al., 2009). The third reported a 
study of 25 pregnant women, showing that a flatter CAR occurring with a higher awakening 
cortisol level was associated with shorter length of gestation, stating that a 2.6% higher 
awakening cortisol predicted a 1 week shorter length of gestation (Entringer et al., 2011). It is not 
clear if there was overlap in the subjects used for these three reports. In a study of 94 pregnant 
women, post-awakening cortisol (AUCg) explained 20% of the variance in birth weight (Bolten et 
al., 2011). Conversely, in a study of 135 pregnant women, compared with women who had 
experienced non-sexual abuse or no abuse in childhood, those who had experienced sexual 
abuse in childhood showed an increasing CAR over the last 2 trimesters of pregnancy (Bublitz 
and Stroud, 2012). Research on CAR in pregnancy is in its infancy, and since current evidence 
suggests that the CAR is affected both in depression and in pregnancy, and may have 
associations with adverse obstetric outcomes, it is relevant to this thesis.  
 
1.4.4.3 Human foetal HPA axis 
The foetal HPA axis is critical for foetal development, maturation and homeostasis. An 
understanding of foetal HPA axis is of relevance to this research, in particular when considering 
potential mechanisms for developmental programming, and is thus now described. It is known 
that the structural components of the HPA axis develop early in gestation and the hormones of 
the HPA axis are present in the 1st trimester. Post mortem studies of human foetuses have shown 
the presence of (i) ACTH in pituitary tissue at 8 weeks, with a 3-fold higher content of ACTH in 
foetuses of mid- compared with early gestation (Pavlova et al., 1968) (ii) cortisol in adrenal tissue 
at 8 weeks (Goto et al., 2006) (iii) CRH immunoreactivity in hypothalamus at 12 weeks (Ackland 
et al., 1986). Further findings from post mortem studies suggest functional activity: (i) adrenal 
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CRH1 receptor mRNA, and CRH-stimulation of adrenal cortical cell cortisol production, 
suggesting direct action of CRH at the foetal adrenal gland, in 16-31 week foetuses (Jaffe et al., 
1998), (ii) GR and MR expression in the hippocampus of preterm (from 24 weeks gestation) 
neonates who died within 4 days of delivery (Noorlander et al., 2006), (iii) a higher concentration 
of cortisol in the umbilical artery than vein in 16-20 week old live foetuses prior to termination of 
pregnancy, providing evidence that the foetus is producing cortisol (Partsch et al., 1991). 
Evidence also exists of foetal HPA axis activity from in-vivo studies (i) foetal cortisol response to 
foetal blood sampling or intra-uterine transfusion demonstrates that HPA axis activity has begun 
by 20 weeks gestation and that foetal cortisol response is independent of maternal cortisol (Gitau 
et al., 2001), (ii) CRH has been detected in 2nd trimester foetus umbilical vessel blood; paired 
maternal plasma samples showed CRH at a higher but positively correlated level (Economides et 
al., 1987, Lockwood et al., 1996), however (iii) foetal stress response evidenced by a rise in foetal 
cortisol and ACTH did not include a rise in CRH, suggesting that foetal CRH emanates from 
another source, likely the placenta (Gitau et al., 2004). 
The above studies of Gitau demonstrated that foetal cortisol levels are about 13-fold lower than 
the maternal level, although about one third of variation in foetal cortisol is attributable to maternal 
cortisol (Gitau et al., 2001). Maternal cortisol is rendered inactive to the foetus by the actions of 
the placental enzyme 11-β hydroxysteriod dehydrogenase type 2 (11β-HSD-2), nonetheless 
about 10-20% of maternal cortisol crosses to the foetal compartment (Benediktsson et al., 1997). 
It is estimated that the foetus is exposed to 5% of any elevation of maternal cortisol (Gitau et al., 
1998). Placentas from term and preterm deliveries were used to demonstrate that the expression 
of 11β-HSD-2 increases throughout pregnancy (Schoof et al., 2001) and drops abruptly at term 
(Murphy and Clifton, 2003); this facilitates maturation of foetal organs by maternal glucocorticoids.  
 
1.4.4.4 The HPA axis and pregnancy outcome 
As discussed in detail in section 1.3 above, the HPA axis plays a pivotal role in foetal growth and 
development, maintenance of pregnancy and parturition (Mastorakos and Ilias, 2003). To 
summarize data on HPA axis and obstetric outcome, overactivity of the gestational HPA axis, 
including elevated CRH (McLean et al., 1995) and cortisol (Giurgescu, 2009), larger CAR in later 
pregnancy (Buss et al., 2009) and decreased attenuation of CAR over pregnancy have been 
associated with shortened length of gestation and/or PTB. Lower birth weight has been 
associated with post-awakening cortisol (Bolten et al., 2011), IUGR with antenatal prescription of 
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steroids (Mongelli and Gardosi, 2000) and PTB and IUGR in Cushing’s disease (Kamoun et al., 
2014). CRH in early third trimester has been shown to predict length of gestation (Wadhwa et al., 
1998). 
 
1.4.5 The hypothalamic-pituitary-adrenal axis in antenatal depression  
The hypothalamic-pituitary-adrenal axis in antenatal depression is a principal focus of this thesis 
and is thus reviewed in detail below. A number of studies have investigated the HPA axis in 
antenatal depression, although the HPA axis has not been the primary focus in some of these 
studies. The majority of these studies have not defined cases of major depression in pregnancy; 
rather they have used self-report depression rating scales. The studies based on depression 
symptom scores rather than operationally defined MDD are reviewed first in section 1.4.5.1 below 
and those based on operationally defined MDD are then reviewed in section 1.4.5.2 below. 
 
1.4.5.1 HPA axis and symptoms of depression in pregnancy 
To date, eight studies (six from the same research group) using depression symptom scores 
rather than operationally defined MDD suggest an association between depressive symptoms in 
pregnancy and HPA axis (see Table 1). One of these studies assessed CRH and seven assessed 
cortisol. The majority of the studies demonstrating higher levels of HPA axis hormones compared 
groups with high v low depression symptom scores. In contrast, six studies using depression 
symptom scores rather than operationally defined MDD suggest no association between 
depressive symptoms in pregnancy and HPA axis (see Table 2). Two of these studies assessed 
CRH and five assessed cortisol; all but 2 of these studies were based on correlations rather than 
group differences (high v low) of depression scores. 
 
To summarise, the majority of currently available research demonstrates that maternal antenatal 
HPA axis measures do not correlate with depressive symptom severity scores, but differences in 
HPA axis measures become apparent when cut-off scores suggestive of clinical depression are 
used. On consideration of the seven studies that defined a depressed group according to self-
rated symptom severity scores, 5 studies showed a group difference suggestive of overactivity of 
the HPA axis; three measured cortisol in a morning urine sample in the second or third trimester 
of pregnancy (Field et al., 2004b, Field et al., 2001, Lundy et al., 1999). One (Peer et al., 2013) 
measured CAR and total post-awakening cortisol (no group difference) and evening saliva cortisol 
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at a mean of 19 weeks gestation, the other (Rich-Edwards et al., 2008) measured serum CRH 
between 26 and 28 weeks gestation. Two of the studies that defined a depressed group 
according to self-rated symptom severity scores found no group difference; one of them 
measured plasma CRH at <20 weeks and 24-29 weeks gestation (Meltzer-Brody et al., 2011) and 
the other measured CAR between 25 and 33 weeks gestation (Shea et al., 2007).  
 
Regarding the opposing findings for CRH, both studies were based on a large sample of pregnant 
women (n >800) with similar socio-demographic characteristics (which were controlled for in the 
analyses), and both studies recruited subjects from antenatal clinics on the East Coast of the 
USA. However, there were differences that may account for the opposing findings. The first may 
be related to differences in the proportion with depression symptom scores above cut-off for 
antenatal depression: 8.8% with EPDS ≥13 (Rich-Edwards et al., 2008) v 24.8% with CES-D ≥17 
(Meltzer-Brody et al., 2011). The former appears to be more in line with prevalence rates for 
antenatal depression described in the literature (see section 1.2.4.3 above). Furthermore, both 
studies also rated symptoms of depression postnatally; in the former study, the proportion with 
EPDS ≥13 at 6 months postnatal was 7.5% (similar to the antenatal rate of 8.8%) but in the latter 
study, rather than CES-D, EPDS was used at 4 months postnatal and identified 7.6% with EPDS 
≥13 (in contrast to the antenatal depression rate of 24%). Given these points, it is possible that 
the latter study may have falsely identified antenatal cases, which might account for the absence 
of an association with CRH. Indeed, a study of screening for perinatal depression used both 
instruments (EPDS and CES-D) on the same perinatal women found that a statistically significant 
greater proportion of women scored above cut-off on CES-D than EPDS (Mosack and Shore, 
2006). Furthermore, the study of Rich-Edwards et al. took account of pregnancy complications 
and prescription medications including antidepressants; this was not the case in the study of 
Meltzer-Brody et al. Lastly, in contrast to that of Rich-Edwards, the latter study did not use the 
gold standard RIA to quantify CRH, instead using an enzyme-linked immune-assay, which may 
also have affected the findings (Glynn and Sandman, 2014).  Based on these factors, it seems 
that Rich-Edwards et al. report more compelling findings of increased CRH in antenatal 
depression.  
 
The second study reporting no association between depression and HPA axis measured CAR by 
the change in cortisol from awakening to +30 minutes (Shea et al., 2007). This study divided the 
63 
subjects who they had defined as depressed (EPDS ≥13 and/or MADRS ≥9) into those with or 
without comorbid anxiety based on STAI score, no differences were found in CAR between the 
three groups, however, the comorbid groups had higher depression scores than the depression-
alone group and there was no report of findings for a combination of those two groups. 
Furthermore, it was reported that depression scores were statistically significantly lower at the 
time when the cortisol was measured than at recruitment, so it seems probable that some of the 
cases groups may not have had depression. Moreover, the influence of other potential 
confounding factors was inadequately accounted for, since there was no report of indices of 
social-economic status, ethnicity, obstetric complications, medical conditions or medications, 
other than that 14 of the depressed women were taking antidepressant medication. Lastly, 
another study found no difference in CAR, indexed by the change in cortisol from awakening to 
+30 minutes or in post-awakening cortisol (AUCg) (Peer et al., 2013) (although a higher evening 
cortisol was reported in the depressed group, as described above). This paper shared the last 
author with that of Shea et al., (2007) although surprisingly, the findings from that paper were not 
discussed. Although Peer et al. examined the influence of potential confounding factors more 
adequately, there were only 8 cases of depression, and these cases were defined by a lower cut-
off score (≥12) on EPDS. Thus there are a number of limitations to the two current studies of CAR 
and depression (based on depression symptom score severity); indeed, both papers state that 





Table 1 Summary of studies showing an association between symptoms of depression and HPA 
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Table 2 Summary of studies showing no association between symptoms of depression and HPA 
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1.4.5.2 HPA axis and operationally defined MDD in pregnancy 
To date, eight studies, three from the same research group, compared HPA axis measures in 
pregnant women, either healthy or with an operationally defined diagnosis of MDD. Five of these 
studies found significantly higher cortisol in the depressed group (Evans et al., 2008, Field et al., 
2009, Field et al., 2007, O'Connor et al., 2013b, O'Keane et al., 2011), one found mixed results 
(Parcells, 2010) and two found no association (Field et al., 2010, Hellgren et al., 2013).  Each 
study is described below; the studies of O’Connor (O'Connor et al., 2013b) and Hellgren (Hellgren 
et al., 2013) are described in sections 1.4.5.3 (diurnal cortisol) and 1.4.5.4 below (CAR). 
 
In their study of antenatal depression and the HPA axis, O’Keane et al. studied 65 pregnant 
women either with or without a SCID (Structured Clinical Interview for DSM-IV Axis I Disorders) 
diagnosis of MDD; they measured saliva cortisol at awakening and 8pm at 32 weeks gestation; 
compared to healthy controls (n=33) they found significantly higher mean evening cortisol in those 
with MDD (n=13). Additionally they made fuller assessments of the HPA axis and demonstrated, 
compared with the control group (n=36), significantly higher plasma CRH in the MDD group 
(n=19) at 25 weeks gestation and a trend for higher CRH at 36 weeks gestation, but no group 
differences for ACTH (see Table 3) (O'Keane et al., 2011). This study was undertaken in the 
same setting as this current research and informed the protocol; however it is on an entirely 
separate group of study subjects. 
 
In their study of pregnant black women and birth outcome, Field et al. reported on 131 with, and 
205 without a SCID diagnosis of MDD in pregnancy. Cortisol in first morning urine was measured 
at 20 and 32 weeks gestation. Compared to the women without MDD, the MDD group had 
significantly higher cortisol at 32 weeks gestation (M, 10.5 and 71.0 respectively, F=6.69, p=0.01). 
Neither standard deviations, nor the units of cortisol measurement were reported in this 




Table 3: Antenatal depression and HPA axis measures - derived from O'Keane et al. 2011  
 Control, M (SD) 
(n = 33-36) 
MDD, M (SD) 
(n = 17-20) 
Statistical test 
2nd trimester CRH (pg/ml), M (SD) 
 287.22 (79.26) 334 (86.75) t(53) = 2.04, p < 0.05 
3rd trimester CRH (pg/ml), M (SD) 
 546.45 (248.3) 627.21 (223.7) t(49) = 2.02, p = .07 
2nd trimester ACTH (pmol/l), M (SD) 
 4.49 (2.31) 4.83 (1.4) t (54) = 0.73, p = 0.47 
3rd trimester ACTH (pmol/l), M (SD) 
 6.45 (2.5) 7.61 (2.3) t(49) = 1.6, p = 0.11 
Awakening saliva cortisol (nmol/l), M (SD) 
 17.17 (3.93) 16.63 (7.9)1 t(44) = 0.28, p = 0.78 
Evening saliva cortisol (nmol/l), M (SD) 
 4.81 (2.0) 7.13 (3.9)1 t(44) = 2.67, p = <0.02 
 
                                                       
1 n = 13 
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In their study of sleep disturbances in depressed pregnant women and their newborns, Field et al. 
studied 253 pregnant women, of whom 83 had a SCID diagnosis of MDD or dysthymia (80% and 
20% respectively). Cortisol in first morning urine was measured at 20 and 32 weeks gestation. 
Compared with the control group, the depressed group had significantly higher urine cortisol at 20 
weeks gestation (M (SD), 137.1 (86.4) v 154.8 (89.4) respectively; F=4.8, p=0.05). Again, the 
units of cortisol measurement were not reported in this publication (Field et al., 2007). 
 
In their study of cortisol in antenatal depression and anxiety, Evans et al. reported on 182 
pregnant women (123 healthy controls, 16 with MDD or dysthymia, 34 with current anxiety 
disorder and 9 with both MDD and anxiety according to a SCID diagnosis). Saliva cortisol was 
measured between 10.30am and 11.30am at 36 weeks gestation. The comorbid group, but not 
the other groups, had significantly higher cortisol than the controls. Cortisol values were not 
reported in the text but on interpretation of the graph, mean cortisol was approximately 4ng/ml for 
controls and 5.5ng/ml for the comorbid group. Of note, the cases groups were small and 
combining the depression groups was not reported, however, depression scores were 
significantly higher than controls in all three groups. The study included appropriate analyses of 
potential confounding factors (Evans et al., 2008).  
 
Another study with operationally defined MDD reported a mixed picture of association between 
MDD in pregnancy and overactive HPA axis. In a study of depression, anxiety and stress during 
pregnancy, Parcells reported on 59 women in the early- and mid-third trimester of pregnancy, 
according to a SCID diagnosis, 32% of the sample had MDD at 26-28, and 23% at 32-34 weeks 
gestation. Cortisol was measured from saliva samples obtained between 10am and 11.30am. 
There was no statistically significant difference in cortisol levels between the depressed and non-
depressed group. However, levels of self-reported symptoms of depression were not high and 
were similar between the 2 groups. When the groups were defined by a cut-off of symptom 
severity on BDI, those with the higher level of symptoms had significantly higher cortisol (Parcells, 
2010).  
 
In contrast, one study with operationally defined MDD found no association between MDD in 
pregnancy and overactive HPA axis. In their study of the effect of comorbid depression and 
anxiety on pregnancy and neonates, Field et al. reported on 911 pregnant women (345 non-
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depressed or no diagnosis, 77 anxiety disorder, 181 depressive disorder and 308 comorbid 
anxiety-depressive disorder). Cortisol was measured in a mid-morning urine sample at 20 and 32 
weeks gestation. There was no significant difference in cortisol level between any of the groups at 
either time point in pregnancy. Limitations include no reporting of the use of prescribed 
medication, alcohol or illicit drugs nor the awakening time. (Field et al., 2010).  
 
1.4.5.3 Diurnal variation in cortisol secretion in antenatal depression 
In a study of 101 pregnant women at high psychosocial risk for developing depression, those with 
a diagnosis of depression had significantly lower morning cortisol and a flatter slope and higher 
cortisol level across the day at twenty and thirty-two weeks gestation (O'Connor et al., 2013b).  
Another study (described in section 1.4.5.1 above) of 53 women at high psychosocial risk for 
developing depression compared women with high or low levels of depressive symptomatology; 
they found higher levels of evening cortisol in women with high levels of depressive 
symptomatology (Peer et al., 2013); this demonstrates a group difference in the diurnal pattern of 
cortisol secretion since there was no statistically significant group difference in the awakening 
levels. 
 
1.4.5.4 The cortisol awakening response and post-awakening cortisol in antenatal 
depression 
The study of O’Connor described in section 1.4.5.3 above found no significant association 
between antenatal depression and CAR at twenty or thirty-two weeks gestation (O'Connor et al., 
2013b). These findings reflect those of other studies: In a study (n = 134) using diagnostic 
interview, CAR and post-awakening cortisol were measured in late pregnancy (36-39 weeks 
gestation), no association with MDD was apparent (Hellgren et al., 2013). As described in section 
1.4.5.1 above, using a self-rated depression score above or below a cut-off level, CAR was 
measured between 25-33 weeks (n = 66) (Shea et al., 2007), or <27 weeks (n = 53) gestation 
(Peer et al., 2013); neither found a difference between groups. 
 
1.4.5.5 Summary of hypothalamic-pituitary-adrenal axis in antenatal depression 
In summary, there is mixed evidence for an association of HPA overactivity and depression in 
pregnancy and there are a number of limitations to the current evidence. The majority of studies 
use self-report measures of depressive symptoms rather than operationally defined diagnoses, 
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many of these studies have not been designed specifically to elucidate the relationship between 
HPA axis and depression in pregnancy, and there are a number of methodological issues such as 
controlling for potential confounding factors, including antidepressant medication, use of illicit 
drugs and alcohol, pre-pregnancy BMI, timing of sample collection, pregnancy factors and 
physical health. On balance, it appears that the larger and/or methodologically superior studies, in 
particular, those making a specific timed quantification of an HPA axis measure and using 
diagnostic interview to define the cases groups, for example O’Connor et al. (2013) and O’Keane 
et al. (2011), or adequate assessment of, and control for potential confounding factors and a large 
number of subjects, for example, Rich-Edwards et al. (2008), lend support to the hypothesis that 
the HPA axis is overactive in depression, in particular, evening and diurnal cortisol and CRH.  
However, the evidence regarding awakening cortisol, CAR and post-awakening cortisol in 
antenatal depression is limited and further study is warranted. 
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1.5 Developmental programming 
 
1.5.1 Introduction  
Since developmental programming is a principal focus of this thesis, the concept and current 
evidence is now described. First I introduce the concept, next I focus on studies in animals 
including research paradigms, outcomes and mechanisms in section 1.5.2. Lastly I have reviewed 
developmental programming studies in humans in section 1.5.3, beginning with the effects of 
prenatal stress in general, next the specific effects of antenatal depression and finally a review of 
proposed mechanisms. 
 
The hypothesis that adversity in the environment of the developing foetus may influence the 
occurrence of chronic disease in adulthood has developed over the past three decades since the 
influential epidemiological studies of Barker et al. which demonstrated a link between 
geographical infant mortality rates or birth weight, and death in adulthood from ischaemic heart 
disease (IHD) (Barker and Osmond, 1986, Barker et al., 1989). Initially, the investigators 
concluded that processes linked to growth in prenatal or early postnatal life strongly influence the 
risk of ischaemic heart disease. These findings are corroborated by other studies in Europe and 
North America (Buck and Simpson, 1982, Notkola and Tiedeseura, 1985, Forsdahl, 1977). The 
concept developed that foetal and early-infancy undernutrition induces permanent changes in 
offspring organ structure, physiology and metabolism leading to ischaemic heart disease in 
adulthood. In the 1990s it became recognised further that the in utero environment afforded not 
only by maternal nutrition, but also by maternal hormones or metabolism can permanently 
programme offspring structure and physiology (Barker, 1995). Within the past decade the depth of 
knowledge has further advanced, providing clear indication that exposure to undernutrition, stress 
or excess glucocorticoids during foetal development leads to permanent effects on offspring 
cardiovascular system (CVS), metabolism and cognition (Meaney et al., 2007, Harris and Seckl, 
2011). Indeed it is now postulated that glucocorticoids are the final common factor linking the 
effects of maternal undernutrition, stress and 11β-HSD-2 activity with programming outcomes of 
low birth weight with its associated chronic medical problems in adulthood (Cottrell et al., 2012). It 
is also apparent that the effect of developmental programming is dependent on the tissue, the 
type of environmental adversity and the timing of its occurrence during foetal development (Harris 
and Seckl, 2011). 
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Developmental programming has been demonstrated in humans and other animals and its 
occurrence is thought to confer evolutionary advantage. Foetal life is a period of rapid growth and 
development; during this phase there is plasticity i.e. the development of foetal organs and 
systems is adapted by their environment; later, there is loss of plasticity and systems are fixed. 
This ‘developmental plasticity,’ appears adaptive in evolutionary terms as the function of the 
developed organism is well matched to the environment in which it developed (West-Eberhard, 
1989, Glover and Hill, 2012). Although this is likely to promote survival to reproductive age, this 
‘programming’ may be less advantageous to the organism later in life, particularly if the 
environment at that stage is dissimilar to that which shaped early development (Harris and Seckl, 
2011). The evidence regarding mechanisms and outcomes of developmental programming 
pertaining to glucocorticoids and prenatal stress attained from animal, as opposed to human, 
studies is most advanced and since it has greatly informed the research in humans, both are 
described in sections 1.5.2 and 1.5.3 below. 
 
1.5.2 Studies in animals  
The study of developmental programming in animals is described first, since it has informed and 
advanced the understanding of this concept in humans. One advantage of studying animals is the 
ability to design experiments with strictly controlled environments and the use of experimental 
manipulations that would be impossible in human studies; this provides clearer clues as to 
mechanisms and outcomes. The majority of these studies have been in rodents, mainly rats, but 
also mice and guinea pigs; other species include sheep and non-human primates. However, 
despite many similarities with humans, for example, about 90% of rat genes (Gibbs et al., 2004) 
and 99% of mice genes (Gunter and Dhand, 2002) have a human equivalent, differences should 
be borne in mind. For example, much neural and endocrine maturation occurs after birth in rats 
and mice, as they are born at an earlier developmental stage (Matthews, 2002); for instance, 
brain development at birth for rats is equivalent to that of the end of the second trimester in 
humans (Bayer et al., 1993); furthermore only primates have placental CRH (Weinstock, 2008).  
 
1.5.2.1 Paradigms for animal research in developmental programming 
Since the concept of developmental programming is based on the premise of the effects on 
offspring of an adverse environment during the early development of an organism, three major 
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paradigms have been employed in the study of this phenomenon in animals: maternal 
undernourishment, antenatal administration of synthetic glucocorticoids and prenatal stress. 
Prenatal stress has been administered throughout, or at specific times in pregnancy, and 
achieved by methods such as tail suspension, repeated electric shocks, crowding, noise or 
restraint in rodents and noise in monkeys. Furthermore, additional experimental manipulations 
have informed the understanding of mechanisms of developmental programing; natural HPA axis 
activity has been abolished by maternal adrenalectomy and replacement of resting levels of 
corticosterone (CORT) in pregnant rats. Thus, these rats are unable to mount an HPA axis 
response to stress and their offspring have then been compared with control prenatally stressed 
rats (Barbazanges et al., 1996). Finally, in this paradigm, the HPA axis response to stress has 
been mimicked by injection of CORT at the time of stress administration so that three groups of 
offspring can be compared. These paradigms provide an understanding of mechanisms for 
offspring neurodevelopment, health and behaviour as described in sections 1.5.2.2 to 1.5.2.2.4 
below. 
 
1.5.2.2 Prenatal stress in animals 
 
1.5.2.2.1 Offspring HPA axis 
Prenatally stressed, compared to control rats, show differences in HPA axis reactivity, including 
higher glucocorticoid secretion at the end of a light period in both sexes, and greater total daily 
glucocorticoid secretion in females (Koehl et al., 1999). Prenatally stressed male rats and mice 
have abnormal feedback regulation of the HPA axis with down-regulation of MR and GR (Koenig 
et al., 2005, Chung et al., 2005, Maccari et al., 2003). Overall, the evidence indicates that prenatal 
stress in rodents can disrupt offspring HPA axis when it is of sufficient intensity and applied at 
critical stages of development (Weinstock, 2008). Furthermore, there are similar findings in other 
species (Schneider et al., 2002, Clarke et al., 1994, de Vries et al., 2007); for example, compared 
to controls, prenatally stressed juvenile offspring of rhesus monkeys showed higher basal levels 
of ACTH and cortisol and a larger cortisol response to stress. Moreover, these alterations in 
offspring HPA axis regulation appear to be permanent (Welberg et al., 2000) and can even persist 
to the next generation (Schopper et al., 2012). Cross-fostering experiments have shown that 
these changes originate from prenatal rather than postnatal causes (Schneider et al., 2002, Del 
Cerro et al., 2010). 
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1.5.2.2.2 Offspring behaviour 
Prenatally stressed animals show altered behaviour. This includes depressive-like behaviour, 
anxiety and impaired coping in adversity (see below, reviewed by (Weinstock, 2008). Animal 
models of depression include immobility in the forced swim test (which informs about learned 
helplessness or loss of active coping) and decreased sucrose preference (for anhedonia) (Czeh 
et al., 2016). These paradigms have been used to demonstrate an increase in depressive-like 
behaviours in prenatally stressed (particularly female) rodents (Alonso et al., 1991, Alonso et al., 
2000, Keshet and Weinstock, 1995). Furthermore, some studies have shown that depressive-like 
behaviour in prenatally stressed rats is associated with altered HPA axis reactivity (Morley-
Fletcher et al., 2003, Weinstock, 2008, Maccari et al., 2003, Poltyrev et al., 1996), although others 
have shown that it is not (Solberg et al., 2003, Stohr et al., 2000). Animal models of anxiety can 
be demonstrated using the elevated plus maze or open field which illicit fear-like reactions. Both 
male and female prenatally stressed rats have been shown to display higher levels of anxious 
behaviour using these paradigms (Dickerson et al., 2005, Estanislau and Morato, 2005, Fride and 
Weinstock, 1988, Murmu et al., 2006, Poltyrev et al., 1996, Salomon et al., 2011, Vallee et al., 
1997, Van den Hove et al., 2005, Ward et al., 2000, Zagron and Weinstock, 2006); anxious 
behaviour was also seen in prenatally stressed rhesus monkeys (Schneider, 1992, Clarke et al., 
1994). As for depressive behaviour, anxious behaviour has been correlated with increased HPA 
axis activity (Vallee et al., 1997, Ward et al., 2000), but not if the prenatal stress was mild or brief 
(Fride and Weinstock, 1988, Van den Hove et al., 2005, Richardson et al., 2006). Like the 
changes in offspring HPA axis, these behaviours can persist to the next generation (Matthews 
and Phillips, 2010). 
 
1.5.2.2.3 Offspring cognitive function and brain development 
Several studies have demonstrated learning and memory deficits in prenatally stressed rats and 
mice (Gue et al., 2004, Ishiwata et al., 2005, Lemaire et al., 2000, Nishio et al., 2001, Son et al., 
2006, Wu et al., 2007, Yang et al., 2006). Animal studies (in rodents, sheep and primates) have 
provided clear evidence that prenatal stress affects offspring brain morphology, and are 
comprehensively reviewed by Charil et al. The brain regions studied thus far have been chosen 
by dint of their association with the behavioural or cognitive effects seen in prenatally stressed 
animals and include both micro- and macroscopic changes, for example, decreased tissue 
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volumes or neurogenesis; the brain areas studied include hippocampus (Barros et al., 2006, 
Lemaire et al., 2000, Uno et al., 1994, Uno et al., 1990) amygdala (Kerchner et al., 1995, 
Kraszpulski et al., 2006, Salm et al., 2004), corpus callosum (Coe et al., 2002), neocortex (Barros 
et al., 2006, Fleming et al., 1986, Poland et al., 1999), cerebellum (Ulupinar and Yucel, 2005, 
Ulupinar et al., 2006) and hypothalamus (Anderson et al., 1985, Kerchner and Ward, 1992, Rhees 
et al., 1999). Although the mechanisms for these effects remain unclear, the placenta and 
maternal and foetal HPA axes are the principal candidates hypothesized to be the mediators 
(Charil et al., 2010).  
 
1.5.2.2.4 Offspring physical health 
Adverse health outcomes have been demonstrated in prenatally stressed rats including adverse 
cardiovascular response to stress (Igosheva et al., 2007) and impaired glucose tolerance (Lesage 
et al., 2004). A wealth of physiological/health effects (for example on blood pressure, glucose 
tolerance, birth weight and organ development) in offspring exposed to prenatal stress or 
synthetic glucocorticoids is reviewed by (Meaney et al., 2007). 
 
1.5.2.3 Mechanisms for developmental programming 
Since clear evidence exists, in several species (Matthews, 2002), that developmental 
programming occurs, and prenatal stress has a range of effects on offspring HPA axis, behaviour 
and health, attention has turned to elucidating the underlying mechanisms for this phenomenon. 
As described in section 1.5.2.1 above, experimental manipulations employed in studying 
developmental programming include maternal glucocorticoid exposure, prenatal stress, 
malnutrition or hypoxia (Xiong and Zhang, 2013). Since it is the focus of this thesis, and it is 
considered that glucocorticoids are the final common factor linking the effects of maternal under-
nutrition, stress and 11β-HSD-2 activity with programming outcomes (Cottrell et al., 2012), the 
HPA axis is now considered. Several lines of evidence implicating the HPA axis in the 
programming effects of prenatal stress are explored in sections 1.5.2.3.2 to 1.5.2.3.5 below. 
 
1.5.2.3.1 Prenatal stress and maternal HPA axis 
Firstly, stressing a pregnant animal affects not only the offspring, as described in the preceding 
section, but also activates the maternal HPA axis. Prenatal stress has been shown to lead to 
elevated CORT (Takahashi et al., 1998, Williams et al., 1999, Ward and Weisz, 1984, Weinstock 
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et al., 1988) and decreased corticosterone binding globulin in the pregnant rat (Takahashi et al., 
1998) and elevated cortisol in the pregnant rhesus monkey (Schneider et al., 1999). Significantly, 
maternal glucocorticoids and CRH both reach the foetal brain (Weinstock, 2005), thus activation 
of maternal HPA axis by prenatal stress will affect the foetal environment. 
Secondly, elegantly designed studies in rats further demonstrate the role of maternal 
glucocorticoids in mediating the long-term effects of prenatal stress on offspring HPA axis activity. 
For example, pregnant dams were administered restraint as a prenatal stressor; one group with 
intact CORT secretion and two groups of adrenalectomized dams with replacement steady-dose 
CORT, one group of which also received an injection of CORT during stress (mimicking the 
control condition). Whereas prenatally stressed adult offspring displayed a prolonged CORT 
response to stress and decreased hippocampal MR and GR, this effect was not seen in offspring 
whose adrenalectomized mothers could not mount a CORT response to the restraint stress, but 
was reinstated in the group receiving CORT injection during the stress (Barbazanges et al., 1996, 
Wilcoxon and Redei, 2007, Maccari et al., 2003). Using the same paradigm, others have 
demonstrated the role of maternal glucocorticoids in mediating the long-term behavioural effects 
of prenatal stress. For example, in adrenalectomized dams given resting levels of CORT (who 
were thus unable to mount a CORT response to stress), anxious behaviour in their offspring was 
prevented (Zagron and Weinstock, 2006) but reinstated when CORT was injected to the dam 
during the prenatal stress (Oliveira et al., 2006, Salomon et al., 2011, Wilcoxon and Redei, 2007). 
Furthermore, elevated anxiety displayed in prenatally stressed adult rats is associated with 
increased plasma CORT stress response (Vallee et al., 1997) and increased CRH in the 
amygdala (Cratty et al., 1995), and a CRH antagonist diminished anxious behaviour in prenatally 
stressed rats (Ward et al., 2000). 
 
1.5.2.3.2 Synthetic glucocorticoids 
Since synthetic glucocorticoids freely cross the placenta (Seckl and Holmes, 2007) their 
administration informs on the effects of excess maternal glucocorticoids on offspring. These 
studies, in sheep, rats, mice, guinea pigs and non-human primates demonstrate lifelong changes 
in offspring HPA axis regulation (Hauser et al., 2007, Levitt et al., 1996, Sloboda et al., 2002, 
Sloboda et al., 2007). Furthermore some studies have shown an association between this altered 
HPA axis regulation and change in glucocorticoid receptor expression in pituitary, hypothalamus 
and hippocampus in the adult offspring (Banjanin et al., 2004, Liu et al., 2001, Sloboda et al., 
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2008). It seems that the long-term consequences on offspring HPA axis, of prenatal exposure to 
synthetic glucocorticoids depend on the sex of the offspring; females appear more resistant than 
males (Seckl and Holmes, 2007, Liu et al., 2001). Furthermore, as in prenatally stressed rats, the 
offspring of rats given synthetic glucocorticoids in pregnancy display an increase in depressive 
and anxious behaviour (Oliveira et al., 2006). Moreover, effects on health-related physiology, for 
example glucose intolerance in adulthood (Nyirenda et al., 1998) also persist to the next 
generation (Drake et al., 2005). To summarise, just like the effects of prenatal stress, 
administration of synthetic glucocorticoids causes alterations in offspring HPA axis, behaviour and 
brain development and health-related physiology. 
 
1.5.2.3.3 Placental 11β-HSD-2 
Having established that prenatal stress and maternal or synthetic glucocorticoids have similar 
programming effects on offspring, attention must turn to the pathway from these factors to the 
effects in offspring. The first step concerns 11β-HSD-2, a placental ‘barrier’ to maternal cortisol. 
Pharmacological inhibition of 11β-HSD-2 in pregnant rats results in high exposure of the foetus to 
CORT; these offspring resemble prenatally stressed rats with overactivity of the HPA axis and 
depressive and anxious behaviours (Welberg et al., 2000). Furthermore prenatal stress may alter 
the expression and activity of 11β-HSD-2 (Mairesse et al., 2007). Much information about the 
effects of alterations in 11β-HSD-2 have been gleaned from genetic manipulation of 11β-HSD-2 in 
mice, and 11β-HSD-2 has been proposed as a ‘hub’ for developmental programming (reviewed 
by (Cottrell et al., 2014)).  
 
1.5.2.3.4 Glucocorticoid receptors (GR) 
The next step is to elucidate the pathway from increased foetal exposure to glucocorticoids to 
alterations in offspring HPA axis, behaviour and health. Glucocorticoids reaching the foetal brain 
affect areas with high levels of GR and MR, such as hippocampus and hypothalamus, these are 
areas critical in the regulation of the HPA axis via CRH. Studies in rodents have shown, in 
addition to programming effects in offspring, a marked reduction in hippocampal GR expression in 
association with glucocorticoid exposure or prenatal stress (Levitt et al., 1996, McCormick et al., 




Lastly, animal research establishes epigenetics as a likely molecular mechanism for programming 
effects. Epigenetics refers to the reversible regulation of gene expression mediated principally 
through changes in DNA methylation and/or chromatin structure; epigenetic processes are 
developmentally regulated and relatively dynamic and thus are a route by which the environment 
may alter gene expression.  
 
Epigenetic alterations have been demonstrated in the hypothalamus of prenatally stressed when 
compared with control adult male mice; reduced DNA methylation in the promoter region of the 
CRH gene and increased methylation in the promoter region of the NR3C1 (GR) gene; there were 
correlated changes in the expression of these genes in addition to group differences in 
behavioural and HPA axis response to stress (Mueller and Bale, 2008).  Similarly alterations in 
global methylation were identified following prenatal administration of glucocorticoids in guinea 
pigs (Crudo et al., 2012). An epigenetic effect of early (a period corresponding to the 3rd trimester 
of pregnancy in humans) maternal care in rats has also been demonstrated. Compared to adult 
offspring exposed to low levels of early maternal care behaviours, those exposed to high levels 
displayed differences in DNA methylation at the exon 17 GR promoter in hippocampus in addition 
to increased expression of hippocampal GR gene (NR3C1) and blunted HPA axis stress 
responsiveness (Weaver et al., 2004). 
 
1.5.2.4 Animal studies conclusion 
In conclusion, many, but not all animal studies have shown that raised levels of maternal 
glucocorticoids can lead to permanent changes in foetal neuroendocrine development changing 
the ‘set-point’ of the offspring HPA axis (Reynolds, 2013), resulting in alterations in development 
and function of brain areas such as amygdala and hippocampus, in behaviours including 
depression-like and anxious behaviours and in health-related physiology, as described in sections 
1.5.2.2 to 1.5.2.2.4 above. It is clear that there are sex differences in the effects (Weinstock, 
2011, Glover and Hill, 2012) and the timing, duration and intensity of prenatal stress or 




1.5.3 Studies in humans   
As described in section 1.5 above, robust evidence regarding the phenomenon of developmental 
origins of disease exists in humans. A variety of chronic disorders in adulthood, for example 
cardiovascular disease, obesity and increased insulin resistance are attributed, in part, to 
developmental programming (Reynolds, 2013); and evidence accrued over the past two decades 
points to maternal glucocorticoid excess as a mechanism for this phenomenon. Since the HPA 
axis and depression in pregnancy are the focus of this thesis, and depression can be 
conceptualised as a form of chronic stress, the current evidence on these factors as they pertain 
to developmental programming in humans is now presented. 
 
1.5.3.1 Stress in pregnancy and developmental programming  
Studies aimed at understanding processes underlying developmental programming in humans 
have, thus far, generally focussed on the umbrella term ‘prenatal stress’. This term encompasses 
symptoms of anxiety, pregnancy-specific anxiety, daily hassles, depression symptoms and 
exposure to life events including severe natural disasters or terrorist attacks. 
 
1.5.3.1.1 Prenatal stress and offspring HPA axis  
To date there are relatively few studies published on this topic in humans. Interpretation is limited 
as a variety of methodologies have been employed, most have quite small numbers of subjects 
and these studies have not yet been replicated. The diverse types of ‘prenatal stress’, described 
above, have been rated by a variety of instruments and at differing gestational ages (Nast et al., 
2013). Further variety exists both in the method of offspring HPA axis assessment, for example, 
basal or diurnal saliva cortisol samples, cortisol and ACTH response to a stressor; and in the 
timing of HPA axis assessment, ranging from 1 week postnatal to young adulthood. Despite these 
limitations which hamper a general interpretation, these types of study, reviewed by Glover 
(Glover et al., 2010), Hunter (Hunter et al., 2011)  and Pearson (Pearson et al., 2015) have 
generally found an association between prenatal stress and offspring HPA axis, specifically 




1.5.3.1.2 Prenatal stress and offspring behaviour and cognitive function 
A number of studies have shown an effect of maternal prenatal self-reported anxiety or other 
stressors on many facets of offspring behaviour, including infants with increased crying/fussing 
(Wurmser et al., 2006) and decreased attention regulation and temperamental difficulty (Huizink 
et al., 2002), toddlers with impaired intellectual and language development (Laplante et al., 2004, 
Bergman et al., 2007), 4-year-olds with behavioural or emotional problems (O'Connor et al., 
2002b), 6-year-olds with reduced attention (Gutteling et al., 2006) and school marks (Niederhofer 
and Reiter, 2004), children and adolescents with emotional problems, attention deficit or 
hyperactivity (Van den Bergh and Marcoen, 2004). Clearly, there are a variety of behavioural 
outcomes; these may depend on the gestational stage at which stress occurred (Glover et al., 
2010). Furthermore, in contrast to that in rodents, study of the role of genetics and postnatal 
environment in the development of behavioural outcomes in humans is less advanced. None-the-
less, there are data, including a large and elegantly designed study of IVF offspring, either 
related, or not related to the mother (Rice et al., 2010). Their findings, in the 4-10-year-old 
offspring, suggested that prenatal stress determined antisocial behaviour; but postnatal, as 
opposed to prenatal maternal symptoms accounted for offspring anxiety symptoms. However, 
others found that offspring anxiety was not dependent on postnatal maternal mood (O'Connor et 
al., 2002b, O'Connor et al., 2002a, Bergman et al., 2007, Van den Bergh and Marcoen, 2004).  
 
1.5.3.2 Depression in pregnancy and developmental programming  
Although the relatively small number of studies of the broad term prenatal stress and 
developmental programming inform on the potential impact of antenatal depression on 
developmental programming, those specifically concerning antenatal depression are fewer. 
However, it is an area of importance as depression is common in pregnancy, is recognised to be 
associated with adverse obstetric outcomes (which are also associated with developmental 
programming) and is a condition readily diagnosed and treated, thus providing an opportunity for 
intervention. Since this is a principal focus of this research, antenatal depression and 
developmental programming are now considered. 
 
1.5.3.2.1 Antenatal depression and offspring HPA axis 
To date, there is one published prospective study of exposure to operationally defined depression 
in utero and offspring HPA axis. Field et al. (2010) looked at the effects of depression and anxiety 
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on pregnancy and neonatal outcome. They compared four groups; healthy controls (n=345), 
SCID diagnosis of comorbid depression and anxiety (n=308), depression alone (n=181) and 
anxiety alone (n=77); cortisol was measured in the urine of their 1 to 2 day-old neonates. 
Compared with neonates of both the healthy and anxiety alone groups, cortisol was higher in 
neonates of both the comorbid and the depression alone groups. However, although the study 
benefits from a large sample size, it was hampered by a number of limitations, for example, no 
account was taken of PTB, birth weight (significant group differences were reported for both these 
factors), gestational age at birth, mode of delivery or maternal factors, including, antidepressant 
use. Furthermore, the focus of the studies was on which type, or combination of types, of disorder 
had worse outcomes and the concept of developmental programming was not mentioned. 
Moreover, the fact that details of sampling, for example the time of sample collection was not 
reported, suggests that the HPA axis was a subsidiary rather than a major focus of this study 
(Field et al., 2010). 
 
Other published studies of antenatal depression and offspring HPA axis use psychiatric rating 
scale scores rather than operationally defined MDD. Of the current literature, the largest and most 
recent study is that of O’Donnell et al. who used the ALSPAC cohort (described in section 
1.2.4.6.3.3 above). Basal HPA axis activity was assessed by measuring saliva cortisol in 889 15-
year-old adolescents at 4 time-points on up to 3 consecutive days. Maternal self-rated symptoms 
of anxiety (using the Crown Crisp Experiential Inventory (Crown and Crisp, 1966)) and symptoms 
of depression (using the EPDS) had been ascertained in the second and third trimesters of 
pregnancy. The main focus of the study was 3rd trimester anxiety, however, symptoms of 
depression were also analysed. Findings included a modest reduction in cortisol awakening 
response and a flatter diurnal slope of cortisol secretion in the offspring of women with above cut-
off symptoms of depression or anxiety in pregnancy. The effects of these diagnoses were not 
independent of each other but were independent of potential confounding factors such as lifestyle, 
psychosocial and obstetric factors, postnatal anxiety and indicators of adolescent health and 
behaviour. The authors concluded that their study provides strong evidence of an effect of 
maternal antenatal mood on offspring HPA axis (O'Donnell et al., 2013). 
 
Complementing the basal HPA axis examined by O’Donnell et al., HPA axis reactivity was 
assessed in a further study on the ALSPAC cohort. On this occasion the effect of exposure to 
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self-rated symptoms of depression (EPDS) in the third trimester of pregnancy on cortisol 
response to a carbon dioxide (CO2) stress test (a physiological challenge) in 139 of the15-year-
old offspring was examined. Those exposed to high levels of symptoms of depression in the third 
trimester of pregnancy showed a blunted HPA axis response to stress (Vedhara et al., 2012). 
 
In their sample of 116 normal pregnant women and their full-term infants, Davis et al. found no 
correlation between antenatal symptoms of depression, anxiety or stress and cortisol response to 
heel-stick procedure in newborns. However, mean psychological assessment scores were low, 
indicating a psychologically healthy group of subjects (Davis et al., 2011b).  
 
De Brujin et al. did not distinguish between depression and anxiety in their study of in utero 
exposure to these symptoms; they generated mean depression (EPDS) and anxiety scores from 
self-ratings in each trimester, including those with EPDS scores above 12 as depressed. They 
endeavoured to measure basal activity and stress reactivity (to a frustration task) of the HPA axis 
in the toddlers or preschool children of 51 exposed cases and 52 unexposed controls. They 
analysed boys and girls separately and found that, compared to the non-exposed, exposed girls, 
had higher initial, pre- and post- test cortisol; there were no group differences for the boys. The 
exposed girls showed significantly higher cortisol than the exposed boys for the first two cortisol 
samples, but there was no group difference between the non-exposed girls and boys. The 
frustration test did not elicit a cortisol response in either sex, however, although previously shown 
to elicit distress in toddlers (Calkins and Johnson, 1998) this test has not been shown to elicit a 
cortisol response in this age-group. Results were only presented for boys and girls separately, not 
for the whole group (de Bruijn et al., 2009). 
 
In their study of cortisol response to a stress paradigm in 171 6-month-old infants, Brennan et al. 
assessed in utero exposure to depression by retrospectively administered maternal SCID 
interview. MDD in pregnancy and/or postpartum (n=104) predicted to higher infant cortisol 
reactivity to stress (Brennan et al., 2008).  
 
In their small epigenetic study, Oberlander et al. found a correlation between second and third 
trimester symptoms of depression (EPDS score) in pregnancy and increased methylation at a 
nerve growth factor inducible A gene (NGFI-A) binding site of the GR gene, NR3C1. Furthermore, 
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increased methylation was associated with increased saliva cortisol response to stress in the 3-
month-old infants, although association between antenatal depressive symptoms and infant 
stress response was not reported (Oberlander et al., 2008). 
 
In their study of the effect of maternal depression on 69 new-borns up to 2 weeks old, Diego et al. 
showed higher urine cortisol in those born to women with high levels of self-rated symptoms of 
depression (CES-D cut-off score) at both later second trimester and the very early postnatal 
period (Diego et al., 2004). 
 
In a similar study from the same group, Lundy et al. showed higher basal urine cortisol in infants 
(n=35) within 24 hours of delivery in those born to women with high levels of self-rated symptoms 
of depression (CES-D cut-off score) in the third trimester (Lundy et al., 1999).  
 
Lastly, using the ALSPAC cohort, O’Connor et al. (2005) reported a study of prenatal symptoms 
of anxiety and HPA axis activity in 10-year-old offspring (n = 74); however they also reported on 
symptoms of depression in pregnancy. In this study MANOVA established a significant 
association between anxiety at 32 weeks gestation and offspring awakening cortisol, however 
there was no report of a similar analysis with prenatal depression. When antenatal symptoms of 
depression were included as covariates in a regression analysis, symptoms of depression were 
shown to predict lower awakening cortisol but this finding was dismissed as artefact. Furthermore, 
as for the other measures of prenatal mood, depression symptom scores were significantly 
correlated with the rise in cortisol from awakening to 30 minutes. Thus it is difficult to form a 
conclusion about the effect of symptoms of depression from this study, since depression was not 
the principal focus (O'Connor et al., 2005). 
 
In summary, despite the variety of methods by which mood and infant cortisol were assessed and 
the limitations of several of these studies, there is currently evidence to suggest that, as for the 
broader concept of prenatal stress, depression in pregnancy may have a programming effect on 
offspring HPA axis from new-born to adolescence. This thesis addresses the current gap in the 
literature regarding the possible programming effects of operationally defined depression. 
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1.5.3.2.2 Antenatal depression and offspring behaviour, cognitive function and health 
This topic is reviewed in section 1.2.4.6.3 above; to summarize, antenatal depression, or 
symptoms thereof, has been associated with a wide variety of outcomes in offspring, from 
neonates to adolescents. These outcomes include (i) behaviour, ranging from poorer performance 
on NBAS in neonates to symptoms of anxiety, antisocial behaviour, poor attention and depression 
in older offspring, (ii) cognitive function, with developmental delay and (iii) health indicators, with 
higher central adiposity.  
 
1.5.3.3 Mechanisms 
Although not yet elucidated, mechanisms for the phenomenon of developmental programming in 
humans have begun to attract research interest in recent years. The appreciation and synthesis of 
several lines of research lead towards a fuller understanding of mechanisms and are described in 
sections 1.5.3.3.2 to 1.5.3.3.6 below. 
 
1.5.3.3.1 Prenatal stress and/or depression and maternal antenatal HPA axis  
When trying to unravel the potential mechanisms involved in the programming effects of prenatal 
stress or depression, elucidating their biological effect on the pregnant woman is key. Some 
studies have demonstrated an overactive maternal HPA axis in stressed pregnant women 
(Kivlighan et al., 2008, Obel, 2003, Wadhwa et al., 1996), and on balance, the evidence outlined 
in section 1.4.5 above, suggests that the maternal HPA axis is also overactive in depression in 
pregnancy. 
 
1.5.3.3.2 Prenatal exposure to glucocorticoids in humans 
Administration of synthetic glucocorticoids will effect the regulation of the maternal and foetal HPA 
axes. Firstly, some synthetic glucocorticoids freely cross the placenta (Seckl and Holmes, 2007) 
thus the foetus is directly exposed to glucocorticoid, and secondly, in contrast to suppression of 
the HPA axis by synthetic glucocorticoids in the non-pregnant state, administration of synthetic 
glucocorticoids stimulate placental CRH production (see section 1.4.4 above); hence the HPA 
axis is activated (King et al., 2001). 
Evidence for altered offspring HPA axis function in infants exposed to synthetic glucocorticoids in 
utero is largely based on preterm infants and suggests suppression of the cortisol response to 
pain that persists to at least 8 weeks postnatal (Schaffer et al., 2009, Ashwood et al., 2006, Davis 
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et al., 2006, Davis et al., 2004). However, numerous other stressors associated with PTB interfere 
with the interpretation of the effect of prenatal glucocorticoids on infant HPA axis (Grunau et al., 
2005). Yet, one study assessed healthy infants born at full-term, 30 of whom were exposed to a 
single course of betamethasone in utero and 60 who were not so-exposed; they found, in the 
exposed group, a larger cortisol response to the heel-stick procedure (which is performed within 
24 hours of birth, furthermore, gestational age at exposure to betamethasone was negatively 
correlated with size of cortisol stress-response (Davis et al., 2011c). These findings are 
complemented by another study of 209 children born at full term; aged 6-11 years, those exposed 
to synthetic glucocorticoid in utero, showed greater cortisol response to the Trier Social Stress 
Test for children (more pronounced in female offspring), suggesting that the effects may persist in 
the longer term (Alexander et al., 2012).  
 
1.5.3.3.3 Maternal antenatal HPA axis and infant HPA axis  
Some researchers have shown an association of maternal cortisol in pregnancy and infant HPA 
axis measures. For example, in a small longitudinal study maternal cortisol was measured in the 
second trimester of pregnancy. Compared with children of mothers with lower levels of cortisol, 
those of mothers with higher levels of cortisol showed higher cortisol concentrations following 
immunizations aged 3-5 years (n=24) (Gutteling et al., 2004) and in response to starting school 
(n=29) (Gutteling et al., 2005). In a lager study maternal cortisol was measured in 116 women; 
higher maternal cortisol in late second and the third trimester was associated with a larger cortisol 
response to a heel-stick procedure within 24 hours of birth. These findings were independent of 
mode of delivery, prenatal medical history, socio-economic status or child race, sex or birth order 
(Davis et al., 2011b). Finally O’Connor et al. measured cortisol in amniotic fluid in the second 
trimester of 125 uncomplicated pregnancies. Cortisol response to stress was measured in the 
infants at 17 months of age. Those exposed to higher levels of cortisol in utero had higher pre-
stress cortisol levels and a blunted cortisol response to stress (a separation-reunion paradigm); 
again these findings were independent of potential confounding factors. Together these data 
suggest that children’s HPA axis function may be predicted from their antenatal exposure to 
cortisol (O'Connor et al., 2013a). However, correlations across mother and infant HPA axis 
function could be due to traditional genetic transmission (DNA variants), for example, genetic 
influences on infant HPA axis function might be inherited by the offspring from the mother in the 
usual way, leading to correlated biological traits that can manifest as direct genetic effects or be 
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mediated through heritable epigenetic marks. Animal studies have used paradigms, for example 
maternal adrenalectomy, to demonstrate that traditional genetic transmission is not mediating 
offspring HPA axis programming (see section 1.5.2.3.1). Clearly such paradigms cannot be 
employed in human research, however the ‘prenatal cross-fostering’ design used by Rice et al. 
(2010) (described in section 1.5.3.1.2 above) could provide a means of further exploring the 
genes versus environment question. 
 
Of note, placental CRH is another theoretical mechanism by which foetal exposure to 
glucocorticoids might be influenced. Most animal studies of developmental programming use 
rodents, these animals do not have placental CRH, thus placental CRH is not a consideration. 
However, in humans, in contrast to the negative feedback by cortisol on hypothalamic CRH, 
placental CRH secretion is stimulated by cortisol; CRH is secreted directly into the foetal 
compartment, thus bypassing the placental barrier, by 11β-HSD-2, to cortisol. In vitro studies 
demonstrate that CRH has a direct functional effect at the foetal adrenal (reviewed in section 
1.4.4.3 above), however, to my knowledge, there are no studies of maternal CRH in pregnancy 
and offspring HPA axis. The programming effects of CRH on offspring behaviour and 
development are reviewed in section 1.5.3.3.4 below.  
 
1.5.3.3.4 Maternal antenatal HPA axis and infant behaviour and development 
Just as in studies of prenatal stress or depression, which demonstrate an effect on offspring 
behaviour and development (described in section 1.5.3.1.2 above), other studies have 
demonstrated associations between maternal antenatal HPA axis and offspring behaviours. For 
example maternal antenatal cortisol and CRH in the second trimester of pregnancy and infant 
negative reactivity at 2 months of age (Davis et al., 2005, Davis et al., 2007), and antenatal 
cortisol and cognitive development in 1-year-old offspring (Davis and Sandman, 2010). Infants of 
mothers with high versus low levels of cortisol in late pregnancy displayed more crying and 
fussing over the first 5 months of life (de Weerth et al., 2003). Higher cortisol in late pregnancy 




1.5.3.3.5  Placental 11β-HSD-2 
As outlined in section 1.4.4 above, the placental enzyme 11β-HSD-2 inactivates a large 
proportion of maternal cortisol, thus protecting the foetus from glucocorticoid exposure. Evidence 
from animal research lends support to the role of 11β-HSD-2 in developmental programming 
(1.5.2.3.3 above). 11β-HSD-2 is inhibited by glycyrrhizin, which is found in liquorice; this has 
provided some indirect evidence in a region (Finland) where consumption of large amounts of 
liquorice is common. Compared with offspring of those who did not consume liquorice in 
pregnancy, 8-year-old offspring of women who consumed large amounts of liquorice were shown 
to have raised saliva cortisol and impaired cognitive and behavioural development (Raikkonen et 
al., 2009, Raikkonen et al., 2010). Another study demonstrated a negative correlation between 
symptoms of anxiety prior to delivery and placental 11β-HSD-2 mRNA expression (O'Donnell et 




Animal research establishes epigenetics as a plausible molecular mechanism for developmental 
programming and is described in section 1.5.2.3.5 above. To recap, epigenetics refers to the 
reversible regulation of gene expression mediated principally through changes in DNA 
methylation and/or chromatin structure. Epigenetic processes are essential for normal cellular 
development and differentiation, and allow the regulation of gene function through non-mutagenic 
mechanisms. Epigenetic processes are developmentally regulated and relatively dynamic and 
thus are a route by which the environment may alter gene expression. Informed by the animal 
literature in this field, research in humans has begun to provide preliminary evidence for the role 
of epigenetics in the broader field of developmental programming.  For example, adults who were 
exposed to famine prenatally had less DNA methylation of IGF2 (insulin-like growth factor) gene 
than their unexposed siblings (Heijmans et al., 2008). Furthermore increased cytosine methylation 
of an NR3C1 exon 1F (GR) promoter (and decreased GR mRNA) was found in the post-mortem 
hippocampus of suicide victims with a history of abuse in childhood compared with suicide victims 
with no abuse history and with controls (McGowan et al., 2009). Radke et al. demonstrated 
persisting epigenetic changes with increased DNA methylation in the GR promoter in 9-11 year 
old offspring of women who experienced intimate partner violence in pregnancy (Radtke et al., 
2011). Lastly, some studies have shown an association between stress or depression in 
88 
pregnancy, and epigenetic differences in genes involved in the regulation of the HPA axis (see 
the examples below). One study of prenatal stress demonstrated a positive correlation between 
stress and NR3C1 promoter methylation in cord blood DNA (Mulligan et al., 2012). Specifically 
considering antenatal depression, some small studies have shown an association between 
severity of symptoms of depression in pregnancy and epigenetic differences in genes involved in 
the regulation of the HPA axis. An association between methylation of the GR gene (NR3C1) in 
cord blood DNA and severity of symptoms of depression in the second or third trimester of 
pregnancy is reported (Oberlander et al., 2008) and a similar finding in buccal cells of 2-month old 
male, but not female, infants (Braithwaite et al., 2015). Furthermore, in the study of Oberlander et 
al., the increased methylation of NRC31 was also associated with increased cortisol response to 
stress in infants at 3 months of age, and the methylation status of this gene was thus 
hypothesised as a mediating factor linking prenatal maternal mood and infant HPA axis activity 
(Oberlander et al., 2008). Conversely, Schroeder et al. (2012) explored the association between 
maternal psychiatric illness and treatment during pregnancy and neonatal DNA methylation 
patterns in a prospective study of 201 dyads; they found no large effects on neonatal DNA 
methylation. While this cannot exclude a role for environmental factors on neonatal methylation, it 
is consistent with there being no strong or global environmental effects on foetal methylation 
profiles caused by psychiatric illness or psychotropic drugs, although these could be uncovered 
by larger or more comprehensive epigenetic studies (Schroeder et al., 2012). Interestingly, Teh et 
al. (2014) demonstrated the importance of gene x environment interactions on the epigenome in 
their study of genotype and DNA methylomes in the cord blood of 237 neonates whose in utero 
environment had been phenotyped (including symptoms of depression and by other factors know 
to influence a range of developmental outcomes). They concluded that genotype explained 
approximately 25% of differences in methylation of the epigenome, but the interaction of genotype 
and the in utero environment explained the remaining 75% of differences. Accordingly, they 
suggest that in order to avoid underestimating the impact of the environment, studies of the 
influence of the in utero environment on subsequent disease risk should also assess the extent to 




1.5.3.3.7 Human studies conclusion 
A solid evidence base demonstrates, in humans, that exposure to an adverse prenatal 
environment is associated with chronic disease in adulthood.  Although it is a relatively new 
research field in humans, the pursuit of an understanding of the mechanisms for this 
developmental programming is underway. This quest is much informed by the more advanced 
findings from animal experiments, which demonstrate that foetal exposure to glucocorticoids 
mediates the effect of prenatal stress on offspring HPA axis, and molecular mechanisms for this 
mediation may be epigenetic in nature. In humans, prenatal stress, which includes studies of 
depression, is a paradigm by which the mechanisms for developmental programming may be 
further studied and understood. Although these mechanisms are likely to be complex and multi-
faceted, it seems likely that exposure of the foetus to high levels of glucocorticoids is key and 
effects on subsequent HPA axis regulation, behaviour, cognitive function and physical health of 
the offspring result. Epigenetic mechanisms are postulated to underlie the process of 
developmental programming, however, this line of research in antenatal depression is in its 
infancy. Lastly, to date, studies of antenatal depression have not incorporated the measures of 
maternal antenatal HPA axis that would facilitate examination of potential pathways to altered 
offspring HPA axis.  
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1.6 Principal research questions  
 
1.6.1 Antenatal depression and the maternal HPA axis in pregnancy 
As detailed in section 1.4.5 above, evidence regarding the association of antenatal depression 
and maternal HPA axis is limited. Only a minority of these type of studies are of operationally 
defined MDD according to a diagnostic instrument; furthermore, few measure more than one 
index of the HPA axis across different stages of gestation with adequate control for potential 
confounding factors, thus further study is warranted. On balance, as in MDD outside of 
pregnancy, the evidence is suggestive of overactivity of the HPA axis, particularly evening and 
diurnal cortisol and CRH. The evidence regarding awakening cortisol, CAR and post-awakening 
cortisol in antenatal depression is limited, however, it is reasonable to hypothesise that findings in 
pregnant depressed women will mirror the differences found in these measures in non-pregnant 
depressed v controls, since that appears to be the case for evening and diurnal cortisol, which 
have been better-studied. Thus, my hypotheses regarding awakening cortisol and CAR are 
formulated with the additional consideration of HPA axis findings in depression outside of 
pregnancy (i.e. increased morning cortisol in a meta analysis (Knorr et al., 2010), increased post-
awakening cortisol (AUCg) (Vreeburg et al., 2009), and increased CAR indexed by change in 
cortisol between waking and +30 minutes (Dienes et al., 2013), and a larger increase in cortisol 
between awakening and +30 minutes measured in pregnant women compared with the same 
women in the non-pregnant state (de Weerth and Buitelaar, 2005). 
 
1.6.1.1 Hypotheses 
1.6.1.1.1 Compared with healthy pregnant women, those with operationally defined MDD will 
have higher CRH at 25 weeks gestation. 
1.6.1.1.2 Compared with healthy pregnant women, those with operationally defined MDD will 
have lower CRHBP at 25 weeks gestation. 
1.6.1.1.3 Compared with healthy pregnant women, those with operationally defined MDD will 
have higher total (serum) cortisol at 25 weeks gestation. 
1.6.1.1.4 Compared with healthy pregnant women, those with operationally defined MDD will 
have higher free (saliva) cortisol at 25 and 32 weeks gestation, indexed by: 
Raised awakening cortisol  
Raised evening cortisol   
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Raised total daily cortisol secretion 
Elevated CAR (AUCi) and post-awakening cortisol (AUCg) 
 
1.6.2 Antenatal depression and pregnancy outcome 
As described in section 1.2.4.6.2 above, evidence regarding the effect of antenatal depression on 
obstetric outcome is limited. There have been 2 meta-analyses of antenatal depression and PTB 
and LBW, which included 1 each of IUGR/SGA, birth weight as a continuum and length of 
gestation. The majority of published studies are not of operationally defined MDD according to a 
diagnostic instrument; moreover, much of the data are from studies with methodological 
weaknesses. This study will contribute to the small amount of evidence derived from studies of 
operationally defined MDD and obstetric outcome; furthermore potential confounding factors such 
as maternal smoking, use of illicit drugs and alcohol, medication, medical conditions, age, pre-
pregnancy BMI, pregnancy factors and physical health, are controlled for providing a 
methodologically robust design.  
 
1.6.2.1 Hypotheses 
1.6.2.1.1 Compared with healthy pregnant women, those with operationally defined MDD will 
have a higher rate of PTB, LBW and SGA babies and a shorter length of gestation. 
 
1.6.3 Maternal HPA axis in pregnancy and pregnancy outcome 
As described in section 1.4.4.4 above, previous studies have demonstrated that maternal HPA 
axis measures in pregnancy are correlated with obstetric outcome. For example shortened length 
of gestation and/or PTB have variously been associated with elevated CRH, elevated cortisol, a 
larger CAR in later pregnancy and decreased attenuation of CAR over pregnancy.  
 
1.6.3.1 Hypothesis 
1.6.3.1.1 HPA axis measures (CRH, CRHBP, awakening, evening and diurnal cortisol secretion, 
CAR and post-awakening cortisol) will be correlated with obstetric outcomes (PTB, 
length of gestation, LBW and SGA). 
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1.6.4 Antenatal depression, maternal HPA axis and pregnancy outcome 
As described in sections 1.2.4.6.2 and 1.4.5 above, although antenatal depression is associated 
with adverse obstetric outcomes, and furthermore, the presence of an overactive HPA axis in 
antenatal depression is suggested, there are no studies of operationally defined antenatal 
depression and the role of the HPA axis in obstetric outcome. 
 
1.6.4.1 Hypothesis 
1.6.4.1.1 The maternal antenatal HPA axis is a mediator or moderator in the pathway from 
antenatal depression to pregnancy outcome. 
 
1.6.5 Antenatal depression and offspring HPA axis 
As described in section 1.5.3.2.1 above, to date there is only one published prospective study of 
exposure to operationally defined depression in utero and offspring HPA axis, it seems this study 
was not designed to investigate developmental programming of offspring HPA axis and has a 
number of important limitations. Studies of depressive symptoms in pregnancy and offspring HPA 
axis have found a reduction in cortisol awakening response, a flatter diurnal slope of cortisol 
secretion and a blunted HPA axis response to stress in 15 year-old offspring; higher pre and post 
stress test cortisol in female pre-school or toddlers and higher urine cortisol in new-borns. In 
summary, despite the limitations, there is currently evidence to suggest that, as for the broader 
concept of prenatal stress, symptoms of depression in pregnancy may have a programming effect 
on offspring HPA axis from new-born to adolescence. This thesis addresses the current gap in the 
literature regarding the possible programming effects of operationally defined depression. 
 
1.6.5.1 Hypotheses 
1.6.5.1.1 Antenatal depression and offspring HPA axis at 8 weeks postnatal 
1.6.5.1.1.1 Compared with those not exposed, 8-week-old infants exposed to MDD in utero will 
have a larger saliva cortisol response to pain stress. 
1.6.5.1.1.2 Compared with those not exposed, 8-week-old infants exposed to MDD in utero will 
have higher basal saliva cortisol levels  
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1.6.5.1.2 Antenatal depression and offspring HPA axis at 1 year postnatal 
1.6.5.1.2.1 Compared with those not exposed, 1-year-old infants exposed to MDD in utero will 
have a larger saliva cortisol response to pain stress. 
1.6.5.1.2.2 Compared with those not exposed, 1-year-old infants exposed to MDD in utero will 
have higher basal saliva cortisol levels  
 
1.6.6 Antenatal depression, maternal HPA axis in pregnancy and offspring HPA axis 
As described in sections 1.5.3.3.3 and 1.5.3.2.1 above, although some studies have shown an 
association between maternal cortisol levels in pregnancy and offspring HPA axis function, and 
furthermore, studies of depressive symptoms in pregnancy suggest an effect on offspring HPA 
axis, there are no studies of operationally defined antenatal depression and the role of the 
maternal HPA axis in offspring HPA axis function. 
 
1.6.6.1 Hypotheses 
1.6.6.1.1 Antenatal depression, maternal HPA axis in pregnancy and offspring HPA axis at 8 
weeks postnatal 
1.6.6.1.1.1 Maternal antenatal HPA axis measures will be correlated with offspring HPA axis 
measures at 8 weeks postnatal. 
1.6.6.1.1.2 The maternal antenatal HPA axis is a mediator or moderator in the pathway from 
antenatal depression to offspring HPA axis at 8 weeks postnatal. 
 
1.6.6.1.2 Antenatal depression, maternal HPA axis in pregnancy and offspring HPA axis at 1 year 
postnatal 
1.6.6.1.2.1 Maternal antenatal HPA axis measures will be correlated with offspring HPA axis 
measures at 1 year postnatal. 
1.6.6.1.2.2 The maternal antenatal HPA axis is a mediator or moderator in the pathway from 





Chapter 2  METHODOLOGY
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2.1 Design 
This thesis describes a prospective longitudinal observational study designed to test the 
hypotheses described in section 1.6 above. A control group of healthy pregnant women, and their 
offspring, were compared with a cases group of women with a DSM-IV diagnosis of MDD in 
pregnancy, and their offspring up to one year postnatal. A schematic of the study schedule is 
presented in Figure 7. 
 
The number of subjects varies for some of the measures, as the protocol was revised part way 
through the study in order to improve the protocol, in terms of procedure and measures, and to 
improve subject recruitment. Thirty-six subjects (control n = 25 and case n = 11) were assessed 
within the original (‘pilot’) protocol and 46 subjects (control n = 21 and case n = 25) were 
assessed within the second (‘main’) protocol, without overlap. A list of differences (in the inclusion 
and exclusion criteria, the recruitment process and the some aspects of the study procedure) is 
presented in Table 47, Appendix A. 
 
2.1.1 Contribution of work by the candidate 
The original research idea is attributable to Dr Veronica O’Keane (former head of the Section of 
Perinatal Psychiatry, Institute of Psychiatry, KCL). With Dr O’Keane’s guidance I was responsible 
for the set-up and conduct of the study. This included writing the study protocol, preparing the 
documents for Research Ethics and Research and Development and administration of matters 
pertaining to these boards throughout the study. 
I wrote and compiled the assessment schedules. Following liaison with the scientists who were to 
perform the different analyses of biological samples, I wrote the protocols for handling and 
processing the samples. I coordinated the collection and storage of all the biological samples 
throughout the study. I performed all the venepuncture for the original protocol, processed these 
samples and stored the plasma and serum. I set up and managed the Human Tissue Act (HTA) 
log for all biological samples and located samples and arranged transport for the analyses that 
were performed outside of our own laboratory. I inspected all of the results of analyses of the 
biological samples and determined which were suitable to use in the data analyses. 
Using the pilot protocol I undertook all recruitment, baseline and 8 weeks postnatal assessments. 
I was not able to perform many of the 1-year postnatal assessments due to my maternity leave; 
however, I trained a colleague to do the assessments in my place and reviewed all of the data on 
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return from my leave. The neonatal examination (NBAS) was performed by my colleague Dr 
Susan Pawlby and the infant development (Bayley) assessment was performed by my colleague 
Ms Susan Conroy. Biological samples were analysed by laboratory colleagues as described in 
section 2.4.2.3 below. 
Following the appointment of my first supervisor, Dr Carmine Pariante, as the new head of 
Section of Perinatal Psychiatry, I contributed to the revision of the protocol in 2010, and was 
responsible for training and supervising new researchers who also helped in data collection. I 
continued to undertake the clinical assessments within the second protocol and, where others 
performed them, I personally reviewed all diagnostic interviews with that researcher. My colleague 
Susan Conroy and I designed the databases and undertook the data entry. I cleaned all of the 
databases, coded the variables and performed all of the data analyses. 
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2.2 Ethical considerations 
The study was granted a favourable opinion by King’s College Hospital Research Ethics 
Committee (ref. 07/Q0703/48). Approvals were also obtained from Research and Development 
Committees at King’s College Hospital and South London and Maudsley NHS Trusts. Participants 
provided written informed consent for themselves and their offspring. 
 
2.3 Participants 
Participant recruitment took place at King’s College Hospital, London between 2007 and 2012 
and subject follow-up was completed in 2013. 
2.3.1 Selection criteria 
2.3.1.1 Inclusion criteria 
2.3.1.1.1 All participants 
• Adult women between 18 and 45 years of age 
• Singleton pregnancy 
• In late second or early third trimester  
2.3.1.1.2 Cases 
• DSM-IV diagnosis of Major Depressive Disorder in pregnancy (prior to or at baseline) 
2.3.1.2 Exclusion criteria 
2.3.1.2.1 All participants 
• Uterine anomaly 
• Known obstetric complications in the index pregnancy 
• Severe or relevant chronic medical conditions for example cardiovascular disease, 
metabolic or endocrine disorder 
• Substance misuse 
• Unable to communicate in English 
2.3.1.2.2 Controls 
• Current or past DSM-IV axis I diagnosis 
2.3.1.2.3 Cases 
• Any current DSM-IV diagnosis (other than MDD  & anxiety disorder) 
• History of psychosis or bipolar affective disorder 
• Taking antidepressant medication at baseline 
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2.3.1.3 Rationale for selection criteria 
An upper age limit of 45 years was set, as the risk of maternal and foetal complications increases 
with increasing maternal age. This upper limit was required in order to balance recruitment of 
sufficient numbers with the increased obstetric risk with higher maternal age; incidence of 
advanced maternal age has increased in recent years but ≥45 years is currently considered, in 
the obstetric literature, as ‘very advanced maternal age’. 
Uterine anomaly, obstetric complications and a multiple pregnancy were all exclusion criteria as 
these factors are associated with an increased risk of PTB.  
Participants were recruited in the late second or early third trimester of pregnancy based on 
previous pilot work (O'Keane et al., 2011) which did not find group differences in HPA axis 
measures earlier in pregnancy, but allowed HPA axis quantification at two distinct time points in 
later pregnancy. 
Since this was a study of MDD in pregnancy, cases were required to have met DSM-IV criteria for 
MDD in the index pregnancy, and for appropriate comparison, controls were required to be free 
from lifetime psychiatric disorder. Ideally cases would not have experienced any lifetime DSM-IV 
axis I diagnoses other than MDD, but this ideal was balanced with the practicalities of finding such 
participants, however, those with a history of severe mental illness (psychosis or bipolar affective 
disorder) were excluded. 
The use of antidepressant medication at recruitment was an exclusion criterion as it has been 
associated with adverse obstetric outcome and furthermore, may affect activity of the HPA axis. 
Severe or relevant chronic medical conditions were exclusion criteria because of a link with 
obstetric complications and/or with HPA axis activity.  
Finally participants were excluded if they were not able to comply with the study protocol because 
of an inability to communicate adequately in English. 
 
2.3.2 Method of selection 
2.3.2.1 Controls 
A convenience sample of controls was identified from women attending for routine antenatal 
anomaly ultrasound scan at King’s College Hospital. 
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2.3.2.2 Cases 
A convenience sample of cases was identified from midwife and GP referrals to the Perinatal 
Psychiatry Service of South London and Maudsley NHS Foundation Trust, based at King’s 
College Hospital (KCH). 
 
2.3.3 Recruitment process 
The recruitment process for the main protocol is described; the process did not differ substantially 
between pilot and main protocols. 
2.3.3.1 Controls 
2.3.3.1.1 Recruitment strategy 
The recruitment of controls was achieved by the weekly attendance of a researcher at the 
antenatal ultrasound department at KCH.  
 
2.3.3.1.1.1 Step 1 
The ultrasound list for routine anomaly ultrasound scans was used to identify women’s names 
and to check that they met the inclusion criteria of maternal age, gestational age and singleton 
pregnancy. Furthermore, since KCH is a regional centre for ultrasound scans, it ensured that the 
woman to be approached was booked for antenatal care at KCH. Women were approached in the 
ultrasound department whilst waiting for, or following, their scan. A recruitment script was used to 
ensure uniformity in the recruitment process. The researcher called out the woman’s name, and 
the contact began by the researcher giving a brief introduction of themselves and explanation for 
the approach. Women who were prepared to engage further were then provided with a more 
detailed description of the study and were given the opportunity to ask questions. If they were 
prepared to consider participation further, they were provided with a concise colour pamphlet 
about the research and a more detailed ‘Patient Information Sheet’ and they provided the 
researcher with a contact telephone number. Lastly all women approached were asked to provide 
some details confidentially (postcode, age, parity and ethnicity) in order to examine how those 
who ultimately did participate compared to the sample population.  
 
2.3.3.1.1.2 Step 2 
The next stage in recruitment of controls took place within a few days of the initial contact and 
entailed a telephone call, from the same researcher, to the potential participant. Again a script 
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was used; having ascertained that the woman was still interested in participating in the research, 
they were asked a series of questions regarding the inclusion and exclusion criteria (medical 
disorders, medication, any known problems with the pregnancy and mental health screening). At 
this stage an appointment was made for the baseline assessment if appropriate, alternatively they 
were told that they could not be included and were given the reason. 
 
2.3.3.1.2 Recruitment effectiveness and representativeness 
The effectiveness of recruitment of controls was recorded with the total number of women who 
were screened and approached, those who refused to participate, those who subsequently could 
not be contacted, and those who were ultimately included. Of the 186 women screened and 
approached, 11% were included in the study as controls (see Table 4). To ascertain if those who 
were ultimately included were representative of women who were eligible to participate, the 
groups were compared on ethnicity, age, parity and IMD1. 
Compared with women who were included in the study, those who refused or were not 
contactable following the initial approach did not differ significantly in age (z = -1.8, p = .07), parity 
(z = -0.4, p = .67), ethnicity (χ2(1) = 3.3, p = .07), or IMD quintiles (χ2(4) = 5.2, p = .27). 
 
2.3.3.1.2.1 Recruitment representativeness for controls within the pilot protocol 
The total number of women who were screened and approached was not recorded for the pilot 
protocol; therefore to gauge the representativeness of these subjects, control women recruited 
within the pilot protocol were compared with those recruited within the main protocol. 
Compared with women who were included in the study within the main protocol, those who were 
included in the study within the pilot protocol did not differ significantly in age (t(44) = 0.4, p = .73), 
parity (z = -0.0, p = .97), ethnicity (χ2(1) = 0.1, p = .76), or IMD quintiles (χ2(2) = 4.2, p = .12). 
 
 
                                                       
1 Index of Multiple Deprivation (IMD) was derived from the woman’s postcode using an online tool  (which 
uses the Ordnance Survey Code-Point Open Feb 2013 and the Office of National Statistic Indices of Mass 
Deprivation 2010) from the National Perinatal Epidemiology Unit (NPEU) (http://tools.npeu.ox.ac.uk/imd/). 
The scores, reflecting socio-economic factors, are divided into quintiles representing the level of deprivation 
(1 (≤8.49 (least deprived)), 2 (8.5 – 13.79), 3 (13.8 – 21.35), 4 (21.36 – 34.17), 5 (≥ 34.18 (most deprived))). 
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Table 4: Recruitment effectiveness and representativeness for controls 
CONTROLS  Subjects 
approached 
 




 (n = 96, 52%) 
Met ≥1 exclusion 
criteria2  
 




(n = 21, 11%) 
 Included in 
pilot protocol 
 
(n = 25) 
Age (years), M (SD) 30.3 (5.9) 29.6 (5.5) 30.6 (6.7) 32.3 (5.0)  32.4 (3.8) 
Parity, M (SD)  0.8 (1.0) 0.8 (0.9) 0.8 (1.0) 0.7 (0.9)  0.6 (0.6) 











 80.0 (20) 
20 (5) 
Index of multiple deprivation       
 IMD quintile 1 (least deprived), %  (n) 
 IMD quintile 2, %  (n) 
 IMD quintile 3, %  (n) 
 IMD quintile 4, %  (n) 
 IMD quintile 5 (most deprived), %  (n) 
3.2 (6) 
2.7 (5) 























                                                       
1 Reasons for refusal included too busy, and not interested. 
2 The exclusion criteria included age, English not adequate, previous mental health problem, twin pregnancy, medication and medical problem 
3 Ethnicity data was not available on all the women who were screened (all subjects screened n = 185, refused or not contactable n = 95) 
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2.3.3.2 Cases 
2.3.3.2.1 Recruitment strategy 
The recruitment of cases was achieved by the weekly attendance of a researcher at the referrals 
meeting of The Department of Perinatal Psychiatry of South London and Maudsley NHS 
Foundation Trust, held at KCH.  
 
2.3.3.2.1.1 Step 1 
At this meeting a researcher screened all referrals in collaboration with the clinical team. A record 
was kept of any potential participant who was thought may be depressed, and also met the 
inclusion criteria of maternal age, gestational age and a singleton pregnancy. If the referral was 
accepted to Perinatal Psychiatry and the appointment with a clinician was to occur before the 
woman would be 25 weeks gestation the researcher liaised with the responsible clinician about 
seeing the woman after her appointment in order to discuss the study or where this was not 
possible asking the clinician to obtain permission from the patient for the researcher to contact 
them by telephone. If the appointment with a clinician was to occur beyond 25 weeks gestation, 
the woman did not attend her appointment or the referral was not accepted to the service, then 
the researcher made telephone contact and used the recruitment script as for controls (described 
in section 2.3.3.1.1.1 above). In order to maximise recruitment of cases, if it was not possible to 
make telephone contact, a letter was sent to that individual providing information about the reason 
for contact and a date that the researcher would visit to discuss the research. If the woman was 
not at home for that appointment an explanatory letter was left giving a contact number and 
inviting the woman to make contact should she wish. These attempts to recruit cases were 
abandoned after the woman reached 30 weeks gestation. 
 
2.3.3.2.1.2 Step 2 
When a researcher was able to make contact with a potential recruit, having established that they 
were interested in participating in the research, as for controls, they were asked a series of 
questions regarding the inclusion and exclusion criteria (medical disorders, medication, any 
known problems with the pregnancy and mental health screening). At this stage an appointment 
was made for the baseline assessment if appropriate, alternatively they were told that they could 
not be included and were given the reason. 
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2.3.3.2.2 Recruitment effectiveness and representativeness 
As with controls, the effectiveness of recruitment of cases was recorded with the total number of 
women who were screened and approached, those who refused to participate, those who could 
not be contacted, and those who were ultimately included. Of the 243 women screened and 
approached, 10% were included in the study as cases (see Table 5). 
To ascertain how those who were ultimately included were representative of women who were 
eligible to participate, the groups were compared on ethnicity, age, parity and IMD.  
Compared with women who were included in the study, those who refused or were not 
contactable following the initial approach did not differ significantly in age (z = -1.2, p = .19), parity 
(z = -0.9, p = .39), ethnicity (χ2(1) = 2.2, p = .14) or IMD quintiles (χ2(3) = 4.5, p = .21). 
 
2.3.3.2.2.1 Recruitment representativeness for cases within the pilot protocol 
As with controls, the total number of women who were screened and approached was not 
recorded for the pilot protocol; therefore to gauge the representativeness of these subjects, cases 
women recruited within the pilot protocol were compared with those recruited within the main 
protocol. 
Compared with women who were included in the study within the main protocol, those who were 
included in the study within the pilot protocol did not differ significantly in age (t(34) = 0.9, p = .39), 






Table 5: Recruitment effectiveness and representativeness for cases 
CASES Subjects screened 
  
(n = 243) 
Refused1 or not 
contactable 
(n = 107, 44%) 
Met ≥1 exclusion 
criteria2  
(n = 111, 46%)   
Included 
 
(n = 25, 10%) 
 Included in 
pilot protocol 
(n = 11) 
Age (years), M (SD) 29.2 (6.2) 28.3 (6.1) 30.0 (6.1) 29.6 (6.3)  32.3 (3.8) 
Parity, M (SD)  1.0 (1.2) 1.3 (1.4) 0.7 (1.1) 0.8 (0.9)  1.2 (0.9) 











 45.5 (5) 
54.5 (6) 
Index of multiple deprivation (IMD)       
 IMD quintile 1 (least deprived), %  (n) 
 IMD quintile 2, %  (n) 
 IMD quintile 3, %  (n) 
 IMD quintile 4, %  (n) 


























                                                       
1 Reasons for refusal included too busy, too unwell, and not interested 
2 The exclusion criteria included English not adequate, no longer pregnant, not depressed (n = 24), history of bipolar affective disorder, medical condition and taking 
antidepressant.  
3 Ethnicity data was not available on all the women who were screened (all subjects screened n = 202, refused or not contactable n=87, met ≥1 exclusion criteria n = 
90)  
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2.3.4 Subject follow-up 
2.3.4.1 Subject retention 
Subject retention details for the follow-up assessments are presented in Table 6. Subject 
retention reduced over the course of the study, furthermore the number providing usable samples 
for measurement of cortisol was fewer than those who were assessed. However, I compared the 
proportion of cases v controls at baseline with the proportion of cases v controls completing each 
follow assessment and there was no statistically significant difference at any time point. 
Furthermore, I compared socio-demographic information for cases in the smallest sets of follow-
up (infant cortisol response at immunization at 8 weeks and at 1 year postnatal) with cases at 
baseline, there were no statistically significant differences. Likewise, I did the same for controls 
and there were no statistically significant differences. This indicates that despite the reduction in 
subject numbers over the course of the study, that compared with baseline there was no 
significant difference in the proportion of cases v controls at each follow-up assessment. 
Furthermore, both the cases group and the controls group at follow-up were representative of 
their respective groups (in socio-demographic factors) at baseline. 
 
2.3.4.2 Equity of follow-up procedures 
Researchers performing the study interviews at baseline and follow-up were not blind to 
caseness. However, all other study measures were performed blind to caseness. Delivery details 
were obtained from obstetric medical notes and so were not subject to researcher bias. Both the 
neonatal examination and the assessment of infant development at 12 months were performed by 
researchers blind to caseness. The laboratory analyses were also performed by technicians who 
were blind to caseness. 
Clinical obstetric management of all subjects was naturalistic and undertaken by NHS staff 
independent of the study. Clinical psychiatric management of cases was also naturalistic and 
undertaken by NHS staff and was not determined by study protocol. 
In an attempt to optimise subject retention over the course of the study for the main protocol, 




Table 6: Subject retention 
Assessment  Controls 
 % (n) 
Cases 
% (n) 
Statistic (proportion of 
cases and controls at 
baseline v follow-up) 
Baseline     
 Interview completed 
 Usable saliva cortisol sample 








χ2(1) = 0.1, p = .76 
χ2(1) = 0.0, p = .95 
32 weeks gestation    
 Psychiatric assessment 





χ2(1) = 0.4, p = .54 
χ2(1) = 0.3, p = .58 
Delivery details    
 100 (46) 100 (36)  
Neonate assessment    
 100 (46) 92 (33) χ2(1) =0.1, p = .78 
8 weeks postnatal    
 Interview completed 
 Usable infant stress response 
 cortisol sample 










χ2(1) = 0.2, p = .62 
χ2(1) = 1.5, p = .21 
 
χ2(1) = 0.3, p = .58 
1 year postnatal    
 Interview completed 
 Usable infant stress response 
 cortisol sample 
 Usable infant basal cortisol 
 sample 
87 (40) 







χ2(1) = 0.4, p = .51 
χ2(1) = 0.5, p = .47 
 
χ2(1) = 0.9, p = .35 
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2.4 Data collection 
2.4.1 Procedure 
A schematic of the study schedule is presented in Figure 7. Briefly, assessments took place in 
pregnancy at 25 and 32 weeks gestation, the neonatal period and at 8 weeks and 1 year 
postnatal. 
 
2.4.1.1 Baseline  
The baseline assessment took place as close as possible to 25 weeks gestation1. According to 
participant preference, assessments were undertaken in the participant’s home or work place, in 
the clinical department of Perinatal Psychiatry, KCH or at the Institute of Psychiatry, KCL. 
Following a verbal reminder about the study and an opportunity for the participant to ask 
questions, written informed consent was obtained prior to any study assessments. 
 
2.4.1.1.1 Participant characteristics 
A semi-structured interview was devised to collect information on socio-demographics, current 
medication, medical history, obstetric history and current health behaviours (see Appendix B) and 
pre-morbid IQ was assessed. 
 
2.4.1.1.2 Psychiatric assessment  
This consisted of a diagnostic interview and assessment of symptom severity according to self-
rated psychiatric rating scale scores. 
 
2.4.1.1.3 HPA axis assessment 
2.4.1.1.3.1 Blood 
Blood was taken and processed in accordance with a blood sampling and processing protocol 
(see Appendix C) in order to measure plasma CRH and CRHBP and serum cortisol. The samples 
were obtained between 12pm and 3pm at the baseline assessment,2 transported to the laboratory 
on ice packs and processed within 2 hours of venepuncture. To process the blood, samples were 
                                                       
1 Mean 26.3, SD 1.6, min. 23.9 to max. 31.7 weeks 
2 When venepuncture was not possible at the baseline assessment the sample was taken 
(between 12 and 3pm) as close as possible to 25 weeks gestation. 
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centrifuged at 1500G at 4°C for 10 minutes. Cryovials were used to store aliquots of plasma and 
serum, which were frozen immediately at -80°C, pending analysis. 
 
2.4.1.1.3.2 Saliva 
Six saliva samples were obtained over the course of one day at baseline: at awakening, 15, 30 
and 60 minutes after awakening, midday and 8pm. Salivettes containing a polymer swab 
(Sarstedt, UK) were used. Subjects were given a demonstration, verbal and written instructions 
and a mechanical timer for sample collection (see protocol in Appendix D and sample collection 
record in Appendix E). Emphasis was placed on the accuracy of timings and procedure. Subjects 
were instructed not to eat, drink or smoke in the first hour after awakening or the thirty minutes 
before sample collection at midday and 8pm. Subjects were asked to complete a collection record 
on which to record sample timings and protocol deviations. Samples were refrigerated by 
participants then posted to the research centre at the beginning of the next working week or were 
collected in person by a researcher. On receipt, samples were checked for completeness against 
the collection record, then frozen at -20°C pending analysis. 
 
2.4.1.2 Thirty two weeks gestation 
This assessment was conducted by telephone and post. 
2.4.1.2.1 Psychiatric assessment  
This consisted of completion of self-rated psychiatric rating scales. 
2.4.1.2.2 HPA axis assessment 
As at baseline, six saliva samples were obtained to measure cortisol levels.  
 
2.4.1.3 Birth of the baby  
Details of the labour, delivery and neonate were obtained from the maternal summary, which is a 
standard electronic document prepared by midwives following the birth of a child in the NHS. In 
cases where this information was not available, for example, a home birth attended by a private 




2.4.1.4 Six days postnatal 
An assessment of neonate behaviour (NBAS) was performed as close as possible to six days 
postnatal1.   
 
2.4.1.5 Eight weeks and one year postnatal 
This assessment was made on the day of the infant’s routine immunizations at 8 weeks and at 1 
year postnatal. 
 
2.4.1.5.1 Participant characteristics 
2.4.1.5.1.1 Maternal 
A semi-structured interview was devised to collect information on any change in maternal socio-
demographics since the previous assessment, current medication and current health behaviours 
(see Appendix F and Appendix G).  
 
2.4.1.5.1.2 Infant 
The same semi-structured interview included questions about the infant including health, 
medication and feeding details. 
 
2.4.1.5.2 Maternal Psychiatric assessment  
As at baseline, the psychiatric assessment consisted of a diagnostic interview (covering the 
period from previous assessment to the current time); assessment of symptom severity according 
to self-rated psychiatric rating scale scores was used to corroborate diagnostic data. 
 
2.4.1.5.3 HPA axis assessment 
2.4.1.5.3.1 Infant 
Infant saliva samples were obtained before and exactly 20 minutes after the routine immunization 
and at awakening and 8pm on the following day (see protocol in Appendix H and sample 
collection record in Appendix I). In almost all cases a researcher accompanied the mother and 
baby to the immunization clinic to ensure accurate procedure and timing for sample acquisition. 
The researcher then took the samples to the laboratory where they were frozen at -20°C. The 
                                                       
1 Mean 9.3, SD 6.4, min. 4 to max. 42 days 
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mother obtained the infant’s saliva samples on the following day having received a demonstration, 
verbal and written instructions. 
Care was taken to avoid feeding for 15 minutes before a sample was taken; the time of the most 
recent feed and nap were recorded. A Salivette and Salimetrics childrens swab (SCS) was used 
to collect saliva by the researcher on the immunization day. For ease of use, a Sorbette arrow 
was used for infant saliva collection the following day. As for mothers, a sample collection record 
was used to record timings and relevant information. 
 
2.4.1.5.3.2 Maternal 
As at baseline, six saliva samples were taken by the participant the day after the infant 
immunizations; cortisol levels were quantified. 
 
2.4.1.6 One year postnatal  
An assessment of infant development (the Bayley Scales of infant development) was performed 











    
Baseline  
(25 weeks gestation) 
32 weeks gestation Birth of the baby / neonatal 
period 
8 weeks postnatal 1 year postnatal 
Maternal clinical assessment Maternal clinical assessment  Maternal clinical assessment Maternal clinical assessment 
Maternal HPA axis assessment Maternal HPA axis assessment  Maternal HPA axis assessment Maternal HPA axis assessment 
  Record of birth outcomes    
  Neonatal behavioural assessment   
   Infant HPA axis assessment Infant HPA axis assessment 
    Assessment of infant development 
Figure 7: Study schedule 
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2.4.2 Measures  
2.4.2.1 Participant characteristics 
2.4.2.1.1 Socio-demographics 
Maternal age was recorded at baseline. 
The following were recorded and coded: 
• Maternal and paternal ethnicities and were described by the participant and coded as ‘white’ 
or ‘black and minority ethnic’ (BME). 
• The level of maternal education, according to participant report, was coded as GCSE or 
Lower and A level or higher.  
• Maternal and paternal employment status was coded according to whether or not they were 
working outside the home. 
• Maternal and paternal classification of employment was determined and coded according to 
the Office for National Statistics (http://www.ons.gov.uk) and a variable created stipulating 
either ‘professional or managerial’ or ‘not professional or managerial.’ 
• Marital status was coded as ‘married or cohabiting’ or ‘single with or without a partner’. 
 
2.4.2.1.2 Premorbid IQ 
Premorbid IQ was assessed at baseline using the Wechsler test of adult reading1 (WTAR) 
(Wechsler, 2001). In this test the subject is presented with 50 irregularly spelled words and 
prompted to pronounce each; the examiner can assess their vocabulary by their ability to 
pronounce the words and thus estimate their premorbid IQ. WTAR scores have been shown to 
correlate highly with measures of IQ (http://www.pearsonclinical.co.uk). Since maternal IQ is 
known to be a strong predictor of offspring IQ (Eriksen et al., 2013, Tong et al., 2007), WTAR was 
performed on the participants in order to control for any group differences found in infant 
development. Measurement of full sale IQ during an episode of depression could potentially affect 
the score (Kessler et al., 2013, Sackeim et al., 1992) and thus be a source of bias between the 
case and control groups; thus an index of IQ in health (premorbid) rather than during an episode 
of illness was required. 
 
                                                       
1 WTAR is valid only for English-speakers indexed by the following: if the participant was born in 
an English-speaking country, remained in an English-speaking country to at least 9 years of age 
and attended an English-speaking school; or if born outside an English-speaking country, 
attended at least 4 years of secondary school in an English-speaking school. 
113 
2.4.2.1.3 Obstetric history and risk factors 
Obstetric history was determined by participant report at baseline. Data included any previous 
pregnancies, parity, history of PTB, miscarriage, elective termination of pregnancy, intrauterine 
death and age at menarche. Current obstetric risk factors were assessed according to problems 
in the index pregnancy including vaginal bleeding, the severity of that bleeding and urinary tract 
infection. These data were recorded at baseline and categorical variables were dichotomized for 
coding. 
 
2.4.2.1.4 Physical health, medication, health indicators and health behaviours 
The following measures were recorded at interview in pregnancy and at 8 weeks and 1 year 
postnatal: 
Information about physical health was obtained by checklist and a variable was created for the 
presence or absence of a chronic medical condition. 
Details of current medication were obtained and a variable was created to indicate whether or not 
the participant was taking regular medication. A second variable was created to indicate whether 
or not the participant was taking antidepressant medication. A third variable was created to 
indicate whether or not the participant was taking any steroid medication, either regular or ‘as 
required’ (PRN).  
Use of tea, coffee, alcohol (dichotomised as ≤2 units/week or above) and cigarettes (in pregnancy 
prior to baseline and current use) were also recorded. 
At baseline pre-pregnancy BMI (height (m) / wt2 (Kg)) was calculated from the height and pre-
pregnancy weight, which was generally reported in the subjects hand-held maternity notes.  
 
2.4.2.2 Mental health 
Maternal mental health was assessed at interview in pregnancy and at 8 weeks and 1 year 
postnatal; self-report questionnaires were used to corroborate diagnostic data. 
 
2.4.2.2.1 Diagnostic assessment  
Current and past DSM-IV axis1 disorders were assessed using the Structured Clinical Interview 
for DSM-IV Axis I Disorders (SCID-I) (First, 1996). 
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2.4.2.2.2 Assessment of symptom severity 
To corroborate DSM-IV diagnosis of MDD, symptom severity was determined at each interview by 
the Beck Depression Inventory. Symptoms of anxiety were also rated, by the State-Trait Anxiety 
Inventory since they are common in MDD. 
 
2.4.2.2.2.1 Beck Depression Inventory 
The Beck Depression Inventory (BDI) is a self-rated instrument which measures the severity of 
symptoms of depression (Beck et al., 1961). The BDI has been widely used in the assessment of 
depressive symptomatology both clinically and in research. Its use has been validated as a 
screening test for depression in the pregnant population (Holcomb Jr et al., 1996, Su et al., 2007). 
The BDI version IA was used for this research, this tool has 21 items each rated 0-3; question 19 
regarding weight loss was omitted, thus the possible range of scores was between 0 and 60. 
 
2.4.2.2.2.2 State-Trait Anxiety Inventory 
The State-Trait Anxiety Inventory (STAI) is a self-rated instrument which measures intensity or 
frequency of a variety of feelings related to anxiety (Spielberger, 1983). It is divided into two 
sections, one measuring ‘state’ (intensity of symptoms) and the other ‘trait’ (frequency of 
symptoms) of anxiety. The STAI form Y (state) was used for this research, each section has 20 
questions scored from 1 to 4, thus the range of possible scores for each section is 20 to 80. The 
STAI has been widely used in perinatal research although there has been little work towards 
validating its use as a diagnostic screen in pregnancy (Meades and Ayers, 2011). 
 
2.4.2.2.2.3 Pro-rating missing data 
If data were missing for a particular scale, pro-rating was used to correct for this, however, where 
≥20% of items were missing, data for the whole scale were coded as missing for that subject.  
 
2.4.2.3 HPA axis assessment 
2.4.2.3.1 CRH 
Plasma CRH was quantified at the pathology laboratory at King’s College Hospital, London using 
a magnetic radioimmunoassay (RIA) kit supplied by Phoenix Pharmaceuticals Inc, California, 




Plasma CRHBP was quantified by Jo Drury, Liverpool Women's Foundation NHS Trust, UK. 
Enzyme-linked immunosorbent assay (ELISA) methodology was used. The Standard operating 
procedure from the lab is detailed in Appendix K. Samples were analysed in duplicate in three 
batches each with an internal control; CRHBP values were thus corrected to minimise inter-assay 
variation. The minimum reliable value was set at 100 pmol/l.  
 
2.4.2.3.3 Serum cortisol 
Serum cortisol, a measure of total cortisol, was quantified at the pathology laboratory at King’s 
College Hospital, London using a magnetic bead ELISA supplied by Siemens Healthcare 
Diagnostics Ltd, Surrey, UK. The Standard operating procedure from the lab is detailed in 
Appendix L. 
 
2.4.2.3.4 Saliva cortisol 
Saliva cortisol, a measure of free cortisol, was quantified by Dr Patricia Zunszain, Stress, 
Psychiatry and Immunology laboratory, KCL using a high sensitivity salivary cortisol ELISA kit 
supplied by Salimetrics Europe Ltd, Suffolk, UK. The Standard operating procedure is detailed in 
Appendix M. Samples were measured in duplicate where an adequate volume of saliva allowed. 
The minimal reliably detectable concentration was set at 0.33 nmol/l and the assay is reliable up 
to 82 nmol/l. The inter-assay co-efficient of variability (CV) ranged from 8-11%, and the intra-
assay CV ranged from 6-10%; both were within an acceptable range 
(https://www.salimetrics.com).  
 
2.4.2.3.4.1 Maternal cortisol measures in saliva 
2.4.2.3.4.1.1 Awakening cortisol 
The awakening cortisol level was used in the analyses if the sample was acquired within 1 hour of 
waking and the awakening time was between 5am and 10am. Awakening cortisol levels were 
used alone as an index of HPA axis activity. 
 
2.4.2.3.4.1.2 Evening cortisol 
The evening cortisol level was used in the analyses of cortisol if the sample was acquired at 8pm 
±1hour. Evening cortisol levels were used alone as indices of HPA axis activity. 
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2.4.2.3.4.1.3 Diurnal cortisol 
It was planned to evaluate diurnal cortisol secretion by calculating the area under the curve for 
awakening, midday and 8pm cortisol levels. Unfortunately the number of participants with a 
usable cortisol result for each of these three samples was small at every time point across the 
study (controls n = 12-17, cases n = 8-13). For this reason, diurnal cortisol is represented by the 
AUC between the above awakening and evening samples only, since it was preferable to 
maximise the amount of data available. Notably, the association between the diurnal cortisol as 
calculated by both methods was highly positively and strongly correlated at each assessment time 
point (range of r = .55 to .90, all p values < .001). The AUC was calculated using the formula for 
the area of a trapezoid (Pruessner et al., 2003). 
 
2.4.2.3.4.1.4 Cortisol awakening response 
CAR and post-awakening cortisol were only calculated if the subject woke between 5am and 
10am, the awakening sample was acquired within 5 minutes of awakening, the second sample 
was acquired at 15 minutes ±5 after awakening, the third sample was acquired at 30 minutes ±10 
after awakening and the fourth sample was acquired at 60 minutes ±15 after awakening. Missing 
data were not substituted with mean cortisol values or imputations. Cortisol awakening response 
was evaluated by two indices, AUCg and AUCi, which were calculated using the formula for the 
area of a trapezoid (Pruessner et al., 2003). 
 
2.4.2.3.4.2 Infant cortisol measures in saliva 
2.4.2.3.4.2.1.1 Response to the pain of routine immunization 
The infant cortisol level was used in the analyses if the second sample was obtained exactly 20 
minutes after the immunization. 
2.4.2.3.4.2.1.2 Basal cortisol 
Samples were obtained on awakening and in the evening, timings were determined by maternal 
and infant convenience and were recorded for the analysis. 
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2.4.2.4 Obstetric outcome measures 
2.4.2.4.1 Expected date of delivery (EDD) 
The dating ultrasound scan report was used where possible, if the information was not available 
at baseline, EDD was obtained from hospital delivery information. Compared with EDD estimated 
from the date of the last menstrual period, the dating ultrasound provides a more accurate 
measure of gestational age, thus EDD (ACOG, 2009). 
 
2.4.2.4.2 Onset of labour 
A variable was created to represent onset of labour: either spontaneous or not spontaneous (for 
example, induced or no labour). This information was required since only women with a 
spontaneous onset of labour (regardless of the ultimate mode of delivery) were considered in the 
examination of the effect of antenatal depression on length of gestation. The information was 
obtained from the maternal summary where possible, otherwise, from the mother at the six day 
postnatal assessment. 
 
2.4.2.4.3 Other details of the labour 
In order to control for the effect of delivery on infant outcomes, a record was made of mode of 
delivery (vaginal, elective or emergency Caesarean section), duration of rupture of membranes, 
duration of the labour and the use of analgesia in labour. This information was obtained from the 
maternal summary where possible, otherwise, from the mother at the six day postnatal 
assessment. 
 
2.4.2.4.4 Gestational age at birth 
Date of birth and EDD were used to calculate the gestational age at birth to the nearest day. 
 
2.4.2.4.5 Birth weight 
The weight of the baby at delivery was recorded; this information was obtained from the maternal 
summary where possible, otherwise, from the mother at the six day postnatal assessment. A 
variable was also created to indicate if the baby was LBW (2500g). 
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2.4.2.4.6 Weight for gestational age 
A small–for–gestational age index was calculated using a tool from the Perinatal Institute (a 
national not-for-profit organisation set up to enhance the safety and quality of maternity care 
(www.pi.nhs.uk)). The centile, based on a population birth weight at term of 3400g, is calculated 
for each baby, using gestational age at birth, birth weight and sex of the baby. 
 
2.4.2.4.7 Head circumference 
The head circumference at birth was obtained from the maternal summary. 
 
2.4.2.4.8 Sex of the baby 
 
2.4.2.4.9 Apgar score 
The Apgar score at 1 and 5 minutes after delivery was obtained from the maternal summary. The 
Apgar assessment comprises an evaluation of gross cardiovascular, respiratory and neurological 
functions of the newborn; Appearance, Pulse rate, Grimace, Activity and Respiratory effort are 
assessed and each is assigned a score of 0-2 giving a range of 0 to 10. The score at 1 minute 
reflects how well the baby tolerated the birth process, and at 5 minutes how well the baby is doing 
outside the womb, and is used to aid the decision of whether or not the baby requires immediate 
medical attention. 
 
2.4.2.5 Neonatal Behavioural Assessment Scale (NBAS) 
The NBAS is an examination of a wide range of behaviour of newborn babies up to 2 months of 
age (Brazelton, 1995). The NBAS comprises of 28 behavioural, and 18 reflex items. It evaluates 
the baby’s capabilities across different developmental areas and how the baby integrates these 
areas. The examiner endeavours to evaluate the infant’s best performance and accordingly 
provides stepped support in order to achieve this aim. These data are commonly reduced to 
conceptually or empirically derived clusters representing key developmental areas including 
regulation of the autonomic system (e.g. breathing and temperature), motor system (e.g. tone, 
activity level and reflexes) state (e.g. from quiet sleep to full cry, and the transitions between 
levels of state) and social interaction (e.g. assessing how ready babies are to engage in their new 
world). In this study six clusters of neuro-behaviour are reported (orientation, motor, range of 
state, regulation of state and autonomic stability and reflexes). 
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The NBAS has been widely used in research with studies including those of at-risk infants, the 
effects of obstetric medication or mode of delivery, prenatal substance exposure, prediction 
studies and intervention studies (Brazelton, 1995). 
The NBAS examination was performed, blind to caseness, by Dr Susan Pawlby, Section of 
Perinatal Psychiatry, IoP, who is trained and experienced in the use of this measure. 
  
2.4.2.6 Bayley Scales of Infant Development 
Bayley Scales of Infant and Toddler Development (Bayley-III) (Bayley, 2005) uses a series of 
developmental play tasks to assess infant development in cognitive, language and motor 
domains. This instrument is recognised internationally as one of the most comprehensive tools to 
assess child development in the first 3 years of life. The assessment was administered by Ms 
Susan Conroy, Section of Perinatal Psychiatry, IoP, who is trained and experienced in the use of 
this tool and was blind to caseness. 
 
2.4.2.7 Use of the measures 
The primary outcome measures were (i) maternal antenatal HPA axis (CRH, total cortisol, 
awakening, evening and diurnal free cortisol, cortisol awakening response (AUCi) and post-
awakening cortisol (AUCg), (ii) obstetric outcomes (preterm birth, length of gestation, low birth 
weight and small for gestational age) and (iii) infant HPA axis measures (cortisol response to pain 
and basal (resting) cortisol). This research is exploratory in nature; hence a large number of 
comparisons and correlations are tested. The other measures including maternal factors in 
pregnancy (socio-demographics, obstetric history and risk, physical and mental health, 
medication and health behaviours), at 8 weeks and 1 year postnatal (socio-demographics, 
physical and mental health, medication, health behaviours and HPA axis) and infant factors 
(delivery details, feeding, health, medication, neonatal neurobehaviour and cognitive, language 
and motor development at 1 year) were measured in order to assess their influence on any group 
differences observed in the primary outcome measures. 
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2.5 Data analysis 
The statistical analyses were performed in SPSS Statistics Version 21 (IBM Ltd, UK). First, the 
data were visually inspected using boxplots; where potential outliers were identified, the source 
data were checked and z-scores were calculated. The data were examined for normality of 
distribution with the Kolmogorov-Smirnov test and for homogeneity of variance with Levene’s test. 
When necessary, in order to reduce bias, data were transformed prior to analyses and if this 
procedure was of no benefit, non-parametric tests were used.  
 
Continuous data are presented as mean (M) and standard deviation (SD) and categorical data as 
percentage (%) and frequency throughout. Standard error of the mean (SE) is presented in 
graphs. For univariate analyses, group comparisons of continuous data were made using the 
independent samples t-test, and, for non-parametric data, the Mann-Whitney test was used and 
the z-score reported. The Wilcoxon signed-rank test, a non-parametric test for repeated 
measures, allowed examination of the change in infant cortisol at immunization. Pearson’s chi-
square (χ2) test of the independence of variables was used for the analysis of categorical data 
and Fisher’s exact test was used when one or more contingency cells yielded an expected count 
of less than five. Pearson’s correlation (rp) was used for the analysis of association between 
parametric continuous variables and Spearman’s correlation (rs) was applied to non-parametric 
continuous variables. The point-biserial correlation (rpb) was used to test for association between 
a continuous variable and a dichotomous variable (based on ranked scores for non-parametric 
data). Phi (φ) statistics are reported for association between two dichotomous variables. 
 
Statistics are reported to one decimal place except where two decimal places provide additional 
meaningful information. Two decimal places are used for p values > .05 and three decimal places 
for p values ≤ .05. In tables, significant results are highlighted in bold or by an asterisk (*). In 
general the p-values reported are calculated by the asymptotic method; however, in accordance 
with Field (Field, 2013),  in non-parametric tests where the sample size is small (<50) the ‘exact’ 
significance is presented. Multivariate analyses were conducted using general linear modelling 
procedures. The level for type I errors was set at 5%. In addition to reporting p values, confidence 
intervals and effect sizes are reported and discussed in this thesis since they are considered to be 
useful additional information by which findings can be evaluated (APA, 2008, Field, 2013). The 
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effect size for group differences was calculated using the formula r = !!!!!!" for the independent 
samples t-test and r = !√! for non-parametric tests. 
 
2.5.1 Moderation and mediation 
I hypothesised that group differences in obstetric outcomes and in infant HPA axis measures 
would be moderated or mediated by maternal antenatal HPA measures. In the following section I 
present details of the statistical analyses used to test the hypotheses. Moderation and mediation 
are both regression-based models. In this thesis I have tested for these effects using a macro 
named ‘PROCESS for SPSS and SAS’ (version 2.13, Prof. A Hayes, The Ohio State University, 
USA. http://www.afhayes.com), this custom dialogue box was installed to the regression menu of 
SPSS. PROCESS uses an ordinary least squares (OLS) regression-based framework for 
estimating direct and indirect effects in meditation models and interactions in moderation models 
(http://www.processmacro.org). PROCESS is a powerful tool and greatly facilitates testing for 
moderation and mediation, as it is quick and simple to use. 
 
2.5.1.1 Moderation analysis 
Moderation describes the situation in which one variable affects the relationship between two 
others. If moderation of a relationship between an independent (X) and dependent variable (Y) 
exists, the moderating variable (M) determines when, or the circumstances under which, that 
effect exists or may be increased or supressed; for a conceptual diagram see Figure 8. 
Statistically, moderation is modelled by an interaction between the independent and moderator 
variables; see Figure 9. The first step to test for moderation uses hierarchical multiple linear 
regression to ensure that the assumptions for linear regression are met. Next the PROCESS tool 
was used to test for interactions and to explore any interaction with simple slopes analysis and 
the Johnson-Neyman technique.  
 
2.5.1.1.1 Exploring the interaction 
If an interaction was found, the nature of the moderation was elucidated by simple slopes analysis 
or the Johnson-Neyman method. In simple slopes analysis the regression equation is produced 
for the independent and dependent variables at the mean and 1 standard deviation above and 
below the mean of the moderator variable. The slopes can be compared for statistical significance 
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and the value and direction of b; accordingly one can see whether the relationship between 
dependent and independent variables changes at different levels of the moderator. The Johnson-
Neyman technique is more detailed as it computes a regression model for the predictor and 
outcome at many different values of the moderator (within the bounds of the values of the 
moderator that were observed in the data); thus revealing zones of values of the moderator at 
which the association between the predictor and outcome are, or are not significant. 
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Figure 8: Diagram of a conceptual model for moderation 




Figure 9: Diagram of a statistical model for moderation 























2.5.1.2 Testing for mediation  
In contrast to moderation, which describes when an independent variable (X) exerts its effect on a 
dependent variable (Y), testing for mediation is done by a statistical method designed to elucidate 
how this effect is transmitted. Mediation is said to occur when the independent (X) variable exerts 
its effect on the dependent variable (Y) via a third intervening or mediating variable (M).  
 
In explanation, the total effect of an independent variable (X) on a dependent variable (Y) can be 
represented by a regression coefficient (path c) see Figure 10. The total effect represents the 
amount by which two cases that differ in X by one unit are predicted to differ in Y, however the 
total effect may be reached by direct or indirect means. In a simple mediation model a represents 
the coefficient for the path from X to M, b represents the coefficient for the path from M to Y 
controlling for X and c’ represents the coefficient for the path from X to Y see Figure 11. Thus c’ 
quantifies the direct effect of X on Y, and the product of paths a and b (ab) quantifies the indirect 
effect of X on Y through M. The total effect is equivalent to the sum of the direct and indirect 
effects: algebraically, c = c’ + ab. The indirect effect (ab) represents the amount by which two 
cases that differ in X by one unit are predicted to differ in Y though X’s effect on M, which in turn 
affects Y. The direct effect (c’) represents that part of the effect of X on Y that is independent of M 
(Hayes, 2009). 
 
Conventional methods of testing mediation models, for example those expounded by Baron and 
Kenny (Baron and Kenny, 1986) have been criticised1 and modern approaches, for example 
those of Preacher and Hayes (Preacher and Hayes, 2004), are now superseding traditional 
methods (Hayes, 2009).  In this modern method, quantification of the size of indirect effect is 
calculated by regression techniques; an inferential test that does not equal zero establishes that 
there is indeed an indirect effect. PROCESS uses bootstrap confidence intervals for this 
inferential test; bootstrapping is a robust method that does not make assumptions about the 
distribution of the indirect effect; thus it is a non-parametric method (see section 2.5.2 below).  
                                                       
1 Primarily there is no formal quantification of the indirect effect. Instead the indirect effect is 
inferred by logic constructed from a series of tests that must all be statistically significant; thus 




Lastly, Hayes also underscores that, in contrast to conventional methods of testing mediation 
models, in order to test for an indirect effect, there is no requirement of a simple association 
between X and Y. Moreover, he reasons that by a failure to test for indirect effects in the absence 
of a total effect one may miss potentially important mechanisms by which an independent variable 
exerts its effect on a dependent variable. Furthermore, there is no reliance on statistical 
significance for any of the individual paths in a mediation model as this does not determine 
whether the indirect path is significant (Hayes, 2013). 
 
2.5.2 Bootstrap technique 
The bootstrap technique is used to estimate the properties of the sampling distribution from the 
sample data. In explanation, one assumption for parametric tests is that the sampling distribution 
is normal. Where data are normally distributed it is reasonable to infer that the sampling 
distribution is normal, however, if the data are not normally distributed this assumption cannot be 
made; the bootstrap method is a ‘robust’ measure used to overcome this problem. 
In bootstrapping, the sample data are treated as a population from which ‘bootstrap’ samples are 
taken; each score is replaced to the sample data before a new bootstrap sample is drawn 
(‘random sampling with replacement’). The parameter (e.g. the mean or b) is calculated in each 
bootstrap sample. The process is repeated many times (j), for example 1000 to 2000, thus j 
estimates of the parameter are created. The parameter estimates are rank ordered, accordingly 
the limits within which 95% of them fall can be discerned, this is known as the 95% percentile 
bootstrap confidence interval. A slightly more accurate method is the bias-corrected and 
accelerated bootstrap, which adjusts for bias and skewness in the bootstrap sample.  
When testing for mediation, the coefficients for paths a and b are estimated in the resampled data 
sets and the product of the coefficients a and b (ab) is recorded. In order to estimate the indirect 
effect (ab) it is recommended to repeat the resampling process is at least 5000 times. The 
product (ab) is then rank ordered, accordingly the limits within which 95% of them fall can be 
discerned; this is the percentile-based bootstrap confidence interval. If zero does not fall within 
the upper and lower limits of the confidence interval then one can claim 95% confidence that the 




Figure 10: Diagram of a simple model of the total effect of X on Y 






Figure 11: Diagram of a conceptual model for mediation 




















Chapter 3 RESULTS 
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3.1 Characteristics of the sample 
 
3.1.1 Study subjects 
The sample consists of a total of 82 subjects, 46 healthy controls and 36 cases with MDD in 
pregnancy. Of the 36 cases, 26 (72%) met DSM-IV criteria for MDD at baseline (25 weeks 
gestation) and 10 (28%) were assessed, retrospectively at baseline, to have met criteria for MDD 
in pregnancy prior to, but not at, baseline. No subjects were taking antidepressant medication at 
baseline. 
 
3.1.2 Socio-demographic factors 
Socio-demographic characteristics of the participants are presented in Table 7 and the fathers of 
the unborn children in Table 8. There were a number of statistically significant group differences. 
Compared with the control group, the group with MDD in pregnancy had a greater proportion of 
subjects of black and minority ethnic group (21.7% v 52.8%, χ2(1) = 8.5, p = .004, OR = 4.0, 95% 
CI [1.5, 10.5]), without A level or higher qualification (8.7% v 38.9%, χ2(1) = 10.7, p = .001, OR = 
6.7, 95% CI [2.0, 22.7]), not working outside the home (26.1% v 55.6%, χ2(1) = 7.4, p = .007, OR = 
3.5, 95% CI [1.4, 9.0]), not of professional or managerial employment classification (26.1% and 
58.8%, χ2(1) = 8.7, p = .003, OR = 4.0, 95% CI [1.6, 10.4]), living alone (15.2% v 52.8%, χ2(1) = 
13.2, p  < .001, OR = 6.2, 95% CI [2.2, 17.6]) and whose partner was of black and minority ethnic 
group (23.8% v 56.5%, χ2(1) = 4.8, p = .027, OR = 4.2, 95% CI [1.1, 15.2]). However, there were 
no statistically significant group differences in maternal age, maternal premorbid IQ, nor in their 
partner’s employment status or classification of employment.  
129 
Table 7: Characteristics of the sample: maternal socio-demographic factors 
 Control 
(n = 46) 
Case 
(n = 34 - 36) 
Statistical test and 
significance 
Age in years at baseline, mean (SD) 
 32.6 (4.3) 30.9 (6.3) t(59.4) = 1.4, p = .16 
Maternal ethnicity, % (n) 
 White 





χ2(1) = 8.5, p = .004 
Maternal education, % (n) 
 GCSE or lower 





χ2(1) = 10.7, p = .001 
Premorbid IQ (WTAR score), mean (SD)1 
 109.1 (12.8) 99.4 (15.6) t(38) = 2.0, p = .08 
Maternal employment status at baseline, % (n) 
 Working outside the home 





χ2(1) = 7.4, p = .007 
Maternal classification of employment, % (n) 
 Professional or managerial 





χ2(1) = 8.7, p = .003 
Marital status, % (n) 
 Married or cohabiting 





χ2(1) = 13.2, p  < .001 
 
 
                                                       
1 These data were not ascertained on the full sample (controls n = 25, cases n = 15). 
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Table 8: Characteristics of the sample: paternal socio-demographic factors 
 Control 
(n = 19 - 21) 
Case 
(n = 20 - 23) 
Statistical test and 
significance 
Paternal ethnicity, % (n) 
 White 





χ2(1) = 4.8, p = .027 
Paternal employment status at baseline, % (n) 






χ2(1) = 1.1, p = .491 
Paternal classification of employment, % (n)2 
 Professional or managerial 





χ2(1) = 1.3, p = .26  
                                                       
1 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
2 These data were not ascertained on the full sample (controls n= 19, cases n=15). 
131 
3.1.3 Obstetric history and obstetric risk factors  
Obstetric history is presented in Table 9. Compared with controls, cases had a statistically 
significant greater proportion with a history of miscarriage (8.7% v 33.3%, χ2(1) = 7.8, p = .005, OR 
= 5.2, 95% CI [1.5, 18.1]). However, there were no statistically significant group differences in 
history of having had a previous pregnancy, preterm delivery, elective termination of pregnancy, 
intra-uterine death, parity or age at menarche.  
 
Obstetric risk factors are presented in Table 10. There were no statistically significant group 
differences in gestational age at baseline or in obstetric risk factors in the index pregnancy. 
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Table 9 Characteristics of the sample: obstetric history 
 Control 
(n = 44 - 46) 
Case 
(n = 36) 
Statistical test and 
significance 
History of previous pregnancy, % (n) 
 100 (46) 100 (36)  
History of preterm delivery, % (n) 
 Yes 





χ2(1) = 0.6, p = .651 







χ2(1) = 7.8, p = .005 
History of elective termination of pregnancy, % (n) 






χ2(1) = 2.9, p = .09 







χ2(1) = 0.8, p = 1.01 







χ2 (1) = 0.3, p = .58 
Age at menarche (years), mean (SD)2 
 13.2 (2.2) 13.1 (1.4) t(44) = 0.2, p = .83 
                                                       
1 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
2 These data were not ascertained on the full sample (controls n=21, cases n= 25).  
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Table 10: Characteristics of the sample: obstetric risk factors at baseline 
 Control 
(n = 45 - 46) 
Case 
(n = 35 - 36) 
Statistical test and 
significance 
Gestational age at baseline (weeks) by ultrasound dating, mean (SD) 
 26.14 (1.41) 26.48 (1.74) t(80) = 1.0, p = .34 







χ2 (1) = 1.0, p = .32 
Severity of bleeding, % (n) 
 Spotting or slight 





χ2 (1) = 0, p = 1.01 
 







χ2 (1) = 0.0, p = 1.0 
                                                       
1 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
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3.1.4 Physical health, medication, health indicators and health behaviours 
 
3.1.4.1 Baseline 
Health characteristics and medication are presented in Table 11. There were no statistically 
significant group differences in the presence of a chronic medical condition, use of regular 
medication, use of any steroid (regular or PRN) medication, pre-pregnancy BMI, tea, coffee or 
alcohol consumption at baseline or past history of cigarette smoking. However, compared with the 
control group, the group with MDD in pregnancy had a statistically significant larger proportion 
that had smoked in the index pregnancy (4.7% v 31.4%, χ2(1) = 10.0, p = .002, OR = 9.4, 95% CI 
[1.9, 46.0]). 
 
3.1.4.2 Thirty-two weeks gestation 
Medication use at 32 weeks gestation is presented in Table 12. There was a statistically 
significant difference between cases and controls in use of antidepressants at 32 weeks gestation 
(0% v 12.5% respectively, χ2 (1) = 5.8, p = .040), however only 3 of the 25 cases were taking 
antidepressant drugs. There was no significant group difference in the use of medications other 
than antidepressants or in the use of any regular or PRN steroid medication at 32 weeks 
gestation. 
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Table 11: Characteristics of the sample: physical health and health behaviours 
 Control 
(n = 43 - 46) 
Case 
(n = 33 - 36) 
Statistical test and 
significance 
Chronic medical condition, % (n)1 
 Yes 





χ2 (1) = 0.01, p = 1.02 







χ2 (1) = 2.8, p = .164  







χ2 (1) = 0.31, p = 1.04 
Pre-pregnancy BMI, mean (SD) 
 23.7 (4.1) 25.4 (4.8) t(75) = 1.7, p = .11 
Coffee (cups/week) at baseline, mean (SD) 
 2.9 (4.6) 2.6 (4.5) z = -0.6, p = .55 
Tea (cups/week) at baseline, mean (SD) 
 9.7 (9.6) 9.5 (14.5) z = -1.0, p = .30 







χ2(1) = 0.0, p = 1.04 







χ2(1) = 10.0, p = .002 
 
 
                                                       
1 Asthma, eczema, hay fever, urticaria, endometriosis, polycystic ovarian syndrome. 
2 Fisher’s exact test was applied as 1 cell had an expected cell count less than 5. 
3 Steroid inhaler, non-steroid inhaler, proton pump inhibitor, antacid, homeopathic medicines.   
4 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
5 These data were not ascertained on the full sample (controls n= 26, cases n=25). 
6 Flixotide, Betnovate Fucibet 
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Table 12: Characteristics of the sample: medication use at 32 weeks gestation 
 Control 
(n = 43 - 46) 
Case 
(n = 25 - 30)1 
Statistical test and 
significance 







χ2 (1) = 5.8, p = .0402  







χ2 (1) = 3.6, p = .152 







χ2 (1) = 0.9, p = .382 
 
                                                       
1 These data were not ascertained on the full sample of cases (n= 25 - 30). 
2 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
3 Thyroxine, steroid inhaler, non-steroid inhaler, steroid cream, antihistamine, proton pump 
inhibitor or antacid. 
4 Steroid inhaler and steroid cream 
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3.1.5 Mental health  
 
3.1.5.1 Controls 
At baseline, controls were free from current or lifetime history of any DSM-IV axis I diagnosis.  
 
3.1.5.2 Cases 
All cases (n = 36) had a diagnosis of MDD in pregnancy, either at baseline (25 weeks gestation) 
(n = 26, 72%), or prior to but not including baseline (n = 10, 28%). 
 
3.1.5.2.1 Psychiatric DSM-IV diagnoses in pregnancy 
Of the 36 cases with MDD at or prior to baseline, 34 (89%) had MDD alone and four (11%) had a 
contemporaneous anxiety disorder (specific phobia, generalized anxiety disorder, obsessive 
compulsive disorder). There were no other axis I disorders in pregnancy. Diagnostic data are 
presented in Figure 12. 
 
3.1.5.2.2 Psychiatric DSM-IV diagnoses prior to pregnancy 
Of the 36 cases, 19 (53%) had a past history of MDD alone, 5 (14%) had a past history of MDD 
and anxiety disorder but no other diagnoses, 4 (11%) had a past history of MDD and a diagnosis 
other than anxiety disorder, 3 (8%) had a past history of MDD, anxiety disorder and another 
diagnosis, 1 (3%) had a past history of anxiety disorder alone and 4 (11%) had no past history at 
all. The anxiety disorders included post traumatic stress disorder, panic disorder, specific phobia, 
social phobia and obsessive compulsive disorder. The other diagnoses included substance-
related disorders (alcohol abuse, alcohol dependence, cocaine dependence, cannabis abuse, 
amphetamine dependence) and eating disorders (anorexia nervosa, eating disorder not otherwise 
specified). Diagnostic data are presented in Figure 12. 
 
3.1.5.3 Psychiatric rating scale scores at baseline 
As expected, the group with MDD in pregnancy had scores demonstrating higher levels of 
depression symptoms with higher mean scores on BDI, this difference (-16.2, 95% CI [-20.6, -
11.9]) was statistically significant and represented a large sized effect, r = 0.80. Furthermore, the 
group with MDD in pregnancy had scores demonstrating higher levels of anxiety symptoms with 
138 
higher mean scores on STAIS, this difference (-24.8, 95% CI [-29.5 -20.8]) was statistically 
significant and represented a large sized effect, r = 0.81 (Table 13).  
 
3.1.5.4 Psychiatric rating scale scores at 32 weeks gestation 
As described in the methodology, psychiatric rating scales were not completed in all subjects at 
32 weeks gestation. As at baseline, the group with MDD in pregnancy had scores demonstrating 
higher levels of symptoms of depression with higher scores on BDI, this difference (-9.0, 95% CI 
[-13.6, -4.4]) was statistically significant and represented a large sized effect, r = .60. Furthermore, 
the group with MDD in pregnancy had scores demonstrating higher levels of symptoms of anxiety 
with higher scores on STAIS, this difference (-22.9, 95% CI [-30.1, -15.8]) was statistically 
significant and represented a large sized effect, r = .79 (Table 14). 
139 
  
Figure 12: Cases diagnoses in pregnancy and past psychiatric history 
32 
4 
Diagnosis in pregnancy prior 
to baseline 
MDD only in 
pregnancy 









Past psychiatric history 
Past history of MDD alone 
(n=19) 
Past history of MDD and 
anxiety disorder alone (n=5) 
Past history of MDD and a 
diagnosis other than anxiety 
disorder (n=4) 
Past history of MDD, anxiety 
disorder and another 
diagnosis (n=3) 
Past history of anxiety disorder 
alone (n=1) 




Table 13: Characteristics of the sample: mental health at baseline 
 Control 
(n = 44) 
Case 
(n = 31) 
Statistical test and 
significance 
BDI, mean (SD) 
 4.0 (2.8) 20.3 (11.6) t(32.4) = 7.6, p < .001 
STAI state, mean (SD) 





Table 14: Characteristics of the sample: mental health at 32 weeks gestation 
 Control 
(n = 18) 
Case 
(n = 18) 
Statistical test and 
significance 
BDI, mean (SD) 
 3.7 (3.0) 12.8 (8.9) t = 4.0(28.4), p < .001 
STAI state, mean (SD) 
 28.0 (6.3) 51.0 (13.7) t = 6.6(25.6), p < .001 
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3.2 Antenatal depression and maternal HPA axis in pregnancy 
To test the hypotheses relating to maternal antenatal HPA axis, specifically compared to healthy 
pregnant women, those with antenatal depression would have higher CRH and serum cortisol and 
lower CRHBP at 25 weeks gestation and higher awakening, evening, diurnal cortisol secretion 
and cortisol awakening response at 25 and 32 weeks gestation; cases and controls were 
compared on these measures. 
 
3.2.1 Maternal HPA axis at baseline 
 
3.2.1.1 Plasma CRH and CRHBP at baseline  
3.2.1.1.1 Blood sampling details 
76 subjects provided a sample of plasma at baseline. Blood sampling details (gestational age at 
sample acquisition, time of day of sampling, interval between sample acquisition and processing 
and the interval between sample acquisition and CRHBP analysis) were recorded. Baseline CRH, 
CRHBP and blood sampling details for this sample of subjects were examined for any 
associations.  
 
There was a significant positive correlation between CRH and gestational age at sample 
acquisition (rp = .31, p = .007), but there was no difference in the gestational age at sample 
acquisition between cases and controls (weeks, M (SD), 27.7 (2.3) v 27.2 (2.3) respectively, z = -
1.3, p = .19). There was no significant correlation between CRHBP and gestational age at sample 
acquisition, nor between CRH or CRHBP and any other blood sampling characteristics (see 
Appendix N, Table 48).  
 
3.2.1.1.2 Plasma CRH, CRHBP and antenatal depression 
Compared with controls, CRH at baseline was higher in cases, this difference (-15.86 ng/l, 95% 
CI [-37.04, 5.32]) was not statistically significant, t(74) = 1.5, p = .14, and it represented a small 
sized effect, r = .17. 
Compared with controls, CRHBP at baseline was higher in cases, this difference was not 
statistically significant and it represented a small sized effect, r = .13 (Table 15).    
 
142 
Table 15: Plasma CRH and CRHBP and antenatal depression 
 Control 
(n = 43) 
Case 
(n = 33) 
Statistical test and 
significance 
CRH (ng/L), M (SD) 
 118.18 (38.28) 134.04 (54.36) t(74) = 1.5, p = .14 
CRHBP (pmol/L), M (SD)1 
 222.32 (136.38) 249.76 (131.63) z = -1.0, p = .33 
                                                       
1 Controls n = 22, cases n = 16. 
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3.2.1.1.3 Further analysis of CRH 
Since CRH was significantly positively correlated with gestational age at sample acquisition and 
was higher (but not statistically significantly so) in cases, further examination was warranted. A 
scatter plot of CRH by gestational age at sample acquisition suggested a different relationship 
between these two variables in cases and in controls (Figure 13). The next step was to examine 
the data to see if there were any associations between CRH and other characteristics of the 
sample. There was a statistically significant correlation between CRH and paternal employment 
status at baseline and gestational age at baseline; however there was no significant difference in 
either of these two variables between cases and controls. There was no correlation between CRH 
and any other characteristics of the sample (see Appendix N, Table 49 to Table 51), thus no other 
factors were included as covariates in the model. Despite the absence of outliers for CRH in 
univariate analysis, one case was an outlier in the multivariate analysis (CRH = 307.7 ng/l, 
standardized residual = 3.7), however, as advised by Stevens (Stevens, 2012), it was not 
removed from the analysis since the Cook’s distance was <1 (0.2). Furthermore, there was no 
evidence of other outliers or influential cases in the model. PROCESS was used to test if 
gestational age at sample acquisition was moderating the relationship between caseness and 
CRH. The model was significant, R2 = .18, F(3, 72) = 3.8, p = .013 (see Table 16)1. This finding was 
followed up with simple slopes analysis; the conditional effect of caseness on CRH at values of 
gestational age at sample acquisition (mean ±1SD) is shown graphically in Figure 14. Further 
examination of this interaction using the Johnson-Neyman technique showed that when values of 
gestational age at sample acquisition were ≥ 28.49 weeks gestation, CRH was significantly higher 
in cases than in controls, and the size of effect of caseness on CRH increased as gestational age 
at sample acquisition got higher (see Figure 13). This finding suggests that, in this study (where 
gestational age at sample acquisition was simply an artefact of the study design), CRH was 
generally measured at a gestational age too low to show an effect of caseness, but indicates that 
a significant group difference in CRH (cases > controls) existed when samples were acquired, 
serendipitously, at later gestational ages.  
 
                                                       
1 In order to ensure that the possible outlier did not bias this analysis, the data were winsorized; 







Figure 13: CRH and gestational age at sample acquisition by caseness 
 
Note. * When values of gestational age at sample acquisition were ≥ 28.49 weeks gestation, CRH 
was significantly higher in cases than in controls 
 
Zone of significance 




Figure 14: Moderation of CRH  






























Table 16: Linear model of predictors of CRH. 
 B SE B t p 
Constant     
 123.8 [113.9, 133.8] 5.0 24.8 < .001 
Gestational age at sample acquisition 
 5.6 [1.1, 10.1] 2.2 2.5 .014 
Caseness     
 12.5  [-7.9, 33.0] 10.3 1.2 .23 
Caseness x Gestational age at sample acquisition 
 10.4 [1.4, 19.4] 4.5 2.3 .024 
Note. N = 76, R2 = .18, bias-corrected and accelerated 95% confidence intervals are reported in 






3.2.1.2 Serum cortisol at baseline 
 
3.2.1.2.1 Blood sampling details 
Serum cortisol was measured in 42 subjects at baseline. Blood sampling details (gestational age 
at sample acquisition, time of day of sampling and the interval between sample acquisition and 
processing) were recorded. Serum cortisol and blood sampling details for this sample of subjects 
were examined for any associations. 
 
There was a significant negative correlation between serum cortisol and gestational age at 
sample acquisition (rp = -.32, p = .041), but there was no difference in the gestational age at 
sample acquisition between cases and controls (weeks, M (SD) 27.9 (2.4) v 28.1 (2.7), t(40) = 0.2, 
p = .84). There was no significant correlation between serum cortisol and any other blood 
sampling characteristics (see Appendix N, Table 52). 
 
3.2.1.2.2 Serum cortisol and antenatal depression 
Compared with controls, serum cortisol at baseline was higher in cases, this difference (-34.72 
nmol/l, 95% CI [-106.0, 36.5]) was not statistically significant, t(40) = 1.0, p = .33, and it 
represented a small sized effect, r = .16 (Table 17). 
 
3.2.1.2.3 Further analysis of serum cortisol 
Since serum cortisol was significantly correlated with gestational age at sample acquisition and 
was higher (but not statistically significantly so) in cases, further examination (as for CRH in 
section 3.2.1.1.3 above) was warranted. In this instance, there was no moderation of the effect of 
caseness on serum cortisol by gestational age at sample acquisition.  
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Table 17: Serum cortisol and antenatal depression 
 Control 
(n = 19) 
Case 
(n = 23) 
Statistical test and 
significance 
Serum cortisol (nmol/L), M (SD) 
 429.84 (97.04) 464.56 (125.74) t(40) = 1.0, p = .33 
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3.2.1.3 Saliva cortisol 
Data for maternal saliva cortisol are presented in the same way throughout this chapter. Firstly, 
data are presented for awakening and then evening cortisol since I have the largest samples for 
these measures at each time point throughout the study. Subsequently, data are presented for 
diurnal cortisol secretion (AUC) and lastly CAR (AUCi) and post-awakening cortisol (AUCg) since, 
as described in the methodology, there are data on a smaller subset of subjects. As described in 
the methodology saliva cortisol measures are not available for all subjects at baseline (see 
section 2.1) and samples were only used in the analyses if they were taken within the acceptable 
time frames described in section 2.4.2.3.4.1. 
 
3.2.1.4 Awakening saliva cortisol at baseline 
3.2.1.4.1 Saliva sampling details  
39 subjects provided data for awakening cortisol at baseline. Saliva sampling details (gestational 
age at sample acquisition, awakening and sample time and the interval between sample 
acquisition and freezing) were recorded. Awakening cortisol and saliva sampling details for this 
sample of subjects were examined for any associations. 
 
Awakening cortisol was significantly positively correlated with the interval between awakening and 
the awakening sample time at baseline (rs = .35, p = .031), but there was no difference in this 
interval between cases and controls (minutes, M (SD) 2.8 (4.2) v 1.4 (3.5) respectively, z = -1.4, p 
= .16). There was no significant correlation between awakening cortisol and any other saliva 
sampling details at baseline (see Appendix N,Table 53). 
 
3.2.1.4.2 Awakening cortisol at baseline and antenatal depression 
Compared with controls, awakening cortisol at baseline was higher in cases, this difference was 
not statistically significant and it represented a small sized effect, r = .10 (Table 18). 
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Table 18: Awakening saliva cortisol at baseline and antenatal depression 
 Control 
(n = 20) 
Case 
(n = 19) 
Statistical test and 
significance 
Awakening saliva cortisol (nmol/ml), M (SD) 
 10.54 (4.82) 12.71 (5.96) z = -0.6, p = .55 
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3.2.1.5 Evening saliva cortisol at baseline 
 
3.2.1.5.1 Saliva sampling details 
38 subjects provided data for evening saliva cortisol at baseline. Saliva sampling details 
(gestational age at sample acquisition, sample time and the interval between sample acquisition 
and freezing) were recorded. Evening cortisol and saliva sampling details for this sample of 
subjects were examined for any associations. There was no significant correlation between 
evening saliva cortisol at baseline and any saliva sampling characteristics (see Appendix N, Table 
54). 
 
3.2.1.5.2 Evening saliva cortisol at baseline and antenatal depression 
Compared with controls, evening cortisol (natural log transformed for the analysis) at baseline 
was higher in cases, this difference (-0.8 nmol/ml, 95% CI [-2.1, 0.4]) was not statistically 
significant, t(25.0) = 1.0, p = .33, and it represented a small sized effect, r = .19 (Table 19). 
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Table 19: Evening saliva cortisol at baseline and antenatal depression  
 Control 
(n = 19) 
Case 
(n = 19) 
Statistical test and 
significance 
Evening saliva cortisol (nmol/ml), M (SD) 




3.2.1.6 Diurnal cortisol secretion at baseline  
 
3.2.1.6.1 Saliva sampling details  
35 subjects provided data for measurement of diurnal cortisol secretion at baseline. Saliva 
sampling details (gestational age at sample acquisition, awakening time and the interval between 
sample acquisition and freezing) were recorded. Diurnal cortisol and saliva sampling details for 
this sample of subjects were examined for any associations. 
 
Diurnal cortisol secretion was significantly negatively correlated with time of awakening at 
baseline (rp = -.38, p = .04), but there was no difference in time of awakening between cases and 
controls (hours, M (SD) 07:37 (0:56) v 08:04 (1:12) respectively, t(33) = 1.2, p = .24. There was no 
significant correlation between diurnal cortisol secretion and any other saliva sampling 
characteristics (see Appendix N, Table 55). 
 
3.2.1.6.2 Diurnal cortisol secretion at baseline and antenatal depression 
Compared with controls, diurnal cortisol at baseline was higher in cases; this difference was not 
statistically significant and it represented a small sized effect, r = .17 (Table 20).  
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Table 20: Diurnal cortisol secretion at baseline and antenatal depression 
 Control 
(n = 19) 
Case 
(n = 16) 
Statistical test 
and significance 
Diurnal cortisol secretion (mmol/ml2), M (SD) 
 4823.4 (1931.2) 5959.3 (2183.2) z = -1.0, p = .35 
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3.2.1.7 Cortisol awakening response and post-awakening cortisol at baseline 
 
3.2.1.7.1 Saliva sampling details 
21 subjects provided data for cortisol awakening response at baseline. Saliva sampling details 
(gestational age at sample acquisition, awakening time and the interval between sample 
acquisition and freezing) were recorded. CAR and post-awakening cortisol and saliva sampling 
details for this sample of subjects were examined for any associations. 
 
AUCg was negatively correlated with the time of awakening (rp = -.50, p = .026), but there was no 
difference in the awakening time between cases and controls (hours, M (SD), 08:16 (1:15) v 
07:31 (0:56) respectively, t(19)  = 1.5, p = .15). There was no significant correlation between AUCg 
and any other saliva sampling characteristics. There was no significant correlation between AUCi 
and any saliva sampling characteristics  (see Appendix N, Table 56) 
 
3.2.1.7.2 Cortisol awakening response and post-awakening cortisol at baseline and antenatal 
depression  
Compared with controls, CAR (AUCi) at baseline was lower in cases, this difference was not 
statistically significant, however it represented a small to medium sized effect, r = .20 (Figure 15). 
Compared with controls, post-awakening cortisol (AUCg) at baseline was higher in cases, this 
difference (-16.7 nmol/ml2, 95% CI [-353.1, 319.8]) was not statistically significant, t(19) = 0.1, p = 




Table 21: Cortisol awakening response and post-awakening cortisol at baseline and antenatal 
depression 
 Control 
(n = 12) 
Case 
(n = 9) 
Statistical test and 
significance 
AUCi (nmol/ml2), M (SD)  
 60.4 (208.5) 40.7 (179.4) z = -0.9, p = .42  
AUCg (nmol/ml2), M (SD)  
 684.2 (361.6) 700.8 (368.4) t(19) = 0.1, p = .92 
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3.2.2 Maternal HPA axis at 32 weeks gestation 
 
3.2.2.1 Awakening saliva cortisol at 32 weeks gestation 
 
3.2.2.1.1 Saliva sampling details 
66 subjects provided data for awakening cortisol at 32 weeks gestation. Saliva sampling details 
(gestational age at sample acquisition, awakening and sample time, the interval between 
awakening and the sample time, and the interval between sample acquisition and freezing) were 
recorded. Awakening cortisol and saliva sampling details for this sample of subjects were 
examined for any associations. There was no significant correlation between awakening cortisol 
level and any saliva sampling details at 32 weeks gestation (see Appendix N, Table 57). 
 
3.2.2.1.2 Awakening cortisol at 32 weeks gestation and antenatal depression 
Cases had a higher awakening cortisol level at 32 weeks gestation compared with controls, this 
difference (-3.06 nmol/ml, 95% CI [-5.23, -0.89]) was statistically significant and represented a 
medium sized effect, r = .33 (Table 22).  
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Table 22: Awakening cortisol at 32 weeks gestation and antenatal depression 
 Control 
(n = 40) 
Case 
(n = 26) 
Statistical test and 
significance 
Awakening saliva cortisol (nmol/ml), M (SD)  
 9.20 (3.77) 12.26 (5.03) t(64) = 2.8, p = .006 
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3.2.2.1.3 Awakening cortisol at 32 weeks gestation and other characteristics of the sample. 
Further analyses showed that a number of other characteristics of the sample were also 
associated with awakening cortisol at 32 weeks gestation: 
 
3.2.2.1.3.1 Baseline socio-demographics  
Maternal age was significantly positively correlated with awakening cortisol at 32 weeks gestation 
(rp = .28, p = .022); however there was no significant difference, between controls and cases, in 
maternal age (years, M (SD), 32.6 (4.4) v 31.7 (6.5) respectively, t(39.5) = 0.64, p = .56). 
Maternal ethnicity was significantly correlated with awakening cortisol at 32 weeks gestation (rpb = 
.28, p = .024); compared with BME women (n = 18), the white group (n = 48) had significantly 
higher awakening cortisol (nmol/ml, M (SD), 8.36 (5.27) v 11.17 (4.02) respectively, t(64) = 2.3, p = 
.024). Furthermore, there was a significant difference, between controls and cases, in maternal 
ethnicity (white, % (n), 82.5 (33) v 57.7 (15) respectively, χ2 (1) = 4.9, p = .027, OR = 3.5, 95% CI 
[1.2, 10.7]). 
There was no significant correlation between awakening cortisol at 32 weeks gestation and any 
other socio-demographic factors (see Appendix N, Table 58). 
 
3.2.2.1.3.2 Obstetric history and obstetric risk factors 
Vaginal bleeding in the index pregnancy was significantly correlated with awakening cortisol at 32 
weeks gestation (rpb = .29, p = .020); compared with women history of vaginal bleeding in the 
index pregnancy (n = 15), those without such history (n = 51) had significantly higher awakening 
cortisol (nmol/ml, M (SD), 12.78 (4.40) v 9.70 (4.37) respectively, t(64) = 2.4, p = .020).  However 
there was no significant group difference, between controls and cases, in history of vaginal 
bleeding (% (n), 15.0 (6) v 34.6 (9) respectively, χ2 (1) = 3.4, p = .06).  
There was no significant correlation between awakening cortisol at 32 weeks gestation and any 
other obstetric factors (see Appendix N, Table 59) 
 
3.2.2.1.3.3 Physical health and medication at 32 weeks gestation and baseline health behaviours 
There was no significant correlation between awakening cortisol at 32 weeks gestation and 
concurrent use of medication, physical health factors or baseline health behaviours or health 
indicators (see Appendix N, Table 60). 
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3.2.2.1.4 Summary of awakening cortisol at 32 weeks gestation and antenatal depression 
In this sample of 66 women with cortisol data available, I found that caseness and maternal 
ethnicity were both associated with awakening cortisol at 32 weeks gestation. I therefore included 
both predictors in an analysis of variance. The model was significant (F(3, 62) = 7.3, p < .001). 
There was a significant main effect of caseness on awakening cortisol (F(1, 62) = 14.0, p < .001)  
independent of the effect of maternal ethnicity. Similarly there was a significant main effect of 
ethnicity on awakening cortisol (F(1, 62) = 12.4, p = .001) independent of the effect of caseness. 
There was no interaction between ethnicity and caseness on awakening cortisol. Both white and 
BME women with antenatal depression had higher awakening cortisol levels compared with their 
non-depressed counterparts. Furthermore, white women, irrespective of antenatal depression 

















n = 33 
n = 7 
n = 15 
n = 11 
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3.2.2.2 Evening saliva cortisol at 32 weeks gestation  
 
3.2.2.2.1 Saliva sampling details 
61 subjects provided data for evening cortisol at 32 weeks gestation. Saliva sampling details 
(gestational age at sample acquisition, sample time and the interval between sample acquisition 
and freezing) were recorded. Evening cortisol and saliva sampling details for this sample of 
subjects were examined for any associations. 
 
There was a significant positive correlation between evening cortisol level and the gestational age 
at acquisition of the sample (rs = .43, p = .001); however there was no significant group difference, 
between controls and cases, in gestational age at acquisition of the sample (weeks, M (SD), 32.6 
(1.0) v 32.8 (1.4) respectively, z = -0.6, p = .51). There was no significant correlation between 
evening cortisol level and any other saliva sampling details (see Appendix N, Table 61). 
 
3.2.2.2.2 Evening saliva cortisol at 32 weeks gestation and antenatal depression 
The cases had a higher evening cortisol level at 32 weeks gestation compared with controls 
(there were a number of outliers in both groups; natural log transformation of the data corrected 
this source of bias and produced a normal distribution, thus the statistical analyses were 
performed on the transformed data). The (untransformed) difference (-5.11 nmol/ml, 95% CI [-
9.65, -0.58]) was statistically significant, t(59) = 3.4, p = .001, and represented a medium to large 





Table 23: Evening saliva cortisol at 32 weeks gestation and antenatal depression 
 Control 
(n = 38) 
Case 
(n = 23) 
Statistical test and 
significance 
Evening saliva cortisol (nmol/ml), M (SD)  
 3.27 (3.12) 8.38 (10.26) t(59) = 3.4, p = .001 
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3.2.2.2.3 Evening cortisol at 32 weeks gestation and other characteristics of the sample 
Further analyses showed that a number of other characteristics of the sample were also 
associated with evening cortisol at 32 weeks gestation: 
 
3.2.2.2.3.1 Baseline socio-demographics  
Employment status was significantly correlated with evening cortisol at 32 weeks gestation (rpb = 
.29, p = .025). Compared to women working outside the home, those not working outside the 
home had higher evening cortisol (nmol/ml, M (SD), 3.67 (3.47) v 8.11 (10.75) respectively, t(59) = 
2.3, p = .025), however there was no significant group difference, between controls and cases, in 
women who were working outside the home (% (n), 73.7 (28) v 52.2 (12) respectively, χ2 (1) = 2.9, 
p = .09). 
There was no significant correlation between evening cortisol level and any other socio-
demographic characteristics of the sample (see Appendix N, Table 62).  
 
3.2.2.2.3.2 Obstetric history and obstetric risk factors 
Past history of miscarriage was significantly correlated with evening cortisol at 32 weeks gestation 
(rpb = .35, p = .005). Compared to women with a past history of miscarriage, those with no such 
history had a lower evening cortisol (nmol/ml, M (SD), 11.42 (12.91) v 3.51 (2.96) respectively, 
t(59) = 2.9, p = .005) . Furthermore, there was a significant group difference, between controls and 
cases, in women with a past history of miscarriage (% (n), 10.5 (4) v 39.1 (9) respectively, χ2 (1) = 
7.0, p = .012). 
There was no significant correlation between evening cortisol level and any other obstetric factors 
(see Appendix N, Table 63) 
 
3.2.2.2.3.3 Physical health and medication at 32 weeks gestation and baseline health behaviours 
There was no significant correlation between evening cortisol at 32 weeks gestation and any 
physical health factors (see Appendix N, Table 64).   
 
3.2.2.2.4 Summary of evening saliva cortisol at 32 weeks gestation and antenatal depression 
In this sample of 61 women with cortisol data available, I found that caseness and a past history 
of miscarriage were both associated with evening cortisol at 32 weeks gestation. I therefore 
included both predictors in an analysis of variance. The model was significant (F(3, 57) = 6.3, p = 
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.001). There was a significant main effect of caseness on evening cortisol (F(1, 57) = 9.3, p = .004) 
independent of the effect of a history of previous miscarriage.  Past history of miscarriage was no 
longer significant when taking account of caseness. There was no interaction between caseness 
and past history of miscarriage on evening cortisol. Compared with healthy controls, women with 
antenatal depression had a significantly higher evening cortisol level at 32 weeks gestation 









Note. ***p = .001 Evening cortisol was significantly higher in cases than controls independent of 
history of miscarriage. 
*** 
n = 34  n = 4 
n = 14 
n = 9 
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3.2.2.3 Diurnal cortisol secretion (AUC) at 32 weeks gestation  
 
3.2.2.3.1 Saliva sampling details  
55 subjects provided both awakening and evening samples for calculation of the diurnal cortisol 
AUC. Saliva sampling details (gestational age at sample acquisition, awakening time and the 
interval between sample acquisition and freezing) were recorded. Diurnal cortisol and saliva 
sampling details for this sample of subjects were examined for any associations. 
 
There was a significant positive correlation between diurnal cortisol secretion (AUC) and 
gestational age at sampling (rp = .33, p = .017), however there was no significant difference in 
gestational age between cases and controls (weeks, M (SD), 32.9 (1.4) v 32.4 (0.6) respectively, 
z = -1.1, p = .27). There was no significant correlation between diurnal cortisol secretion (AUC) 
and any other saliva sampling details at 32 weeks gestation (see Appendix N, Table 65). 
 
3.2.2.3.1.1 Diurnal cortisol secretion at 32 weeks gestation and antenatal depression 
Diurnal cortisol secretion at 32 weeks gestation was higher in cases compared with controls (the 
analyses were performed on natural log transformed data), this difference (-1878.6 nmol/ml2, 95% 
CI [-3151.9, -605.4]) was statistically significant and represented a medium sized effect, r = .38 





Table 24: Diurnal cortisol secretion (AUC) at 32 weeks gestation and antenatal depression 
 Control 
(n = 34) 
Case 
(n = 19) 
Statistical test and 
significance 
Diurnal cortisol secretion (nmol/ml2), M (SD) 
 4627.9 (2105.1) 6506.5 (2401.4) t(51) = 2.9, p = .005 
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3.2.2.3.1.2 Diurnal cortisol secretion at 32 weeks gestation and other characteristics of the 
sample 
Further analyses showed that a number of other characteristics of the sample were also 
associated with diurnal cortisol secretion at 32 weeks gestation: 
 
3.2.2.3.1.2.1 Baseline socio-demographics  
There was no significant correlation between diurnal cortisol secretion and any socio-
demographic characteristics of the sample (see Appendix N, Table 66). 
 
3.2.2.3.1.2.2 Obstetric history and obstetric risk factors 
There was a significant positive correlation between diurnal cortisol secretion and a history of 
vaginal bleeding in the index pregnancy (rpb = .34, p = .012); however there was no significant 
group difference, between controls and cases, in women who experienced vaginal bleeding (% 
(n), 17.6 (6) v 42.1 (8) respectively, χ2 (1) = 3.8, p = .053). There was no significant correlation 
between diurnal cortisol secretion at 32 weeks gestation and any other physical health factors  
(see Appendix N, Table 67). 
 
3.2.2.3.1.2.3 Physical health and medication at 32 weeks gestation and baseline health 
behaviours 
There was a significant positive correlation between diurnal cortisol secretion and coffee intake at 
baseline (rs = .30, p = .030); however, there was no significant group difference, between controls 
and cases, in coffee intake (cups/day, M (SD), 3.2 (5.1) v 3.3 (5.0) respectively, z = -0.1, p = .96). 
There was no significant correlation between diurnal cortisol secretion at 32 weeks gestation and 
any other physical health factors (see Appendix N, Table 68). 
 
3.2.2.3.1.3 Summary of diurnal cortisol secretion at 32 weeks gestation and antenatal depression 
In this sample of 55 women with cortisol data available, I found that compared with healthy 
controls, women with antenatal depression had a significantly higher diurnal cortisol secretion 




Figure 19: Diurnal cortisol secretion at 32 weeks gestation 
 




























3.2.2.4 Cortisol awakening response and post-awakening cortisol at 32 weeks gestation   
 
3.2.2.4.1 Saliva sampling details  
29 subjects provided data for cortisol awakening response and post-awakening cortisol at 32 
weeks gestation.   
Data for AUCi and AUCg were not normally distributed, but exclusion of one outlier produced a 
normal distribution for both variables. Data for the remaining 28 subjects are presented.  
Saliva sampling details (gestational age at sample acquisition, awakening and sample time and 
the interval between sample acquisition and freezing) were recorded. CAR and post-awakening 
cortisol and saliva sampling details for this sample of subjects were examined for any 
associations. 
 
There was a significant positive correlation between AUCi and the interval between sample 
acquisition and freezing (rs = .61, p = .002). However, there was no significant group difference, 
between controls and cases, in this interval (days, M (SD), 7.5 (6.8) v 6.2 (7.5) respectively, z = -
1.1, p = .28). There was no significant correlation between AUCg or AUCi and any other saliva 
sampling details (see Appendix N, Table 69). 
 
3.2.2.4.2 Cortisol awakening response and post-awakening cortisol at 32 weeks gestation and 
antenatal depression 
Cases had a lower AUCi at 32 weeks gestation compared with controls, this difference (144.7 
nmol/ml2, 95%CI [9.48, 279.84]) was statistically significant, t(26) = 2.2, p = .037, and represented 
a medium to large sized effect, r = .40 (Figure 20 and Table 25). 
Cases had a lower AUCg at 32 weeks gestation compared with controls, this difference (63.8 
nmol/ml2, 95%CI [9.48, 279.84]) was not statistically significant, t(26) = 0.5, p = .60, and it 
represented a small sized effect, r = .10 (Figure 21 and Table 25). 
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Table 25 CAR and post-awakening cortisol at 32 weeks gestation and antenatal depression 
 Control 
(n = 14) 
Case 
(n = 14) 
Statistical test and 
significance 
AUCi (nmol/ml2), M (SD)    
 167.08 (185.10) 22.42 (162.14) t(26) = 2.2, p = .037 
AUCg (nmol/ml2), M (SD)  




Figure 20: Cortisol awakening response (AUCi) at 32 weeks gestation 
 























































3.2.2.4.3 Cortisol awakening response (AUCi) at 32 weeks gestation and other characteristics of 
the sample 
There was no significant correlation between AUCi and any socio-demographic factors (see 
appendix Table 70), obstetric history or obstetric risk factors (see Appendix N, Table 71) or 
physical health and medication at 32 weeks gestation and baseline health behaviour (see 
Appendix N, Table 72). 
 
3.2.2.4.4 Summary of CAR and post-awakening cortisol at 32 weeks gestation and antenatal 
depression 
In this sample of 28 women with cortisol data available, I found that caseness was associated 
with AUCi at 32 weeks gestation but was not associated with AUCg. Therefore, compared with 
healthy controls, women with antenatal depression had a significantly lower AUCi at 32 weeks 




3.2.3 Summary of maternal antenatal HPA axis and antenatal depression 
Compared with healthy pregnant women, those with MDD in pregnancy had significantly higher 
CRH (when it was measured after 28.72 weeks gestation). Furthermore, at 32 weeks, but not at 
25 weeks gestation, they had had significantly higher awakening and evening saliva cortisol, a 
larger diurnal cortisol secretion (AUC) and flatter cortisol awakening response (AUCi); these 
findings were independent of the effect of other characteristics of the sample.  
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3.3 Antenatal depression and obstetric outcome  
To test the hypotheses that compared to healthy women those with antenatal depression would 
have poorer obstetric outcome; cases and controls were compared. Delivery details and obstetric 
outcome data were available for all subjects. 
 
3.3.1 Delivery details 
Delivery details are presented in Table 26. There were no significant differences between cases 
and controls in onset of labour, mode of delivery, duration of rupture of membranes, length of 
labour or use of analgesia in this sample. 
 
 
3.3.2 Obstetric outcome 
Details of obstetric outcome are presented in Table 27. Gestational age at birth for women with a 
spontaneous onset of labour,1 was lower for neonates exposed to antenatal depression in utero 
compared with those not so exposed, this difference, representing 4.6 days, was statistically 
significant and represented a small to medium sized effect, r = .26.  
 
There was no significant group difference in birth weight, head circumference at birth, the 
occurrence of PTB, LBW or SGA baby, Apgar scores at 1 or 5 minutes or the sex of the baby. 
                                                       
1 Since there was only one preterm birth with no significant difference between cases and controls 
(χ2(1) = 0.8, p = 1.0), this subject was excluded from the examination of gestational age at birth in 
spontaneous onset of labour. 
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Table 26: Delivery details and antenatal depression 
 Control 
(n = 44 - 46) 
 Case 
(n = 33 - 36) 
Statistical test 
and significance 
Onset of labour, % (n) 
 Spontaneous 





χ2(1) = 0.1, p = .75 
Type of delivery, % (n)    
 Vaginal3 





χ2(1) = 0.0, p = .86 
Duration of rupture of membranes (hrs), M (SD) 
 8.26 (15.20) 4.09 (6.13) z = -1.1 p = .25 
Duration of labour6 (hours), M (SD) 
 11.3 (10.5) 10.6 (13.0) z = -0.8, p = .44 
Use of analgesia7, % (n)    






χ2(1) = 0.0, p = .559 
Note. C/S – Caesarean Section 
                                                       
1 SROM, post maturity, meconium stained liquor, IUGR, maternal infection, essential 
hypertension, diabetes (controls n=9, cases n=4). 
2 Planned Caesarean section (controls n=3, cases n=4) 
3 Of the vaginal deliveries 6 were by ventouse and 2 were by forceps 
4 Previous LSCS, ultrasound indicated a problem and failed induction of labour, maternal request, 
breech presentation  (controls n=3, cases n=4). 
5 Failure to progress in labour, suboptimal CTG, failed instrumentation, failed induction of labour  
(controls n=8, cases n=4) 
6 Data were not ascertained on the full sample (controls n = 38, cases n = 30) 
7 Data were not ascertained on the full sample (controls n = 39, cases n = 30) 
8 Inhaled (controls n=19, cases n=15), IM (controls n=2, cases n=2), Epidural (controls n=12, 
cases n=9). 
9 Fishers exact test was applied as 1 cell had an expected count less than 5. 
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Table 27: Obstetric outcome and antenatal depression 
 Control 
(n = 46) 
 Case 
(n = 35-36) 
Statistical test and 
significance 
Gestational age at birth, M (SD)1 
 40.59 (1.04) 39.93 (1.08) z = -2.0, p = .045 
Birth weight (g), M (SD) 
 3513.2 (450.9) 3410.5 (511.1) t(80) = 1.0, p = .34 







χ2(1) = 0.8, p = 1.02 







χ2(1) = 0.7, p = 0.582 







χ2(1) = 0.5, p = .692 
Head circumference at birth3 (mm), M (SD) 
 34.7 (1.3) 34.4 (1.2) t(61) = 1.1, p = .28 







χ2(1) = 0.3, p = .87 
Apgar score <8 at 1 minute, % (n) 
 8.5 (1.6) 9.0 (0.6) z = -0.5, p = .592 
Apgar score <9 at 5 minutes, % (n) 
 9.6 (0.7) 9.8 (0.4) z = -1.4, p = .172 
                                                       
1 For spontaneous onset of labour at term, control n = 32, case n = 26 
2 Fishers exact test was applied as 2 cells had an expected count less than 5. 
3 Data not ascertained on whole sample (controls n= 28, cases n = 20) 
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3.3.2.1 Gestational age at birth and characteristics of the sample 
Further analyses showed that a number of characteristics of the sample were also associated 
with gestational age at birth in women who had a spontaneous onset of labour at term: 
 
3.3.2.1.1 Baseline socio-demographic factors 
There was a significant positive correlation between gestational age at birth and maternal age (rs 
= .26, p = .049); however, there was no significant difference in maternal age between cases and 
controls (years, M (SD), 30.8 (6.6) v 32.3 (4.7) respectively, z = -0.9, p = .37). 
There was a significant correlation between gestational age at birth and maternal ethnicity (rpb = 
.30, p = .023); gestational age at birth was significantly lower in BME compared with white women 
(weeks, M (SD), 39.9 (1.1) v 40.5 (1.0) respectively, z = - 2.2, p = .024). However, in contrast to 
the full sample described at baseline, there was no significant difference in maternal ethnicity 
between controls and cases (% white (n), 71.9 (23) v 50.0 (13) respectively, χ2 (1) = 2.9, p = .09). 
There was a significant correlation between gestational age at birth and employment status at 
baseline (rpb = .26, p = .046); gestational age at birth was significantly lower in women who were 
not working outside the home compared with women who were working outside the home (weeks, 
M (SD), 40.0 (1.0) v 40.5 (1.1) respectively, z = - 2.0, p = .047). Furthermore, there was a 
significant difference in employment status between controls and cases (working outside the 
home, % (n), 71.9 (23) v 42.3 (11) respectively, χ2 (1) = 5.2, p = .023). 
There was a significant correlation between gestational age at birth and marital status (rpb = .29, p 
= .029); gestational age at birth was significantly lower in women living alone compared with 
women who were married or cohabiting (weeks, M (SD), 39.9 (1.1) v 40.5 (1.0) respectively, z = - 
2.2, p = .031). Furthermore, there was a significant difference in marital status between controls 
and cases (% living alone (n), 21.9 (7) v 57.7 (15) respectively, χ2 (1) = 7.8, p = .005). 
There was no significant correlation between gestational age at delivery and any other socio-
demographic factors (see Appendix O, Table 73). 
 
3.3.2.1.2 Obstetric history and obstetric risk factors at baseline 
There was no significant correlation between gestational age at birth and any baseline obstetric 
factors (see Appendix O, Table 74). 
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3.3.2.1.3 Physical health, medication, health behaviours and health indicators at baseline. 
There was a significant positive correlation between gestational age at birth and pre-pregnancy 
BMI (rs = .27, p = .048); however there was no significant difference in pre-pregnancy BMI 
between controls and cases (M (SD), 23.4 (4.4) v 24.6 (4.7) respectively, z = -1.1, p = .26). 
There was a significant correlation between gestational age at birth and use of antidepressant 
medication at 32 weeks gestation (rpb = .31, p = .028); gestational age at birth was significantly 
lower in women taking antidepressant medication at 32 weeks gestation compared to women who 
were not (weeks, M (SD), 39.0 (1.0) v 40.4 (1.1) respectively, t(48) = 2.3, p = .028). Furthermore, 
there was a significant difference in use of antidepressant drugs at 32 weeks gestation between 
controls and cases (% (n), 0 v 16.7 (3) respectively, χ2 (1) = 5.7, p = .0421). 
There was no significant difference between gestational age at birth and any other antenatal 
physical health factors, medication use, health behaviours and health indicators (see Appendix O, 
Table 75). 
 
3.3.2.2 Summary of gestational age at birth 
In summary, in this sample of 58 women with spontaneous onset of labour, I found that caseness 
was associated with gestational age at birth. Furthermore, I found that employment status, marital 
status, and antidepressant use at 32 weeks gestation were also associated with both gestational 
age at birth and caseness. Further analysis of the use of antidepressant drugs at 32 weeks 
gestation was precluded since there were only three cases.  
As caseness, maternal employment status and marital status were significantly associated with 
gestational age at birth for spontaneous deliveries at term, I included these predictors in an 
analysis of variance. Because having a partner and working outside the home were highly 
positively associated (rφ = .48, p < .001), I first put marital status into the model with caseness 
predicting to gestational age. The model had a trend level of significance (F(3, 54) = 2.4, p = .075), 
caseness was also a trend level of significance (F(1, 54) = 2.9, p = .095), marital status was not 
significant and there was no significant interaction between marital status and caseness. Next I 
put employment status into the model with caseness and the model was significant (F(3, 54) = 3.4, p 
= .024); caseness remained significant (F(1, 54) = 4.7, p = .034) independently of employment 
                                                       
1 Fishers exact test was applied as 2 cells had an expected count less than 5. 
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status, which was not significant, and there was no interaction between employment status and 
caseness. 
Therefore, in women with a spontaneous onset of labour at term, gestational age at birth was 
significantly lower in cases compared with controls. This was not independent of marital status, 
but was independent of the effect of other characteristics of the sample.  
 
 
3.3.3 Summary of obstetric outcomes and antenatal depression 
In women with spontaneous onset of labour at term, compared with healthy women, those with 
MDD in pregnancy had significantly shorter length of gestation. This finding was independent of 
the effect of characteristics of the sample other than marital status. The potential effect of 
antidepressant medication was not taken into account as only three subjects were taking 
antidepressants. Lastly, cases and controls did not differ in rates of PTB, LBW or SGA babies, or 
in the birth weight of their baby. 
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3.4 Maternal antenatal HPA axis and obstetric outcome 
To test the hypotheses of an association between maternal antenatal HPA axis and obstetric 
outcomes, correlations were performed, among subjects with a spontaneous onset of labour at 
term, between gestational age at birth and those antenatal HPA axis measures where there was a 
significant difference between cases and controls (CRH, controlling for gestational age at sample 
acquisition, and awakening, evening and diurnal cortisol and CAR (AUCi) at 32 weeks gestation). 
There were no significant correlations (Table 28). 
 
Despite the absence of any significant correlation between gestational age at birth and the 
maternal antenatal HPA axis measures, it is theoretically possible that mediation was taking 
place, thus I used PROCESS to examine this phenomenon further. However, I found no support 
for the hypothesis that measures of the maternal antenatal HPA axis were mediating the 
association of caseness with gestational age at birth.  
 
 
Secondly, in this subset of subjects with spontaneous onset of labour at term, using PROCESS, I 
found no evidence that the association between caseness and gestational age at birth was 
moderated by any of the antenatal HPA axis measures (CRH, controlling for gestational age at 
sample acquisition, awakening, evening or diurnal cortisol or CAR (AUCi) at 32 weeks gestation). 
 
 
3.4.1 Summary of maternal antenatal HPA axis and obstetric outcome 
There were no significant correlations between gestational age at birth and the maternal antenatal 
HPA axis measures that differed between cases and controls. Furthermore there was no 
evidence of mediation or moderation, by antenatal HPA axis measures, of the effect of caseness 
on this measure. 
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Table 28: Associations between gestational age at birth and maternal antenatal HPA axis 
measures  
Maternal antenatal HPA axis 
 CRH controlling 
for gestational 
age at sample 
acquisition 
Awakening 
cortisol at 32 
weeks gestation  
Evening cortisol 
at 32 weeks 
gestation  
Diurnal cortisol 
at 32 weeks 
gestation  




age at birth 
-.06 .18 -.16 .04 -.04 
n  50 46 41 35 18 





3.5 Infant HPA axis at 8 weeks postnatal 
 
3.5.1 Study subjects 
At eight weeks postnatal seven (9%) subjects had dropped out of the study leaving 75  (91%) 
subjects, 45  (98%) controls and 30 (83%) cases. 
 
3.5.2 Infant cortisol response to the pain of immunization at 8 weeks postnatal (day 1) 
To test the hypotheses that compared with 8-week-old infants not exposed to depression in utero, 
8-week-old infants so exposed would have a larger cortisol response to the pain of immunization; 
infants of cases and controls were compared. 54 infants provided saliva samples both before and 
20 minutes after routine immunization at 8 weeks postnatal. The saliva sampling details and 
cortisol are presented followed by the characteristics of infants and their mothers. 
 
3.5.2.1 Saliva sampling details  
Cortisol levels before and 20 minutes after routine immunization and the change (delta cortisol) 
were measured. Saliva sampling details (time of sample before the immunization, time of the 
immunization, interval between the first sample and the immunization) were recorded. Infant 
cortisol and saliva sampling details for this sample of subjects were examined for any 
associations. There were no significant correlations between any of the three infant cortisol 
measures and any saliva sampling characteristics at 8 weeks postnatal (see Appendix P, Table 
76). 
 
3.5.2.2 Infant cortisol response to immunization at 8 weeks postnatal and maternal 
antenatal depression 
Infants exposed to depression in utero were compared with those not so exposed. Cortisol after 
the immunization was higher in infants exposed to depression in utero compared with those not 
so exposed, this difference (-10.45 nmol/ml, 95% CI [-21.8, -.1] was at a trend level of 
significance, t(19.9)  = 1.9, p = .069, however it represented a medium to large sized effect, r = .40. 
Delta cortisol was also higher in infants exposed to depression in utero compared with those not 
so exposed, this difference (-4.93 nmol/ml, 95% CI [-11.6, 1.8], was not statistically significant, 
however it represented a small to medium sized effect, r = .20. Cortisol before the immunization 
was higher in infants exposed to depression in utero compared with those not so exposed, 
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however, this difference was not statistically significant and represented only a small sized effect, 
r = .16  (Table 29). 
 
On visual inspection the change in cortisol from before to after the immunization appeared 
different between infants of cases and controls (Figure 22), hence further examination of the data 
was warranted. The Wilcoxon signed-rank test is a non-parametric test for repeated measures 
and it allows examination of the effect size of the change in cortisol for cases and controls 
separately. For both groups the cortisol was significantly higher after than before immunization; 
however, the effect was larger in cases than in controls. Cases, median = 6.5 before and 14.7 
after the immunization, z = -3.2, p = .001, r = -.52, this represents a large effect for the cases 
group. Controls, median = 5.1 before and 10.6 after the immunization, z = -3.2, p = .001, r = -.37, 
this represents only a medium change in levels of cortisol for the control group. Thus the effect 














Table 29: Infant cortisol response to immunization at 8 weeks postnatal and maternal antenatal 
depression 
 Control 
(n = 36) 
Case 
(n = 18) 
Statistical test and 
significance 
Cortisol before the immunization (nmol/ml), M (SD) 
 6.88 (5.38) 12.41 (19.08) z  = -1.2, p = .25 
Cortisol 20 minutes after the immunization (nmol/ml), M (SD) 
 12.69 (9.03) 23.14 (22.18) t(19.9)  = 1.9, p = .069 
Delta cortisol (nmol/ml), M (SD)    
 5.81 (11.14) 10.74 (12.41) t(52)  = 1.5, p = .15 
Effect size for the change in cortisol from pre- to post-immunization 
 Medium effect 
r = .37, p = .001 
Large effect 





Figure 22: Infant cortisol response to immunization at 8 weeks postnatal 
 


























3.5.2.3 Infant cortisol response to immunization at 8 weeks postnatal and other infant and 
maternal factors 
 
The characteristics of infants who provided saliva samples on the day of immunization at 8 weeks 
postnatal are presented; maternal factors are also presented since they are potential confounding 
factors in the analysis of infant cortisol. Infants of cases (thus exposed to antenatal depression in 
utero) and infants of controls (not exposed to antenatal depression in utero) were compared. 
 
3.5.2.3.1 Infant characteristics at 8 weeks postnatal 
Compared with infants of controls, a statistically significant greater proportion of infants of cases 
were taking regular medication at 8 weeks postnatal (0 v 16.7% respectively). There were no 
significant group differences in infant age at assessment, breastfeeding, health or medication use 
(Table 30).  
 
3.5.2.3.2 Infant factors prior to 8 weeks postnatal 
Compared with infants of controls, a greater proportion of infants of cases had been exposed to 
maternal smoking in utero (2.9% v 47.1% respectively, χ2 (1) = 15.6, p < .001, OR = 30.2, 95% CI 
[3.3, 274.1]) and maternal symptoms of anxiety in utero (STAIS, M (SD), 27.9 (7.4) v 52.5 (9.6) 
respectively); this difference was statistically significant, t(52)  = 9.8, p = .001 and represented a 
medium to large sized effect, r = 0.74. There was no significant group difference in exposure to 
antidepressant medication in utero, gestational age at birth, mode of delivery, APGAR scores at 
birth, the sex of the infant or any cluster scores of the NBAS examination (which was performed in 
the neonatal period) (Table 31).  
 
3.5.2.3.3 Maternal characteristics at 8 weeks postnatal (Table 32) 
 
3.5.2.3.3.1 Maternal medication and health behaviours 
Compared with controls, a statistically significant greater proportion of cases were taking regular 
medication (2.9% v 38.9% respectively, χ2 (1) = 12.0, p = .001, OR 21.6 [2.4, 195.8]) and smoking 
(0% v 33.3% respectively, χ2 (1) = 6.6, p = .021) at 8 weeks postnatal. There were no significant 
group differences in any other maternal medication use or health behaviours at 8 weeks 
postnatal.  
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3.5.2.3.3.2 Maternal mental health 
There was no significant difference between cases and controls in a current diagnosis of MDD 
(see Table 32); the two cases who met criteria for MDD at 8 weeks postnatal were both taking 
antidepressant medication at 8 weeks postnatal, however, only two other cases were taking 
antidepressant medication at this assessment, therefore the absence of a group difference in in a 
current diagnosis of MDD 8 weeks postnatal was unlikely to be attributable to use of 
antidepressant medication. However, compared with controls, cases had a longer duration of 
exposure to MDD in the postnatal period (weeks, M (SD), 0 v 1.6 (2.8) respectively), this 
difference was statistically significant and represented a medium to large sized effect, r = .46.  
 
3.5.2.3.3.3 Maternal cortisol 
There was no significant group difference in any maternal cortisol measure (awakening, evening, 
diurnal cortisol, AUCg and AUCi) at 8 weeks postnatal. 
 
3.5.2.3.4 Summary of infant and maternal characteristics 
As described above, there were significant differences between cases and controls in a number of 
infant and maternal characteristics (infants taking regular medication, exposure to smoking in 
utero, exposure to symptoms of anxiety in utero, mothers who were taking regular medication and 
who were smoking at 8 weeks postnatal and maternal duration of MDD in the postnatal period). 
However, there were no significant correlations between the infant cortisol measures and any of 
these potential confounding factors (see Appendix P, Table 77); thus they were not accounting for 
the differences found in infant cortisol response to immunization at 8 weeks postnatal. 
 
3.5.2.4 Summary of infant cortisol response to immunizations and antenatal depression at 
8 weeks postnatal 
In this sample of 54 infants with cortisol data before and 20 minutes after routine immunizations at 
8 weeks postnatal, I found that compared with infants not exposed to depression in utero, infants 
who were exposed to depression in utero had a higher cortisol level after the immunizations. This 
was only at a trend level of significance, however, it represented a medium to large sized effect. 
Furthermore, delta cortisol was also higher in infants exposed to depression in utero; this 
difference was not statistically significant, however it represented a small to medium sized effect. 
Moreover, immunization was associated with an increase in cortisol equivalent to a large effect 
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size in cases but a smaller (medium) effect size in controls. These findings were independent of 
other infant or maternal factors. 
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Table 30: Infant characteristics at 8 weeks postnatal (day 1) 
 Control 
(n = 36) 
Case 
(n = 18) 
Statistical test and 
significance 
Baby’s age at assessment (weeks), M (SD) 
 9.5 (1.8) 9.3 (1.8) t(52)  = 0.4, p = .71 







χ2 (1) = 1.2, p = .421 





5.6 (1)  
94.4 (17) 
χ2 (1) = 2.0, p = .332 







χ2 (1) = 0.2, p = .721 







χ2 (1) = 2.4, p = .151 







χ2 (1) = 6.4, p = .0332 
 
 
                                                       
1 Fisher’s exact test was applied as 1 cell had an expected cell count less than 5. 
2 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
3 These data were not ascertained on the full sample (controls n=17, cases n= 12). 
4 Chloramphenicol eye drops, daktarin oral gel, gaviscon, hydrocortisone cream. 
192 
Table 31: Infant factors prior to 8 weeks postnatal (day 1) 
 Control 
(n = 36) 
Case 
(n = 17-18) 
Statistical test and 
significance 







χ2 (1) = 5.8, p = .072 







χ2 (1) = 15.6, p < .001 
Exposure to symptoms of anxiety in utero (STAIS score), M (SD) 
 27.9 (7.4) 52.5 (9.6) t(52)  = 9.8, p = .001 
Gestational age at birth (weeks), M (SD) 
 40.31 (1.60) 40.06 (1.09) t(52)  = 0.6, p = .55 







χ2 (1) = 0.5, p = .733 
Apgar score at 1 minute, M (SD) 
 8.6 (1.7) 9.0 (0.6) z = 0.0, p = 1.0 
Apgar score at 5 minutes, M (SD)    
 9.6 (0.7) 9.8 (0.4) z = -1.2, p = .25 







χ2 (1) = 0.0, p = .87 
NBAS orientation cluster, median 
 7.7 6.9 z = -1.7, p = .09 
NBAS motor cluster, median 
 5.7 5.6 z = -1.3, p = .20 
NBAS range of state cluster, median 
 2.8 3.3 z = -1.31, p = .20 
                                                       
1 These data were not ascertained on the full sample (cases n= 13). 
2 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5 
3 Fisher’s exact test was applied as 1 cell had an expected cell count less than 5. 
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NBAS regulation of state cluster, median 
 6.0 6.0 z = -0.3, p = .79 
NBAS autonomic stability cluster, median 
 6.0 5.3 z = -1.6, p = .11 
NBAS total number of abnormal reflexes 





Table 32: Maternal characteristics at 8 weeks postnatal (day 1) 
 Control 
(n = 35-36) 
Case 
(n = 16-18) 
Statistical test and 
significance 







χ2 (1) = 12.0, p = .0012 







χ2 (1) = 1.7, p = .323 
Coffee (cups/week) at 8 weeks postnatal, mean (SD)4 
 4.4 (5.3) 4.3 (7.6) z = -1.2, p = .35 
Tea (cups/week) at 8 weeks postnatal, mean (SD)4 
 9.8 (13.4) 10.6 (15.7) z = -0.7, p = .46 
Alcohol use (units/week) at 8 weeks postnatal, % (n)4 
 1.5 (2.1) 0.6 (1.0) z = -1.0, p = .30 







χ2 (1) = 6.6, p = .0213 







χ2 (1) = 4.2, p = .113 
Duration of exposure to MDD in the postnatal period (weeks), M (SD) 
 0 1.6 (2.8) z = -3.4, p = .002 
Awakening cortisol at 8 weeks postnatal (nmol/ml), M (SD)6 
 8.11 (3.45) 8.57 (4.38) t(47) = 0.4, p = .69 
Evening cortisol at 8 weeks postnatal (nmol/ml), M (SD)7 
 1.45 (0.77) 1.53 (0.76) t(36) = 0.3, p = .76 
                                                       
1 Thyroxine, OCP, clexane, beclomethosone inhaler, daktarin cream, sertraline. 
2 Fisher’s exact test was applied as 1 cell had an expected cell count less than 5. 
3 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
4 Not ascertained on full sample (controls n=17, cases n=11) 
5 Not ascertained on full sample (controls n=17, cases n=12) 
6 Awakening cortisol was not ascertained on the whole sample of controls (n = 32) 
7 Evening cortisol was not ascertained on the whole sample (controls n = 23 cases n =15) 
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Diurnal cortisol (nmol/ml2) at 8 weeks postnatal, M (SD)1 
 3511.0 (1245.4) 3561.4 (1371.2) t(34) = 0.1,  p = .91 
Post-awakening cortisol (AUCg) (nmol/ml2) at 8 weeks postnatal, M (SD)2 
 567.1 (229.4) 666.3 (238.2) t(16) = 0.8,  p = .42 
CAR (AUCi) (nmol/ml2) at 8 weeks postnatal, M (SD)2 




                                                       
1 Diurnal cortisol was not ascertained on the whole sample (controls n = 21 cases n =15) 
2 CAR was not ascertained on the whole sample (controls n = 11 cases n = 7) 
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3.5.3 Associations of infant cortisol response to immunizations at 8 weeks postnatal with 
maternal antenatal HPA axis 
 
To test the hypotheses that infant HPA axis function at 8 weeks postnatal would be associated 
with maternal antenatal HPA axis, correlations were performed to examine associations between 
the infant cortisol measures at 8 weeks postnatal and the maternal antenatal HPA axis measures 
that differed between cases and controls (CRH, controlling for gestational age at sample 
acquisition and awakening, evening and diurnal cortisol and CAR (AUCi) at 32 weeks gestation). 
There were no significant associations between the infant cortisol and maternal HPA axis 
measures (Table 33).  
 
Despite the absence of any significant correlation between these maternal antenatal HPA axis 
measures and infant cortisol response to the pain of immunization, it is theoretically possible that 
mediation was taking place, thus I used PROCESS to examine this phenomenon further. 
However, I found no support for the hypothesis that measures of the maternal antenatal HPA axis 
were mediating the association of caseness with infant cortisol response to immunizations at 8 
weeks postnatal.  
 
Using PROCESS, I examined if the infant cortisol measures were moderated by any of the 
maternal antenatal cortisol measures that differed between cases and controls. I found that infant 
delta cortisol was moderated by the interaction of caseness and maternal diurnal cortisol (AUC) at 
32 weeks gestation. No other variables were associated with the infant or maternal cortisol 
measures thus no other covariates were included in the model. The model was significant, R2 = 
.22, F(3, 32) = 3.0, p = .045 (see Table 34). This finding was followed up with simple slopes 
analysis; the conditional effect of caseness on delta cortisol at values of maternal antenatal 
diurnal cortisol is shown graphically in Figure 23; when the value of maternal antenatal diurnal 
cortisol was +1SD above the mean (7648.2 nmol/ml) delta cortisol was statistically significantly 
higher in infants exposed to depression in utero compared with infants not so exposed. Further 
examination of this interaction using the Johnson-Neyman technique showed that the effect of 
caseness on delta cortisol became statistically significant when values of maternal antenatal 
diurnal cortisol were ≥6938.6 nmol/ml2 and this effect became greater with increasing levels of 
maternal antenatal diurnal cortisol (see Figure 24). Putting this into context, as described in 
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section 3.2.2.3.1.3 above, maternal antenatal diurnal cortisol at 32 weeks gestation was higher in 
cases than controls. 
 
There were no other moderating effects of maternal antenatal cortisol on the association between 




Table 33: Infant cortisol response to immunizations at 8 weeks postnatal and maternal antenatal 
HPA axis  
Maternal antenatal HPA axis 
 CRH controlling 
for gestational 
age at sample 
acquisition 
Awakening 




at 32 weeks 
gestation 
Diurnal cortisol 
at 32 weeks 
gestation 
CAR (AUCi) at 
32 weeks 
gestation 
Pre -.04 .01 -.27 .00 -.19 
Post .10 .08 -.09 .06 -.16 
Delta  .13 .19 .03 .20 -.16 
n  47 42 42 36 21 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric 
analysis. Spearman’s correlation coefficients are presented for continuous variables that did not 
permit parametric analysis.   
Pre = cortisol before the immunizations 
Post = cortisol 20 minutes after the immunizations 
Delta = change in cortisol from before to after the immunizations 
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3.5.3.1 Summary of the associations of infant cortisol response to immunizations at 8 
weeks postnatal with maternal antenatal HPA axis 
 
There were no significant correlations between cortisol response to immunization in 8-week-old 
infants and the maternal antenatal HPA axis measures that differed between cases and controls. 
Furthermore, there was no evidence of mediation of the effect of caseness on these infant 
measures. However, the change in cortisol from before to after the immunization (delta cortisol) 
was moderated by the interaction of caseness and maternal antenatal diurnal cortisol at 32 weeks 
gestation such that infants exposed to depression in utero had a larger delta cortisol at 8 weeks 
postnatal when maternal antenatal diurnal cortisol was high. Furthermore, as described above, 
maternal antenatal diurnal cortisol at 32 weeks gestation was higher in cases than controls, 
indicating a continuity of overactivity of both maternal antenatal HPA axis and infant HPA axis.  
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Table 34: Linear model of predictors of infant delta cortisol  
 B SE B t p 
Constant     
 6.2 [2.7, 9.6] 1.7 3.6  < .001 
Maternal antenatal diurnal cortisol 
 0.001 [-0.001, 0.003] 0.001 1.1 .27 
Caseness     
 0.2 [-7.7, 8.0] 3.8 0.04 .96 
Interaction (caseness x diurnal cortisol) 
 0.005 [0.001, 0.009] 0.002 2.8 .009 
Note. N = 54, R2 = .22, bias-corrected and accelerated 95% confidence intervals are reported in 






Figure 23: Moderation of infant delta cortisol at 8 week postnatal 
 


































Figure 24: Moderation of the effect of caseness on delta cortisol  
 
Note. * When maternal antenatal diurnal cortisol, at 32 weeks gestation, was ≥6938.6 nmol/ml2, 
delta cortisol was statistically significantly higher in infants exposed to depression in utero 
compared with infants not so exposed. 
 
 
Zone of significance 
(Johnson-Neyman method) * 
203 
3.5.4 Infant basal cortisol levels at 8 weeks postnatal (day 2) 
 
To test the hypotheses that compared with 8-week-old infants not exposed to depression in utero, 
8-week-old infants so exposed would have higher basal (awakening and evening) cortisol levels, 
infants of cases and controls were compared. 61 infants provided saliva samples in the morning 
and the evening the day after routine immunizations at 8 weeks postnatal. The saliva sampling 
details and cortisol are presented followed by the characteristics of infants and their mothers. 
 
3.5.4.1 Saliva sampling details  
Awakening and evening cortisol levels at 8 weeks postnatal were measured and saliva sampling 
details were recorded and their associations examined. There was no significant correlation 
between infant awakening cortisol and any saliva sampling detail (awakening and sample time, 
interval between awakening and sample, interval between the end of the last feed and sample 
time, and the interval between sample acquisition and freezing) (see Appendix P, Table 78). Nor 
was there a significant correlation between infant evening cortisol and saliva sampling details 
(sample time, interval between the end of the last feed and sample time, interval between the end 
of the last nap and sample time, duration of the last nap before the evening sample and the 
interval between sample acquisition and freezing) (see Appendix P, Table 79).  
 
3.5.4.2 Infant basal cortisol levels at 8 weeks postnatal and maternal antenatal depression 
Compared with infants not exposed to depression in utero, infants who were so exposed had 
higher awakening cortisol; however, the difference (-4.11 nmol/ml, 95% CI [-4.1, 3.3]) was not 
statistically significant and represented only a small sized effect, r = .13. There was no statistically 
significant difference between the two groups in evening cortisol and a negligible sized effect, r = 
.06 (Table 35). 
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Table 35: Infant awakening and evening cortisol at 8 weeks postnatal and maternal antenatal 
depression 
 Control 
(n = 37) 
Case 
(n = 24) 
Statistical test and 
significance 
Infant awakening cortisol (nmol/ml), M (SD) 
 9.80 (8.67) 13.91 (17.33) t(59) = 1.0, p = .30 
Infant evening cortisol (nmol/ml), M (SD) 
 8.35 (14.52) 7.47 (16.75) z = -0.5, p = .59 
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3.5.5 Associations of infant basal cortisol levels at 8 weeks postnatal with maternal 
antenatal HPA axis 
To test the hypotheses that infant HPA axis function at 8 weeks postnatal would be associated 
with maternal antenatal HPA axis, correlations were performed to examine associations between 
infant awakening and evening cortisol at 8 weeks postnatal and the maternal HPA axis measures 
that differed between cases and controls in pregnancy (CRH, controlling for gestational age at 
sample acquisition and awakening, evening and diurnal cortisol and CAR (AUCi) at 32 weeks 
gestation); there were no significant associations (Table 36).  
 
Despite the absence of any significant correlation between these maternal antenatal HPA axis 
measures and infant basal cortisol, it is theoretically possible that mediation was taking place, 
thus I used PROCESS to examine this phenomenon further. However, I found no support for the 
hypothesis that measures of the maternal antenatal HPA axis were mediating an association of 
caseness with infant basal cortisol at 8 weeks postnatal.  
 
Furthermore, using PROCESS, I found no evidence that the association between caseness and 
infant basal cortisol levels at 8 weeks postnatal was moderated by any of the antenatal HPA axis 
measures (CRH or awakening, evening or diurnal cortisol or CAR (AUCi) at 32 weeks gestation).  
 
 
3.5.5.1 Summary of Associations of infant basal cortisol levels at 8 weeks postnatal with 
maternal antenatal HPA axis 
There were no significant correlations between basal cortisol measures in 8-week-old infants and 
the maternal antenatal HPA axis measures that differed between cases and controls. Furthermore 
there was no evidence of mediation or moderation of the effect of caseness on these infant 
measures. 
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Table 36: Infant basal cortisol at 8 weeks postnatal and maternal antenatal HPA axis 
Maternal antenatal HPA axis  
 CRH controlling 
for gestational 
age at sample 
acquisition 
Awakening 
cortisol at 32 
weeks gestation 
Evening cortisol 
at 32 weeks 
gestation 
Diurnal cortisol 
at 32 weeks 
gestation 
CAR (AUCi) at 
32 weeks 
gestation 
Awakening -.17 -.04 -.15 -.07 -.29 
Evening -.10 -.16 -.22 -.29 .11 
n  54 49 48 43 22 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric 
analysis. Spearman’s correlation coefficients are presented for continuous variables that did not 
permit parametric analysis.   
Awakening = infant awakening cortisol 
Evening = infant evening cortisol  
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3.6 Infant HPA axis at 1 year postnatal 
 
3.6.1 Study subjects 
At one year postnatal a further nine subjects had dropped out of the study leaving 66 (80%) 
subjects, 40 (87%) controls and 26 (72%) cases. 
 
3.6.2 Infant cortisol response to the pain of immunization at 1 year postnatal (day 1) 
To test the hypotheses that compared with 1-year-old infants not exposed, 1-year-old infants 
exposed to depression in utero would have a larger cortisol response to the pain of immunization; 
infants of cases and controls were compared. 43 infants provided saliva samples both before and 
20 minutes after routine immunization at 1 year postnatal. The saliva sampling details and cortisol 
are presented followed by the characteristics of infants and their mothers. 
 
3.6.2.1 Saliva sampling details  
Cortisol levels before and 20 minutes after routine immunization at 1 year postnatal were 
measured. Saliva sampling details for this sample (time of sample before the immunization, time 
of the immunization, interval between the first sample and the immunization) were recorded. 
There were no significant correlations between the infant cortisol measures and any saliva 
sampling details at 1 year postnatal (see Appendix Q, Table 80). 
 
3.6.2.2 Infant cortisol response to immunization at 1 year postnatal and maternal antenatal 
depression 
Infants exposed to depression in utero were compared with those not so exposed. Non-
parametric tests were used since there were outliers in both groups and the data were not 
normally distributed and did not benefit from transformation; the standard deviations were large in 
both groups demonstrating a large degree of variation in these infant cortisol measures. Cortisol 
after the immunization was higher in infants exposed to depression in utero compared with those 
not so exposed; this difference was statistically significant and it represented a medium sized 
effect, r = .32 (Figure 25Error! Reference source not found.). Delta cortisol was also higher in 
infants exposed to depression in utero compared with those not so exposed; this difference was 
not statistically significant, however it represented a small to medium sized effect, r = 0.22. 
Cortisol before the immunization was lower in infants exposed to depression in utero compared 
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with those not so exposed, however, this difference was not statistically significant and 
represented only a small sized effect, r = .09.  
 
As at 8 weeks postnatal, on visual inspection the change in cortisol from before to after the 
immunization appeared different between infants of cases and controls (Figure 26), hence further 
examination of the data was warranted and the Wilcoxon signed-rank test was used. For the 
cases group there was a statistical trend for higher cortisol levels after than before the 
immunization (median, 5.34 v 3.63 respectively, z = -1.71, p = .088); this represented a medium 
sized effect, r = .30. For the control group the cortisol levels were not significantly different 
(median = 3.93 after v 3.16 before, z = -0.32, p = .75); this represented a negligible effect, r = .04  
(Table 37). Thus there was a statistical trend for a medium sized effect of immunization on cortisol 






Table 37: Infant cortisol response to immunization at 1 year postnatal and maternal antenatal 
depression  
 Control 
(n = 27) 
Case 
(n = 16) 
Statistical test 
and significance 
Cortisol pre-immunization (nmol/ml), M (SD) 
 6.74 (15.20) 5.65 (4.78) z = -0.6, p = .55 
Cortisol post-immunization (nmol/ml), M (SD) 
 7.00 (15.21) 11.32 (19.82) z = -2.1, p = .038 
Delta cortisol  (nmol/ml), M (SD) 
 0.27 (2.75) 5.67 (16.84) z = -1.4, p = .14 
Effect size for the change in cortisol from pre- to post-immunization 
 No effect 
r = .04, p = .75 
Medium sized effect 




















Figure 26: Infant cortisol response to immunization at 1 year postnatal 
 




























3.6.2.3 Infant cortisol response to immunization at 1 year postnatal and other infant and 
maternal characteristics 
 
The characteristics of infants who provided saliva samples on the day of immunization at 1 year 
postnatal are presented; maternal factors are also presented since they are potential confounding 
factors in the analysis of infant cortisol. Infants of cases (thus exposed to antenatal depression in 
utero) and infants of controls (not exposed to antenatal depression in utero) were compared. 
 
3.6.2.3.1 Infant characteristics at 1 year postnatal 
There were no significant group differences in infant age at assessment, breastfeeding, health or 
medication use, or in Bayley scores for cognitive, language or motor development at 1 year 
postnatal (Table 38). 
 
3.6.2.3.2 Infant factors prior to 1 year postnatal 
Compared with infants of controls, infants of cases had been exposed to higher levels of 
symptoms of anxiety in utero (STAIS, M (SD) 28.6 (6.6) v 48.9 (14.0) respectively), this difference 
was statistically significant, t(16.1) = 5.1, p < .001 and represented a large sized effect, r = .78. 
However, there was no significant group difference in exposure to antidepressants or smoking in 
utero, mode of delivery, gestational age at birth or the sex of the baby (Table 39).  
 
3.6.2.3.3 Maternal characteristics (Table 40) 
3.6.2.3.3.1 Maternal medication and health behaviours 
Compared with controls, a larger proportion of cases were taking regular medication at 1 year 
postnatal (% (n), 8 (2) v 37.5 (6) respectively, χ2 (1) = 5.4, p = .04, OR = 6.9, 95% CI [1.2, 40.3]). 
There were no significant group differences in maternal health behaviours at 1 year postnatal.  
 
3.6.2.3.3.2 Maternal mental health 
There was no significant difference between cases and controls in a current diagnosis of MDD.  
Compared with controls the duration of MDD between the 8 week postnatal and 1 year postnatal 
assessments was significantly higher in cases (months M (SD), 0.03 (0.15) v 1.78 (3.07) 
respectively), this difference was statistically significant, z = -3.0, p = .002 and represented a 
medium to large sized effect, r = .47. 
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3.6.2.3.3.3 Maternal cortisol 
Compared to controls, maternal awakening cortisol at 1 year postnatal was lower in cases 
(nmol/ml, M (SD), 10.48 (5.12) v 6.96 (3.0) respectively), this difference was statistically 
significant, t(36) = 2.4, p = .022 and  represented a medium sized effect, r = .37. There was no 
significant correlation between maternal awakening cortisol level and any saliva sampling details 
at 1 year postnatal, nor with any maternal factors which differed between cases and controls. 
There were no other group differences in any other maternal cortisol measure (evening, diurnal, 
AUCg and AUCi) at 1 year postnatal. 
 
3.6.2.3.4 Summary of infant and maternal characteristics 
As described above there were significant differences between cases and controls in a number of 
infant and maternal factors (exposure to symptoms of anxiety in utero, maternal duration of 
postnatal depression, concurrent use of medication and maternal awakening cortisol). However, 
further analyses showed that none of these differences was associated with the infant cortisol 
measures at immunization at 1 year postnatal; thus they were not accounting for the differences 
found in infant cortisol response to immunization (see Appendix Q, Table 81). 
 
  
3.6.2.4 Summary of infant cortisol response to immunizations and antenatal depression at 
1 year postnatal 
In this sample of 43 infants with cortisol data before and 20 minutes after routine immunizations at 
1 year postnatal, I found that compared with infants not exposed to depression in utero, infants 
who were exposed to depression in utero had a higher cortisol level after the immunizations, the 
difference was statistically significant and represented a medium sized effect. Furthermore, delta 
cortisol was also higher in infants exposed to depression in utero, this difference was not 
statistically significant, however it represented a small to medium sized effect. Moreover, 
immunization was associated with a trend for increase in cortisol equivalent to a medium effect 
size in cases but immunization had no effect on cortisol in controls. These findings were 
independent of other infant or maternal factors. 
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Table 38: Infant characteristics at 1 year postnatal (day 1) 
 Control 
(n = 25 - 27) 
Case 
(n = 16) 
Statistical test and 
significance 
Baby’s age at assessment (months), M (SD) 
 12.7 (0.6) 12.8 (1.6) t(40) = 0.4, p = .75 







χ2 (1) = 0.3, p = .721 







χ2 (1) = 0.4, p = 1.04 







χ2 (1) = 0.9, p = .634 
Taking PRN medication at 1 year postnatal, % (n)6 
 0 0  
Bayley cognitive composite score, M (SD) 
 112.5 (16.1) 111.2 (12.8) t(40) = 0.2, p = .79 
Bayley language composite score, M (SD) 
 104.5 (13.0) 97.7 (12.7) t(40) = 1.6, p = .11 
Bayley motor composite score, M (SD) 
 102.6 (12.0) 102.7 (13.7) t(40) = 0.0, p = .98 
                                                       
1 Fisher’s exact test was applied as 1 cell had an expected cell count less than 5. 
2 These data were not ascertained on the full sample (controls n=12, cases n= 12). 
3 Asthma, eczema, lactose intolerance 
4 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
5 Ventolin, cream for eczema, canestan cream, laxative. 
6 These data were not ascertained on the full sample (controls n=11, cases n= 11). 
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Table 39: Infant factors prior to 1 year postnatal (day 1) 
 Control 
(n = 27) 
Case 
(n = 16) 
Statistical test and 
significance 







χ2 (1) = 4.4, p = .102 







χ2 (1) = 4.4, p = .062 
Exposure to symptoms of anxiety in utero (STAIS score), M (SD) 
 28.6 (6.6) 48.9 (14.0) t(16.1) = 5.1, p < .001 







χ2 (1) = 1.1, p = .48 
Gestational age at birth (weeks), M (SD) 
 40.32 (1.71) 39.90 (1.16) t(41) = 0.8, p = .40 







χ2 (1) = 0.7, p = .39 
 
 
                                                       
1 These data were not ascertained on the full sample of cases (n= 13). 
2 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5 
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Table 40: Maternal characteristics at 1 year postnatal (day 1) 
 Control 
(n = 24 - 27) 
Case 
(n = 14 - 16) 
Statistical test and 
significance 







χ2 (1) = 5.4, p = .042 







χ2 (1) = 0.4, p = 1.02 
Coffee (cups/week) at 1 year postnatal, mean (SD)4 
 6.9 (6.9) 5.3 (7.9) z = -0.9, p = .39 
Tea (cups/week) at 1 year postnatal, mean (SD)4 
 10.6 (11.4) 6.2 (6.2) t(15.2) = 1.1, p = .26 
Alcohol use (units/week) at 1 year postnatal, % (n)5 
 4.0 (4.8) 0.8 (1.0) z = -1.7, p = .10 







χ2 (1) = 1.0, p = .592 







χ2 (1) = 3.4, p = .142 
Duration of MDD between 2 and 12 months postnatal (months), M (SD) 
 0.03 (0.15) 1.78 (3.07) z = -3.0, p = .002 
Awakening cortisol at 1 year postnatal (nmol/ml), M (SD)6 
 10.48 (5.12) 6.96 (3.00) t(36) = 2.4, p = .022 
Evening cortisol at 1 year postnatal (nmol/ml), M (SD)7 
 1.72 (3.36) 1.29 (0.83) z = -0.9, p = .37 
                                                       
1 Thyroxine, antibiotic eye drops, antihistamine, OCP, steroid inhaler, sertraline, imipramine, 
fluoxetine, ranitidine, loratidine, non-steroid asthma inhaler 
2 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
3 Not ascertained on full sample (controls n=12, cases n=12) 
4 Not ascertained on full sample (controls n=11, cases n=12) 
5 Not ascertained on full sample (controls n=11, cases n=8) 
6 Awakening cortisol was not ascertained on the whole sample (controls n = 23 cases n =15) 
7 Evening cortisol was not ascertained on the whole sample (controls n = 22 cases n =12) 
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Diurnal cortisol at 1 year postnatal (nmol/ml2), M (SD)1 
 3891.0 (1589.6) 3450.8 (1314.5) t(28) = 0.8,  p = .43 
Post-awakening cortisol (AUCg) at 1 year postnatal (nmol/ml2), M (SD)2 
 602.3 (218.6) 624.3 (230.5) t(10) = 0.2, p = .87 
CAR (AUCi) at 1 year postnatal (nmol/ml2), M (SD)2 
 83.9 (201.8) 162.8 (142.4) t(10) = 0.8, p = .45 
 
 
                                                       
1 Diurnal cortisol was not ascertained on the whole sample (controls n = 18 cases n =12) 
2 CAR was not ascertained on the whole sample (controls n = 6 cases n = 6) 
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3.6.3 Associations of infant cortisol response to immunizations at 1 year postnatal with 
maternal antenatal HPA axis 
To test the hypotheses that infant HPA axis function at 1 year postnatal would be associated with 
maternal antenatal HPA axis, correlations were performed to examine associations between 
infant cortisol (before and after immunizations and the change in cortisol) at 1 year postnatal and 
the maternal antenatal HPA axis measures that differed between cases and controls (CRH, 
controlling for gestational age at sample acquisition and awakening, evening and diurnal cortisol 
and CAR (AUCi) at 32 weeks gestation) (see Table 41). 
 
Infant cortisol before the immunization was significantly negatively correlated with maternal 
awakening cortisol at 32 weeks gestation (rs = -.38, p = .028) and with diurnal cortisol secretion 
(AUC) at 32 weeks gestation (rs = -.49, p = .006). These findings demonstrate a degree of 
continuity, since, as described in section 3.2.2 above, compared with controls, cases had 
significantly higher awakening and diurnal cortisol (AUC) at 32 weeks gestation and infants of 
cases had lower cortisol before the immunizations than infants of controls, although this was not 
statistically significant. 
 
Infant cortisol 20 minutes after the immunization was positively correlated with maternal evening 
cortisol at 32 weeks gestation at a trend level of significance (rs = .33, p = .060). Again, these 
findings demonstrate a degree of continuity, since, as described in section 3.2.2 above, compared 
with controls, cases had statistically significant higher evening cortisol at 32 weeks gestation and 
infants of cases had statistically significant higher cortisol after the immunizations than infants of 
controls. 
 
The change (delta) in infant cortisol from before to 20 minutes after the immunization was 
significantly positively correlated with maternal evening cortisol at 32 weeks gestation (rs = .48, p 
= .004) and with diurnal cortisol secretion (AUC) at 32 weeks gestation (rs = .47, p = .009). Again, 
these findings demonstrate a degree of continuity, since, as described in section 3.2.2 above, 
compared with controls, cases had significantly higher evening and diurnal cortisol (AUC) at 32 
weeks gestation and infants of cases had a greater delta cortisol than infants of controls, although 
this was not statistically significant. 
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There were no other significant correlations between the infant and maternal cortisol measures 
(Table 41). 
 
PROCESS was used to test for mediation, which showed that maternal antenatal cortisol 
measures had no indirect effect on the association between caseness and infant cortisol 
response to immunizations at 1 year postnatal. Furthermore, there were no significant interactions 
between caseness and maternal antenatal cortisol, indicating that maternal antenatal cortisol was 
not moderating this association at 1 year postnatal. 
 
3.6.3.1 Summary of associations of infant cortisol response to immunizations at 1 year 
postnatal with maternal antenatal HPA axis 
There were a number of significant correlations between cortisol response to immunization in 1-
year-old infants and the maternal antenatal HPA axis measures that differed between cases and 
controls, as described in section 3.6.3 above. These correlations demonstrate continuity between 
maternal antenatal cortisol and infant cortisol at 1 year of age since the direction of the correlation 
corresponded with the direction of the group difference in maternal antenatal cortisol in relation to 
that found in the infant cortisol. However, there was no evidence of mediation or moderation of 
the effect of caseness on these infant measures. 
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Table 41: Infant cortisol response to immunizations at 1 year postnatal and maternal antenatal 
HPA axis 
Maternal antenatal HPA axis 
 CRH controlling 
for gestational 
age at sample 
acquisition 
Awakening 
cortisol at 32 
weeks gestation 
Evening cortisol 
at 32 weeks 
gestation  
Diurnal cortisol 
at 32 weeks 
gestation  
CAR (AUCi) at 
32 weeks 
gestation  
Pre -.04 -.38* -.17 -.49** -.32 
Post .01 -.07 .33∞  .05 -.19 
Delta  .05 .28 .48** .47** .25 
n  37 33 34 30 16 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric 
analysis. Spearman’s correlation coefficients are presented for continuous variables that did not 
permit parametric analysis.   
∞ p = .060, *p <.05, **p <.01 
 
Pre = cortisol before the immunizations 
Post = cortisol 20 minutes after the immunizations 




3.6.4 Infant basal cortisol levels at 1 year postnatal (day 2) 
To test the hypotheses that compared with 1-year-old infants not exposed to depression in utero, 
1-year-old infants so exposed would have higher basal (awakening and evening) cortisol levels, 
infants of cases and controls were compared. 53 infants provided saliva samples in the morning 
and the evening the day after routine immunizations at 1 year postnatal. The saliva sampling 
details and cortisol are presented followed by the characteristics of infants and their mothers. 
 
3.6.4.1 Saliva sampling details  
Awakening and evening cortisol levels at 1 year postnatal were measured and the saliva sampling 
details were recorded. There was no significant correlation between infant awakening cortisol and 
any saliva sampling detail (awakening and sample time, interval between awakening and sample, 
interval between the end of the last feed and sample time, and the interval between sample 
acquisition and freezing (see Appendix Q, Table 82). Nor was there a significant correlation 
between infant evening cortisol and saliva sampling details (sample time, interval between the 
end of the last feed and sample time, interval between the end of the last nap and sample time, 
duration of the last nap before the evening sample and the interval between sample acquisition 




3.6.4.2 Infant basal cortisol levels at 1 year postnatal and maternal antenatal depression 
Infants exposed to depression in utero were compared with those not so exposed. Non-
parametric tests were used since there were outliers in both groups and the data were not 
normally distributed and did not benefit from transformation; the standard deviations were large in 
both groups demonstrating a large degree of variation in these infant cortisol measures. Cortisol 
after the immunization was higher in infants exposed to depression in utero compared with those 
not so exposed. Compared with 1-year-old infants not exposed to depression in utero, 1-year-old 
infants who were exposed had higher evening cortisol (M (SD), 4.66 nmol/ml (12.22) v 12.66 
nmol/ml (24.80)); this difference was statistically significant and represented a medium sized 
effect, r = .30. However, compared with 1-year-old infants not exposed to depression in utero, 
although 1-year-old infants who were exposed had higher awakening cortisol (M (SD), 10.68 
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nmol/ml (13.69) v 11.66 nmol/ml (18.20)), this difference was not statistically significant and 





Table 42: Infant basal cortisol at 1 year postnatal and maternal antenatal depression 
 Control 
(n = 34) 
Case 
(n = 19) 
Statistical test and 
significance 
Infant awakening cortisol (nmol/ml), M (SD) 
 10.68 (13.69) 11.66 (18.20) z = -0.7, p = .50 
Infant evening cortisol (nmol/ml), M (SD) 








Figure 27: Infant basal cortisol at 1 year postnatal 
 
 
Note. *p = .029 
* 
225 
3.6.4.3 Infant basal cortisol levels at 1 year postnatal and other infant and maternal 
characteristics 
 
The characteristics of infants who provided awakening and evening saliva samples the day after 
immunization at 1 year postnatal are presented; maternal factors are also presented, as they are 
potential confounding factors in the analysis of infant cortisol. Infants of cases (thus exposed to 
antenatal depression in utero) and infants of controls (not exposed to antenatal depression in 
utero) were compared. 
 
3.6.4.3.1 Infant characteristics at 1 year postnatal 
There was no significant group difference in infant age at assessment, breastfeeding, health or 
medication use, or in Bayley scores for cognitive, language or motor development at 1 year 
postnatal (Table 43). 
 
3.6.4.3.2 Infant factors prior to 1 year postnatal 
Compared with infants of controls, infants of cases had been exposed to higher levels of 
symptoms of anxiety in utero (STAIS, M (SD), 26.5 (6.8) v 49.6 (11.6) respectively), this 
difference was statistically significant, z = -5.2, p < .001 and represented a large sized effect, r = 
.74. There was no significant group difference in exposure to antidepressants in utero, smoking in 
utero, mode of delivery, gestational age at birth or the sex of the infant (Table 44).  
 
3.6.4.3.3 Maternal characteristics  (Table 45) 
3.6.4.3.3.1 Maternal medication and health behaviours 
There were no significant group differences in any maternal medication or health behaviours at 1 
year postnatal.  
 
3.6.4.3.3.2 Maternal mental health 
Compared with controls, a greater proportion of cases had a current diagnosis of MDD at 1 year 
postnatal (% (n), 0 (34) v 15.8 (3), this difference was statistically significant, χ2 (1) = 5.7, p = .041. 
Furthermore, compared with controls the duration of MDD between the 8 week postnatal and 1 
year postnatal assessments was significantly higher in cases (months M (SD), 0.02 (0.13) v 2.11 
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(3.61) respectively), this difference was statistically significant, z = -3.3, p = .001 and represented 
a medium to large sized effect, r = .47. 
 
3.6.4.3.3.3 Maternal cortisol 
There was no significant difference, between cases and controls, in any maternal cortisol 
measure at 1 year postnatal. 
 
3.6.4.3.4 Summary of infant and maternal characteristics 
As described above there were significant differences between cases and controls in infant and 
maternal factors (exposure to symptoms of anxiety in utero, current diagnosis of MDD and 
duration of postnatal depression). Further analyses showed that neither exposure to symptoms of 
anxiety in utero nor the duration of postnatal depression were associated with the infant basal 
cortisol measures at 1 year postnatal. The small number of subjects (n=3) with MDD at 1 year 
postnatal precluded further analysis. Nonetheless, in order to examine this association further, 
depression symptom scores (according to BDI score at 1 year postnatal) were examined. There 
was no association between infant awakening cortisol and BDI score (either for all subjects, or for 
cases and controls separately, rs = .04, p = .80, rs = .00. p = .99 and rs = .12, p = .50 respectively). 
Furthermore, there was no association between infant evening cortisol and BDI score (either for 
all subjects, or for cases and controls separately, rs = .23, p = .10, rs = .27, p = .27 and rs = .07. p 
= .68 respectively); thus these differences did not seem to be accounting for the differences found 
in infant basal cortisol, see Appendix Q, Table 84. There were no other group differences, in 
infant or maternal factors, between cases and controls. 
 
 
3.6.4.4 Summary of infant basal cortisol levels and antenatal depression at 1 year postnatal 
In this sample of 53 infants with cortisol data at awakening and evening at 1 year postnatal, I 
found that evening cortisol was significantly higher in infants of cases (thus exposed to 
depression in utero), than in infants of controls; these findings appeared to be independent of 
other maternal and infant factors (Figure 25Error! Reference source not found.). 
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Table 43: Infant characteristics at 1 year postnatal (day 2) 
 Control 
(n = 33 - 34) 
Case 
(n = 18 - 19) 
Statistical test and 
significance 
Baby’s age at assessment (months), M (SD) 
 12.7 (0.6) 12.7 (0.8) z = -0.5, p = .64 







χ2 (1) = 0.5, p = .521 







χ2 (1) = 0.1, p = 1.04 







χ2 (1) = 1.6, p = .404 
Bayley cognitive composite score, M (SD) 
 113.24 (14.6) 108.4 (12.2) t(51) = 1.2, p = .23 
Bayley language composite score, M (SD) 
 102.3 (10.7) 99.2 (12.0) t(51) = 1.0, p = .33 
Bayley motor composite score, M (SD) 
 100.9 (11.3) 100.3 (12.2) t(51) = 0.2, p = .86 
                                                       
1 Fisher’s exact test was applied as 1 cell had an expected cell count less than 5. 
2 These data were not ascertained on the full sample (controls n=17, cases n= 12). 
3 Asthma, lactose intolerance 
4 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
5 Atrovent, ventolin, cream for eczema, canestan cream, laxative. 
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Table 44: Infant factors prior to 1 year postnatal (day 2) 
 Control 
(n = 33 - 34) 
Case 
(n = 18 - 19) 
Statistical test 
and significance 







χ2 (1) = 4.7, p = .092 







χ2 (1) = 4.6, p = .082 
Exposure to symptoms of anxiety in utero (STAIS score), M (SD) 
 26.5 (6.8) 49.6 (11.6) z = 5.2, p < .001 







χ2 (1) = 0.1, p = .81 
Gestational age at birth (weeks), M (SD) 
 40.36 (1.55) 40.19 (1.16) z = -0.7, p = .48 







χ2 (1) = 0.0, p = .98 
 
 
                                                       
1 Not ascertained on full sample of cases (n=15) 
2 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
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Table 45: Maternal characteristics at 1 year postnatal (day 2) 
 Control 
(n = 32 - 34) 
Case 
(n = 18 - 19) 
Statistical test and 
significance 







χ2 (1) = 2.0, p = .252 







χ2 (1) = 0.3, p = .684 
Coffee (cups/week) at 1 year postnatal, mean (SD)5 
 7.1 (7.0) 10.5 (13.2) z = -0.2, p = .87 
Tea (cups/week) at 1 year postnatal, mean (SD)5 
 12.5 (11.8) 9.0 (9.9) z = -0.7, p = .48 
Alcohol use (units/day) at 1 year postnatal, M (SD)6 
 4.4 (4.4) 0.9 (1.1) z = -2.0, p = .06 







χ2 (1) = 0.7, p = .624 







χ2 (1) = 5.7, p = .0414 
Duration of MDD between 2 and 12 months postnatal (months), M (SD) 
 0.02 (.13) 2.11 (3.61) z = -3.3, p = .001 
Awakening cortisol at 1 year postnatal (nmol/ml), M (SD) 
 10.02 (4.73) 7.32 (2.96) z = -1.9, p = .052 
Evening cortisol at 1 year postnatal (nmol/ml), M (SD)7 
 1.60 (2.90) 1.34 (0.77) z = -1.0, p = .30 
                                                       
1 Thyroxine, antibiotic eye drops, becotide, flixotide, serevent, ranitidine, thyroxine, antihistamine, 
OCP, sertraline, fluoxetine 
2 Fisher’s exact test was applied as 1 cell had an expected cell count less than 5. 
3 Not ascertained on full sample (controls n=20, cases n=12) 
4 Fisher’s exact test was applied as 2 cells had an expected cell count less than 5. 
5 Not ascertained on full sample (controls n=16, cases n=12) 
6 Not ascertained on full sample (controls n=15, cases n=7) 
7 Evening cortisol was not ascertained on the whole sample (controls n = 30 cases n =14) 
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Diurnal cortisol at 1 year postnatal (nmol/ml2), M (SD)1 
 3794.5 (1550.2) 3580.1 (1015.9) t(37) = 0.4,  p = .66 
Post-awakening cortisol (AUCg) at 1 year postnatal (nmol/ml2), M (SD)2 
 561.1 (245.4) 642.0 (185.8) t(17) = 0.8, p = .43 
CAR (AUCi) at 1 year postnatal (nmol/ml2), M (SD)2 
 49.7 (157.2) 160.6 (189.6) z = -1.8, p = .07 
 
 
                                                       
1 Diurnal cortisol was not ascertained on the whole sample (controls n = 26 cases n =13) 
2 CAR was not ascertained on the whole sample (controls n = 10 cases n = 9) 
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3.6.5 Associations of infant basal cortisol levels at 1 year postnatal with maternal antenatal 
HPA axis 
To test the hypotheses that infant HPA axis function at 1 year postnatal would be associated with 
maternal antenatal HPA axis, correlations were performed to examine associations between 
infant awakening and evening cortisol levels at 1 year postnatal and the maternal HPA axis 
measures that differed between cases and controls in pregnancy (CRH, controlling for gestational 
age at sample acquisition and awakening, evening and diurnal cortisol and CAR (AUCi) at 32 
weeks gestation); there were no significant associations (Table 46).  
 
Despite the absence of any significant correlation between these maternal antenatal HPA axis 
measures and infant basal cortisol, it is theoretically possible that mediation was taking place, 
thus I used PROCESS to examine this phenomenon further. However, I found no support for the 
hypothesis that measures of the maternal antenatal HPA axis were mediating an association of 
caseness with infant basal cortisol at 1 year postnatal.  
 
Furthermore, using PROCESS, I found no evidence that the association between caseness and 
infant basal cortisol levels at 1 year postnatal was moderated by any of the antenatal HPA axis 
measures (CRH, controlling for gestational age at sample acquisition or awakening, evening or 
diurnal cortisol or CAR (AUCi) at 32 weeks gestation).  
 
 
3.6.5.1 Summary of associations of infant basal cortisol levels at 1 year postnatal with 
maternal antenatal HPA axis 
There were no significant correlations between basal cortisol measures in 1-year-old infants and 
the maternal antenatal HPA axis measures that differed between cases and controls. Furthermore 




Table 46: Infant basal cortisol at 1 year postnatal and maternal antenatal HPA axis 
Maternal antenatal HPA axis  
 CRH controlling 
for gestational 
age at sample 
acquisition 
Awakening 
cortisol at 32 
weeks gestation 
Evening cortisol 
at 32 weeks 
gestation  
Diurnal cortisol 
at 32 weeks 
gestation  
CAR (AUCi) at 
32 weeks 
gestation  
Awakening -.13 .18 .00 .16 .30 
Evening -.14 .21 .08 .18 .15 
n  46 45 42 39 22 
Note. Spearman’s correlation coefficients are presented.   
Awakening = infant awakening cortisol 








A prospective longitudinal observational study design was used to examine the effects of 
antenatal depression on maternal HPA axis in pregnancy, obstetric outcomes and offspring HPA 
axis. A control group of 46 healthy pregnant women, and their offspring, were compared with a 
cases group of 36 women with a DSM-IV diagnosis of major depressive disorder in pregnancy, 
and their offspring, up to one year postnatal.  
The cases group was defined by an operational diagnosis of depression rather than depression 
symptom scores because the study was intended to examine the effects of MDD in pregnancy. 
The effect of a disease, as opposed to symptoms of a disease, is more clinically meaningful, for 
example, in the ability to identify relevant cases and apply evidence-based treatment (O'Connor 
et al., 2013b). Furthermore, a focus on symptom scores, as opposed to diagnoses, may lead to 
type II error regarding any true effect of antenatal depression, since symptoms of depression 
have been shown to be more prevalent in pregnant women, compared to their matched, non-
pregnant acquaintances, when concurrent assessment of operationally defined diagnoses of 
depression in the same women revealed the same prevalence in the pregnant and non-pregnant 
groups (O'Hara et al., 1990). Indeed, in support of this idea, the effect of antenatal depression on 
maternal cortisol was stronger for operationally defined diagnosis than for symptom severity when 
tested in the same study (O'Connor et al., 2013b). 
Firstly, a summary of the main findings is presented, followed by a more detailed discussion of the 
individual findings, how they relate to the existing literature and a discussion of their implication. 
Finally the strengths and limitations are discussed along with suggestions for future research. 
 
4.2 Summary of main findings  
 
4.2.1 Antenatal depression and HPA axis in pregnancy 
The findings demonstrate that, compared with women without antenatal depression, those with 
antenatal depression had an overactive HPA axis, including higher levels of CRH, awakening, 
evening and diurnal cortisol in the third trimester of pregnancy; they also had a blunted cortisol 
awakening response (AUCi). However, no group differences in HPA axis measures were 
apparent in the second trimester of pregnancy.  
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4.2.2 Antenatal depression and obstetric outcome 
The findings demonstrate, in those with spontaneous onset of labour at term, that women with 
antenatal depression had a shorter length of gestation than women without antenatal depression. 
However, group differences were not apparent in other obstetric outcomes including birth weight, 
the proportion with PTB, LBW or SGA babies. 
 
4.2.3 Antenatal depression, antenatal HPA axis and obstetric outcome 
I found no evidence to support the hypothesis that the maternal antenatal HPA axis measures 
that differed between cases and controls were moderating or mediating the effect of caseness on 
gestational age at birth. 
 
4.2.4 Antenatal depression and offspring HPA axis at 8 weeks postnatal 
The findings demonstrate that there was a statistically significant increase in cortisol following 
immunization for both groups of infants. However the size of this effect was larger in infants 
exposed to depression in utero than in those not so exposed. There was no statistically significant 
group difference in cortisol after the immunizations, delta cortisol or basal cortisol measures. 
 
4.2.5 Antenatal depression, antenatal HPA axis and offspring HPA axis at 8 weeks 
postnatal 
The findings demonstrate that maternal antenatal cortisol moderated the effect of caseness on 
infant delta cortisol. Specifically, compared with infants who were not exposed to depression in 
utero, infants who were so exposed had higher delta cortisol when maternal antenatal diurnal 
cortisol was high. However, I found no correlations between maternal antenatal HPA axis 
measures and infant cortisol at 8 weeks postnatal nor did I find evidence that the maternal 
antenatal HPA axis measures that differed between cases and controls were moderating or 
mediating the effect of caseness on any other infant cortisol measure at 8 weeks postnatal. 
 
4.2.6 Antenatal depression and offspring HPA axis at 1 year postnatal 
The findings demonstrate that, compared with infants who were not exposed to depression in 
utero, infants who were so exposed had higher cortisol after the immunization. Furthermore, 
immunization was associated with a medium sized effect (increase) on cortisol in infants exposed 
to depression in utero. Conversely, immunization was not associated with an effect on cortisol in 
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infants who were not exposed to depression in utero. Lastly, compared with infants who were not 
exposed to depression in utero, infants who were so exposed had higher basal (evening) cortisol 
the day after immunization. However, the groups did not differ in delta cortisol or basal 
(awakening) cortisol. 
 
4.2.7 Antenatal depression, antenatal HPA axis and offspring HPA axis at 1 year postnatal 
The findings demonstrate that at 1 year postnatal there was a statistically significant negative 
correlation between cortisol before the immunization and maternal antenatal awakening and 
diurnal cortisol at 32 weeks gestation. Furthermore there was a statistically significant positive 
correlation between delta cortisol and maternal antenatal evening and diurnal cortisol and a 
statistical trend for positive correlation between cortisol after the immunization and maternal 
antenatal evening cortisol. However, I found no evidence that the maternal antenatal HPA axis 
measures that differed between cases and controls were moderating or mediating the effect of 
caseness on infant cortisol at 1 year postnatal. 
 
4.2.8 Summary 
In summary, the findings demonstrate that women with MDD in pregnancy had an overactive HPA 
axis in the third trimester (but not the second), a shorter length of gestation and offspring with 
altered HPA axis function at 8 weeks and 1 year postnatal. Furthermore, maternal antenatal 
diurnal cortisol moderated the infants’ delta cortisol at 8 weeks postnatal, such that at higher 
levels of maternal diurnal cortisol infants exposed to MDD in utero had a greater delta cortisol 
than infants who were not so exposed. A number of significant correlations between maternal 
antenatal cortisol and infant cortisol measures at 1 year demonstrated a link between these two 
factors. However, there was no evidence that maternal antenatal HPA axis moderated or 
mediated the effect of caseness on infant cortisol measures at 1 year postnatal. Nor was there 
any evidence that the maternal antenatal HPA axis mediated the effect of caseness on 
gestational age at birth or on infant cortisol measures at 8 weeks. The findings were independent 





4.3 Antenatal depression and HPA axis in pregnancy 
 
I hypothesised that compared with healthy pregnant women those with antenatal depression 
would have overactivity of the HPA axis in the second and third trimesters of pregnancy. I found 
that compared with healthy women, the depressed group had higher levels of CRH, awakening, 
evening and diurnal cortisol but a blunted cortisol awakening response (AUCi) in the third 
trimester of pregnancy. However, group differences were not apparent in the second trimester of 
pregnancy. 
 
In general, as described in section 1.4.5 above there is a paucity of literature on antenatal 
depression and maternal HPA axis in pregnancy. Furthermore, only a minority of these studies 
are of operationally defined MDD according to a diagnostic instrument. Some studies of 
operationally defined MDD had a larger sample size than the current study but they made only a 
single measure of cortisol either once or twice in pregnancy. Compared with other studies in this 
field, the study of O’Keane et al. has provided the broadest HPA axis assessment to date 
(O'Keane et al., 2011). In the following sections, I have considered each HPA axis measure in 
turn and described how it sits in the context of the existing literature; this is followed by a 
summary of the impact and implications of my findings. 
 
4.3.1 Antenatal depression and CRH in pregnancy 
I hypothesised that compared with non-depressed pregnant women those with antenatal 
depression would have higher CRH. My findings support this hypothesis, although this finding 
was only evident following moderation analyses, which showed that the effect of caseness on 
CRH was moderated by the gestational age at sample acquisition, such that the effect only 
became apparent when CRH was measured after 28.49 weeks gestation. 
To my knowledge only one other study of antenatal depression and CRH has a cases group with 
MDD defined by diagnostic interview, and compared them with non-depressed pregnant women 
(O'Keane et al., 2011). In this study CRH was measured at both 25 and 36 weeks gestation, a 
significant group difference was found at 25 weeks (n = 55) and a statistical trend at 36 weeks (n 
= 51) gestation. However, no indication was provided of how gestational age at sample 
acquisition was determined or if there was any deviation from the stated week of sample 
acquisition; thus it is difficult to compare my findings. Nonetheless, on balance, my findings are 
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similar to those described, in that I found CRH was significantly higher in women with MDD 
compared with those without MDD. However, the gestational ages at which this finding was 
apparent differed between the two studies.  I found a group difference only when CRH was 
measured after 28.74 weeks gestation; and (according to the Johnson-Neyman technique) the 
effect of caseness on CRH got larger as gestational age at sample acquisition increased, but no 
samples were taken as late as 36 weeks gestation. In summary my findings partially corroborate 
and further refine the existing literature since this thesis describes a more methodologically robust 
experiment with a larger sample size (n=78), clearly stated means of determining gestational age 
at sample acquisition and with precise documentation of this variable. Furthermore, it is the first 
replication, albeit partial, of the findings of O’Keane et al. As described in section 1.4.5.2 above 
the current study was conducted in the same research and clinical setting as O’Keane et al. but 
with an entirely separate sample of participants. Others have studied antenatal depression using 
self-rated depressive symptom scores at one time-point in pregnancy. One study of preterm birth 
showed no association between antenatal depression (defined by a CES-D score ≥ 16) and CRH 
(both measured at 24-26 weeks gestation) (Kramer et al., 2009). This study mirrors the findings 
described in this thesis, when no group difference was apparent at equivalent gestational ages. In 
contrast, another study showed that higher CRH (measured between 24.6 and 37.4 weeks 
gestation) was associated with higher odds of major or minor depression (defined by EPDS 
scores ≥ 13) (Rich-Edwards et al., 2008). Again, these findings appear to corroborate those 
described in this thesis. 
 
4.3.2 Antenatal depression and CRHBP in pregnancy 
I hypothesised that compared with non-depressed pregnant women those with antenatal 
depression would have lower CRHBP. My findings do not support this hypotheses; I found no 
significant group difference and only a small sized effect (cases > controls) for the group 
difference in CRHBP. The CRHBP protein is quite unstable, thus keeping the blood sample on ice 
and extracting plasma in a timely fashion and under cool conditions is critical and the protein is 
technically difficult to measure; this instability was perhaps reflected in the fact that CRHBP was 
at reliably detectable levels in only 38 subjects (50% of those who provided a blood sample). 
Thus the sample size was reduced considerably and the absence of a difference may be type II 
error; alternatively no difference exists. The interpretation of no difference is also reasonable 
since CRHBP is thought to be stable throughout normal pregnancy until a decline at about 36 
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weeks gestation and in this study CRHBP was measured earlier in gestation. However, CRHBP 
has been shown to be lower in the second and third trimesters of women who went on to have a 
preterm delivery compared with those who had full term births (Hobel et al., 1999). To my 
knowledge, there are no published studies of CRHBP in antenatal depression or even prenatal 
stress, but my hypothesis evolved from the established associations of antenatal depression with 
PTB and CRHBP with PTB. 
 
4.3.3 Antenatal depression and serum (total) cortisol in pregnancy 
I hypothesised that compared with non-depressed pregnant women those with antenatal 
depression would have higher serum cortisol. My findings do not support this hypotheses; I found 
no significant group difference and only a small sized effect (cases > controls) for the difference in 
serum cortisol. To my knowledge only one study in this field reports total cortisol: in this study (of 
a normal pregnant population) there was no correlation between plasma cortisol and BDI scores 
(Salacz et al., 2012). Serum cortisol provides a measure of total cortisol, in contrast to saliva 
cortisol, which provides a measure of free (biologically available) cortisol; however, serum and 
saliva cortisol are known to be correlated (Vining et al., 1983). Indeed, serum cortisol in this study 
was correlated with other saliva cortisol measures at baseline (for example, with awakening 
cortisol rp = .52, p = .001, and diurnal cortisol (AUC) rp = .44, p = .011) and furthermore at 32 
weeks gestation (for example, with awakening cortisol rp = .64, p ≤ .001, and diurnal cortisol 
(AUC) rp = .63, p = .001). Therefore the sample size may account for the lack of significant 
difference1.  
 
4.3.4 Antenatal depression and awakening cortisol in pregnancy 
I hypothesised that compared with non-depressed pregnant women those with antenatal 
depression would have higher awakening cortisol at 25 and 32 weeks gestation. My findings 
support the hypothesis at 32 weeks but not at 25 weeks gestation. 
To my knowledge only two published studies have measured awakening cortisol in pregnancy for 
women with operationally defined MDD at similar gestational ages. My finding of higher 
awakening cortisol at 32 weeks gestation was in contrast to both those studies, one of which 
found no significant difference (O'Keane et al., 2011), and the other found lower awakening 
                                                       
1 Serum cortisol was only available for subjects under the ‘main’ protocol. 
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cortisol (O'Connor et al., 2013b) at 32 weeks gestation. However, these studies differed from the 
current one on a number of factors that may account for the differences between them. Firstly, 
although the study of O’Keane et al. was performed in the same setting as that described in this 
thesis, the cases and control groups differed in a number of socio-demographic or potentially 
confounding factors, for example 81% of cases were Caucasian which would appear to contrast 
with my cases group where 47% were white, 29% of cases were single in contrast to 53% of my 
cases group who were living alone, lastly awakening cortisol was measured in fewer participants, 
33 controls v 13 cases in contrast to 40 controls v 26 cases in my study. Secondly, the study of 
O’Connor et al. cannot be compared so easily since the design was different. However it differed 
in setting as it was conducted in the USA and all the subjects were classed as ‘psycho-socially at-
risk’ by dint of the population served by the recruiting clinic. The proportion of depressed versus 
non-depressed was lower than in my study, furthermore, the depressed group included diagnoses 
of MDD and depression not otherwise specified but no group comparison of symptom severity or 
of social demographic factors was presented.  
No studies have measured awakening cortisol at 25 weeks gestation. However, awakening 
cortisol has been measured at different gestational ages e.g. later in pregnancy (35-39 weeks 
gestation), when no difference was found (Hellgren et al., 2013)  and earlier in pregnancy at 20 
weeks gestation when lower awakening cortisol was found (O'Connor et al., 2013b). My finding of 
increased awakening cortisol in the depressed group mirrors findings in depressed non-pregnant 
populations. Since so few studies are described in the current literature, my findings add to the 
body of evidence and highlight the preliminary nature of this line of research.  
 
Interestingly, awakening cortisol was associated with both caseness and ethnicity in my study 
(see section 3.2.2.1.4 above); compared with white women, black and minority ethnic women had 
lower awakening cortisol, both overall and by caseness. Similar ethnic differences in the HPA axis 
have been reported in pregnant (Glynn et al., 2007, Suglia et al., 2010) and non-pregnant 
(Bennett et al., 2004) women. 
 
4.3.5 Antenatal depression and evening cortisol in pregnancy 
I hypothesised that compared with non-depressed pregnant women those with antenatal 
depression would have higher evening cortisol at 25 and 32 weeks gestation. My findings support 
the hypothesis at 32 weeks but not at 25 weeks gestation.  
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To my knowledge, only one study of operationally defined MDD in pregnancy has reported 
evening cortisol; higher evening cortisol (n=46) at 32 weeks gestation was reported in women 
with MDD (O'Keane et al., 2011). Similarly, one further study found a higher evening cortisol at 
mid gestation in those with high levels of self-rated depression symptoms (Peer et al., 2013).  My 
finding corroborates and refines the small amount of evidence that currently exists, since a larger 
number of subjects are studied. Furthermore, it is the first replication of the findings of O’Keane et 
al.  
 
4.3.6 Antenatal depression and diurnal cortisol in pregnancy 
I hypothesised that compared with non-depressed pregnant women those with antenatal 
depression would have higher diurnal cortisol (AUC) at 25 and 32 weeks gestation. My findings 
support the hypothesis at 32 weeks but not at 25 weeks gestation.  
To my knowledge, only one study of operationally defined MDD in pregnancy has measured 
diurnal cortisol (O'Connor et al., 2013b). In their study of 101 pregnant women at high 
psychosocial risk for developing depression, O’Connor et al. found that those with a diagnosis of 
depression had a flattened, less sharply declining diurnal pattern of cortisol secretion (defined by 
change in cortisol over time, rather than AUC) and overall, a higher cortisol level throughout the 
day both at twenty and thirty-two weeks gestation. Since the authors also report a lower 
awakening cortisol in the depressed group (see section 4.3.4 above), the above statement 
(overall, a higher cortisol level across the day) implies a higher evening cortisol level in the 
depressed group, however, a group comparison of evening cortisol was not presented. Although I 
have measured diurnal cortisol by different means (AUC) and my study design differs (see section 
4.3.4 above), my findings appear to corroborate those of O’Connor et al at 32 weeks gestation, 
but not earlier; thus my findings represent the first replication of this work. 
 
4.3.7 Antenatal depression and cortisol awakening response/post-awakening cortisol in 
pregnancy 
I hypothesised that compared with non-depressed pregnant women those with antenatal 
depression would have higher CAR and post-awakening cortisol at 25 and 32 weeks gestation. 
My findings do not support the hypothesis. In contrast, I found that compared to non-depressed 
controls, women with MDD in pregnancy had a blunted cortisol awakening response (AUCi), but 
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no difference in AUCg at 32 weeks gestation.  There was no group difference in either measure of 
post-awakening cortisol at 25 weeks gestation.  
To my knowledge, only two studies of operationally defined MDD in pregnancy have assessed 
CAR and post-awakening cortisol and neither study found a difference between depressed and 
non-depressed groups. However, both studies differed from that described in this thesis in design 
or measures: one study (n=108) measured CAR and post-awakening cortisol (AUCi and AUCg) 
later in pregnancy, between 35 and 39 weeks gestation in three groups (depressed in pregnancy, 
history of depression, no depression) (Hellgren et al., 2013) and the second study (n=101) used 
the change from awakening cortisol to 45 minutes post-awakening to represent CAR at 20 and 32 
weeks gestation in women at high risk of depression, either with or without MDD in pregnancy 
(O'Connor et al., 2013b). Similarly, studies using high v low levels of self-rated depression 
symptoms found no differences in CAR or post-awakening cortisol (Peer et al., 2013, Shea et al., 
2007). Thus, although the number of subjects providing data for CAR in this study was small, the 
finding of a blunted cortisol awakening response (AUCi) at 32 weeks gestation should be 
considered as an extension of current knowledge rather than conflicting results, and is thus a 
novel finding. 
 
4.3.8 Summary of antenatal depression and HPA axis in pregnancy 
Overall, my findings corroborate those of the majority of the small amount of literature in this field; 
that antenatal depression is associated with overactivity in the HPA axis in the third trimester of 
pregnancy. They also mirror HPA axis findings from studies of MDD in non-pregnant populations. 
Moreover, my findings extend the current knowledge either by more detailed HPA axis 
assessment or a larger sample size; at the same time, potential confounding factors are 
controlled for in the analyses. There is little in the published literature on antenatal depression and 
HPA axis at 25 weeks, and although I found no group differences in HPA axis measures at this 
gestational age, I did find the same pattern of differences in the cortisol measures at baseline as 
at 32 weeks gestation. Although, there was no statistically significant difference in these 
measures between cases and controls at baseline, there were fewer subjects with cortisol data 
available at this assessment. Furthermore, there were statistically significant and strong positive 
correlations between 25 and 32 weeks for awakening cortisol (rp = .62, p < .001), diurnal cortisol 
(rp = .55, p = .003) and post-awakening cortisol (AUCg) (rp = .77, p < .001), and a statistical trend 
for a moderate correlation for evening cortisol (rs = .31, p = .09) but none for CAR (AUCi) (rp = .37, 
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p = .14). One explanation could be that there was insufficient power to show group differences in 
the measures at baseline; alternatively, my findings could be a true reflection of no group 
difference at this gestational age. 
 
In addition to the paucity of literature on MDD in pregnancy and maternal HPA axis, there is little 
literature regarding the effect of other forms of stress or anxiety in pregnancy on the maternal 
HPA axis. This is surprising since there is much literature hypothesising overactivity of maternal 
HPA axis as a biological mechanism underlying developmental programming. It appears that this 
first step in unravelling the mechanisms between suboptimal maternal mental health and 
developmental programming has been somewhat understudied, perhaps because animal studies 
have already suggested the link convincingly; nonetheless one cannot assume that the same will 
apply in humans. Thus, confirmation of overactivity of maternal HPA axis in antenatal depression 
is an important addition to the literature in the emerging field of research into the mechanisms of 
developmental programming in humans.  
 
Moreover, and critically, overactivity of maternal HPA axis in antenatal depression is of clinical 
relevance. There is already a mandate, in the UK, to screen for and actively treat depression in 
pregnancy because of its known association with a range of adverse obstetric and offspring 
outcomes. However, my findings reinforce the notion that antenatal depression is also associated 
with altered maternal physiology in a system (HPA axis) that is not simply a vital homeostatic one, 
but one that is also central to the maintenance of pregnancy, timing of delivery, foetal maturation 
and foetal development. Thus, my findings strengthen the argument for this mandate; clinicians 
responsible for treating MDD can feel more confident that MDD should be managed both in a 
timely fashion and actively, because not to do so has the clear potential for adverse 
consequences. Moreover, the findings add evidence to the clinician’s armamentarium in the 
difficult arena of clinical decision-making when evaluating the risks and benefits of using 







4.4 Antenatal depression and obstetric outcome 
 
I hypothesised that compared with non-depressed pregnant women those with antenatal 
depression would have a higher rate of PTB, a greater proportion of LBW and SGA babies, a 
shorter length of gestation and babies of lower birth weight. 
The findings demonstrate, in women with spontaneous onset of labour at term, that those with 
antenatal depression had a shorter length of gestation (mean = 4.6 days) than women without 
antenatal depression; this difference represented a small to medium sized effect. The finding was 
reduced to a trend level of significance when marital status was taken into account, however 
marital status is an important risk factor for MDD, thus the effect of martial status on gestational 
age at birth cannot be disentangled from the effect of caseness. Because of the small number of 
instances, the potential effect of antidepressant medication was not taken into account although 
the difference in length of gestation was not accounted for by any other potentially confounding 
factors. Lastly, group differences were not apparent in PTB rate, birth weight, low birth weight 
babies or small for gestational age babies. 
 
Information regarding the effect of operationally defined MDD in pregnancy on obstetric outcome 
is limited (as described in section 1.2.4.6.2 above). Only six studies included in the two (relatively 
recent) meta-analyses of this area were of operationally defined MDD (5 of PTB, 2 of LBW, 1 of 
IUGR, 2 of length of gestation and 4 of birth weight) (Diego et al., 2009, Field et al., 2010, Field et 
al., 2006a, Suri et al., 2007, Wisner et al., 2009, Rahman et al., 2004). To my knowledge, only 
two other relevant studies are not included in these meta-analyses: Firstly, O’Keane et al. 
reported a shorter length of gestation in a depressed, compared with a non-depressed group in 
their case control study (n=54) (O'Keane et al., 2011). Secondly, in their population-based cross-
sectional study of all singleton births in Finland between 2002 and 2010, Raisanen et al. reported 
that compared to women without depression in pregnancy, those with physician-diagnosed ICD-
10 depression had increased odds (very similar values to those reported in the 2 meta-analyses) 
of PTB, LBW and SGA (n = 511,938); length of gestation and birth weight were not reported in 
this study (Raisanen et al., 2014). The evidence for the association of MDD in pregnancy with 
increased rates of PTB, LBW and SGA is compelling. There are fewer publications on length of 
gestation (only 1 of the three studies found a significant difference (O'Keane et al., 2011), but on 
closer scrutiny, the two studies finding no difference reported gestational age at birth for all 
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deliveries, rather than those with spontaneous onset of labour (Diego et al., 2009, Suri et al., 
2007)).  
 
4.4.1 Summary of antenatal depression and obstetric outcome 
In summary, my finding of shorter length of gestation in women with MDD in pregnancy compared 
with women without MDD mirrors the results of the only other similar study (O'Keane et al., 2011). 
Crucially, any association of length of gestation with MDD will be masked if all deliveries, rather 
than only those with a spontaneous onset of labour are considered; thus the two other studies 
reporting on this phenomenon are not comparable, nor are they informative regarding this 
measure. An emerging literature is suggestive of subtle impairments in brain development and 
cognitive ability in addition to respiratory health and increased risk of SIDS for children born at 
lower gestational ages, within the ‘at term’ range. Thus even small differences in length of 
gestation may have a clinically relevant effect on offspring. Therefore, since MDD in pregnancy is 
common, an association with shorter length of gestation may be of importance for public health.  
I found no difference in PTB, LBW, SGA or birth weight. However, the number of subjects in my 
study was small compared with studies showing an effect (which have subject numbers in the 
hundreds or more), and thus lacked the power to show an effect when the relative risk is of the 
order of magnitude suggested in the literature. 
 
 
4.5 Antenatal depression, antenatal HPA axis and obstetric outcome 
 
I hypothesised that obstetric outcome would be associated with maternal antenatal HPA axis 
measures. However, I found no correlation between gestational age at birth (in spontaneous 
deliveries at term) with the antenatal HPA axis measures that differed between cases and 
controls. Furthermore, I hypothesised that the antenatal HPA axis would be a moderator or 
mediator in the pathway from AND to pregnancy outcome but I found no evidence to support this.  
Associations between HPA axis and obstetric outcomes are reviewed in section 1.4.4.4. In brief, 
fairly consistent links between CRH and length of gestation and/or PTB are described in the 
literature, although one large study of preterm birth found no association with CRH (adjusted for 
potential confounding factors) measured at 24-26 weeks gestation (Kramer et al., 2013). 
Antenatal cortisol and CAR have also been associated with adverse obstetric outcomes. To my 
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knowledge there are no studies of the role of maternal HPA axis in the association between 
operationally defined MDD in pregnancy and obstetric outcomes, although the stress in 
pregnancy literature contains some findings of associations between stress, CRH and PTB 
(Himes and Simhan, 2011, Mancuso et al., 2004, Rich-Edwards and Grizzard, 2005, Sandman et 
al., 1997, Kramer et al., 2009).  
Although associations of antenatal HPA axis and obstetric outcomes have been described in the 
literature, the samples sizes used are larger than mine; thus my study may have lacked the power 
to show any such associations. Alternative explanations might be that pathways to suboptimal 
obstetric outcomes may be more complex, involving other biological systems that have not been 
assessed in this study. 
As discussed in section 4.3.8 above, my findings are also of clinical relevance to obstetric 
clinicians (obstetricians, midwives and GPs) since confirmation of an association between 
antenatal depression and altered maternal physiology in a system (HPA axis) that is not simply a 
vital homeostatic one, but one that is also central to the maintenance of pregnancy, timing of 
delivery, foetal maturation and foetal development and obstetric outcome is of clinical relevance 
despite the absence of a finding in this study of an association between the combination of all 
three factors (antenatal depression, maternal antenatal HPA axis and obstetric outcome).  
 
 
4.6 Antenatal depression and offspring HPA axis at 8 weeks and 1 
year postnatal 
 
I hypothesised that compared with infants not exposed to depression in utero those who had been 
exposed would have greater cortisol reactivity, indexed both by cortisol response to 
immunizations and higher cortisol after the immunizations, at 8 weeks and 1 year of age. 
Furthermore, that they would have higher basal (awakening and evening) cortisol at both ages. 
 
4.6.1 Cortisol reactivity 
The findings demonstrate that compared with 1-year-old infants not exposed to depression in 
utero, those who had been exposed had a higher cortisol level after the immunization. In 8-week-
old infants a similar pattern of difference was apparent but reached only a trend level for statistical 
247 
significance; however, the size of the effect was medium, as it was at 1 year postnatal, and the 
95% confidence intervals did not cross zero. Univariate analyses showed that delta cortisol at 
both postnatal time points was higher in infants exposed to depression in utero compared with 
infants who were not so exposed; however, this difference was not statistically significant at either 
time, although it represented a small to medium sized effect at both assessments. 
Furthermore, in 8-week-old infants, immunization was associated with a statistically significant 
effect (increase) on cortisol in both groups. This effect was greater in infants who had been 
exposed to depression in utero than in those not so exposed (r = .52 v .37 respectively). Lastly, in 
1-year-old infants, immunization was associated with a moderate sized effect (increase) on 
cortisol. This was at a trend level of statistical significance in infants who had been exposed to 
depression in utero, but there was no effect in infants not exposed to depression in utero (r = .30 
v .04 respectively). 
 
4.6.2 Basal cortisol 
The findings demonstrate, in 1-year-old infants, that compared with infants not exposed to 
depression in utero those who were exposed had higher evening cortisol and the difference 
represented a medium sized effect; however, no such group difference was apparent in 8-week-
old infants. There was no significant group difference in awakening cortisol in 8-week or 1-year-
old infants.  
 
A small number of prospective studies have examined the effect of self-rated symptoms of 
depression on offspring HPA axis (as described in section 1.5.3.2.1 above). Overall, the findings 
suggest that, as for the broader concept of prenatal stress, symptoms of depression in pregnancy 
may have a programming effect on offspring HPA axis; this has been evaluated in a range of 
offspring ages from newborn to adolescence and by either basal cortisol or cortisol reactivity to 
stress.  To my knowledge only one other prospective study of HPA axis in offspring who were 
exposed to operationally defined MDD in utero has been published. An association between 
antenatal depression (and depression comorbid with anxiety) and higher neonatal basal cortisol 
was reported, but interpretation of this study is hampered by a narrow assessment of offspring 
HPA axis and number of important methodological limitations (Field et al., 2010). Therefore, my 
findings are in line with the existing literature; moreover, they represent an important addition, 
being the first to report persisting heightened HPA axis function, in 8 week-old and 1-year-old 
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infants, and increased basal HPA axis activity in 1-year-old infants exposed to operationally 
defined MDD in utero. Consequently this is an important addition both to the developmental 
programming and antenatal depression literature. 
 
In contrast to my findings in 1-year-old infants, 8-week-old infants exposed to depression in utero 
showed no significant difference in basal cortisol, (awakening or evening) compared to infants 
who were not exposed. In general an association between basal cortisol in offspring and 
antenatal depression has been reported. For example higher urinary cortisol in neonates who 
were exposed to depression or a high level of depressive symptoms in pregnancy (Diego et al., 
2004, Field et al., 2010, Lundy et al., 1999) or decreased CAR and flatter diurnal cortisol slope in 
15-year-old offspring who were exposed to high levels of symptoms both of depression and of 
anxiety in pregnancy (O'Donnell et al., 2013). The absence of such an association at 8 weeks 
postnatal appears to be in contrast to the findings of others; however, it is not directly comparable 
as cortisol in the above studies was measured at different offspring ages. The emergence of a 
difference at 1 year postnatal may reflect the dynamics of HPA axis development over time. 
Alternatively it may be related to other unmeasured factors; interestingly it did not appear to be 
accounted for by further exposure to maternal depression in the postnatal period. The lack of 
difference in awakening cortisol together with higher evening cortisol in 1-year-olds exposed to 
depression in utero can be likened to the finding of O’Donnell of a flattened diurnal slope of 
cortisol secretion in 15 year olds and represents an altered set point of offspring HPA axis. 
 
Moreover, my finding of an effect of immunization on infant cortisol at 1 year postnatal in infants 
who were exposed to depression in utero (albeit at a trend level of statistical significance), but no 
effect in infants not so exposed adds to the broader literature on cortisol response to pain in 
infants. Cortisol response to a variety of stressors, from age 0-18 years, has been reviewed 
(Jansen et al., 2010, Gunnar et al., 2009). Pain is fairly consistently shown to produce an increase 
in cortisol in studies of children up to 6 months of age but seldom beyond that. However, to my 
knowledge, there are no published studies comparing cortisol response to pain in infants of 
women with high v low levels of psychological symptoms or of stress in pregnancy. A cortisol 
response to immunization in the infants of controls at 8 weeks postnatal, which is no longer 
present at 1 year of age, is consistent with the published literature. However, the finding of an 
effect of immunization on cortisol of 1-year-old infants exposed to depression in utero is 
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seemingly out of kilter with the existing literature. However, the phenomenon has not been 
studied in infants exposed to an adverse intrauterine environment such as in this study. This 
finding suggests that the set point of the HPA axis, which does not normally mount a response to 
immunization much beyond the age of 6 months, is altered in infants who were exposed to MDD 
in utero, and is thus a novel finding. 
 
4.6.3 Summary of antenatal depression and offspring HPA axis at 8 weeks and 1 year 
postnatal 
In summary my findings demonstrate an association between antenatal depression and infant 
HPA axis function and activity in the first year of life. This is in keeping with the broader human 
and animal literature on the effect of stress in pregnancy and developmental programming and 
extends and refines the knowledge base on the specific effects of antenatal depression.  
 
Confirmation of overactivity and altered set point of offspring HPA axis in infants exposed to 
depression in utero is an important addition to the literature in the emerging field of research into 
developmental programming in humans. It further strengthens the mandate to screen for and 
actively treat depression in pregnancy (discussed in section 4.3.8 and 4.5 above). My findings not 
only reinforce the notion that antenatal depression is associated with altered maternal physiology 
in pregnancy (discussed in 4.3.8 above), but also that occurrence of MDD in pregnancy is 
associated with alterations in the same vital system in the offspring. By extension, these findings 
indicate that since the HPA axis is altered in infants exposed to depression in utero, adverse 
health outcomes may be associated and so the findings are of clinical relevance. Available 
evidence affords little doubt that exposure to an adverse early environment is associated with 
cardiovascular disease, metabolic syndrome and other unfavourable health outcomes in 
adulthood and it is hypothesized that alterations in offspring HPA axis mediate these effects. 
Should this be the case, individuals who were exposed to depression in utero may benefit from 
clinical monitoring in order to identify emerging health problems, which thus may be prevented or 
ameliorated before the onset of symptomatic disorders in adulthood. Moreover, an opportunity for 
earlier intervention would also be afforded: animal and human literature suggest that alterations in 
offspring HPA axis or other programming effects may be reversed by early care maternal care or 




4.7 Antenatal depression, antenatal HPA axis and infant HPA axis at 8 
weeks and 1 year postnatal 
 
I hypothesised that maternal antenatal HPA axis measures would be correlated with offspring 
HPA axis measures at 8 weeks and at 1 year postnatal. The findings demonstrate that at 1 year 
postnatal there was a statistically significant negative correlation between both maternal antenatal 
awakening cortisol and diurnal cortisol (AUC) at 32 weeks gestation and infant cortisol before the 
immunization at 1 year postnatal; the strength of the associations were moderate to strong. 
Furthermore there was a statistically significant positive correlation between both maternal 
antenatal evening cortisol and diurnal cortisol (AUC) at 32 weeks gestation and infant delta 
cortisol at 1 year postnatal; again, the strength of the associations were moderate to strong. 
Lastly, there was a trend level of statistical significance for a positive correlation between 
maternal antenatal evening cortisol at 32 weeks gestation and infant cortisol after the 
immunization at 1 year postnatal; the strength of the association was moderate. There were no 
significant correlations between maternal antenatal HPA axis measures and offspring HPA axis 
measures at 8 weeks postnatal. These finding demonstrate that a relationship exists between 
maternal antenatal cortisol and infant HPA axis and furthermore, demonstrate a degree of 
continuity, since the direction of the correlation corresponded with the direction of the group 
difference (between cases and controls) in maternal antenatal cortisol in relation to that found in 
the infant cortisol.  
 
Secondly, I hypothesised that maternal antenatal HPA axis measures would moderate or mediate 
the pathway from antenatal depression to offspring HPA axis activity at 8 weeks and at 1 year 
postnatal. The findings demonstrate that maternal diurnal cortisol at 32 weeks gestation 
moderated the effect of caseness on infant delta cortisol at 8 weeks of age. To expand further, 
compared with infants who were not exposed to depression in utero, infants of women so 
exposed had significantly higher delta cortisol when antenatal diurnal cortisol was ≥6938.6 
nmol/ml2 and I have already shown that diurnal cortisol at 32 weeks gestation was higher in 
depressed cases than non-depressed controls. This finding demonstrates that a relationship 
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exists between antenatal depression, antenatal cortisol and infant HPA axis function, although no 
evidence of mediation was found.  
 
I found no evidence that the maternal antenatal HPA axis measures that differed between cases 
and controls were moderating or mediating the effect of caseness on any other infant cortisol 
measures at 8 weeks or at 1 year postnatal. The lack of evidence for mediating effects may well 
be due to the relatively small sample sizes for the infant cortisol measures (ranging from 43 at the 
1 year postnatal immunizations to 61 for basal cortisol at 8 weeks postnatal). Given these sample 
sizes, the effect size for both the ‘a’ and the ‘b’ paths in the mediation model (see section 2.5.1.2 
above) would both need to be relatively large to have the power to find a positive result. Sample 
sizes of approximately 400 to 500 would be required in order to avoid type II error if the effect size 
was small for both paths, and in the region of 100-150 for more moderate sized effects (Fritz and 
Mackinnon, 2007). Alternatively, the pathways to infant HPA axis may be more complex, involving 
other biological systems that have not been assessed in this study. 
 
There is some evidence that a high (versus low) level of maternal cortisol in pregnancy is 
associated with cortisol response to stress in offspring (Davis et al., 2011b, Gutteling et al., 2004, 
Gutteling et al., 2005). Furthermore, a high (versus low) level of amniotic fluid cortisol (an index of 
direct in utero exposure to cortisol) was shown to be associated with cortisol response to stress in 
offspring (O'Connor et al., 2013a). Indeed, my findings of correlation between some of the 
maternal antenatal and infant HPA axis measures are in keeping with these studies. Furthermore, 
on balance, the evidence in the literature, outlined in section 1.4.5 above and from this current 
study (section 4.3.8 above) suggests that the maternal HPA axis is overactive in depression in 
pregnancy. However, to my knowledge there are no published studies of the combination of these 
three factors, i.e. antenatal depression, maternal antenatal cortisol and infant cortisol. Indeed, that 
the effect of caseness on infant delta cortisol at 8 weeks postnatal was moderated by maternal 
antenatal diurnal cortisol (AUC) further strengthens the case for the existence of a mechanistic 
pathway from maternal antenatal HPA axis to the programming of offspring HPA axis, is a novel 





4.8 Methodological strengths and limitations  
 
This study had a number of important strengths, for example the prospective design, diagnoses 
obtained through semi-structured clinical interview and a relatively broad assessment of HPA axis 
in mothers and their infants over several time points. Furthermore, much information was 
collected in order to examine for potential confounding factors. This included socio-demographic 
factors for both parents, obstetric history, obstetric risk factors, maternal antenatal physical health, 
health behaviours, medications and mental health. Moreover, these factors were examined in 
relation to infant HPA axis measures with the addition of exposure of the foetus to antenatal 
symptoms of anxiety (much existing literature on developmental programming examines the effect 
of antenatal symptoms of anxiety), exposure to maternal postnatal depression (this may affect the 
handling of the infant and, in turn, their cortisol), concurrent (postnatal) maternal HPA axis 
measures (cortisol is secreted in breast milk, thus may account for cortisol levels in breastfed 
infants (Benjamin Neelon et al., 2015)), neonatal neurobehaviour, infant health and medication 
and infant development (cognitive, language and motor). Despite this there are a number of 
methodological limitations, which are discussed in the following section.  
 
The first limitation was the sample size. With 82 participants the sample size was unlikely to be 
adequate to demonstrate differences in outcomes where the effect sizes between groups was 
potentially small, for example the categorical obstetric outcomes, or to demonstrate anything 
other than large indirect (mediation) effects, accordingly the lack of positive findings where 
hypothesised could reflect type II error as opposed to no true difference. Furthermore, the sample 
size diminished further over the course of the study, which was approximately 18 months per 
participant. Subject retention is an inevitable issue in longitudinal studies. However, this issue is 
particularly pertinent in longitudinal studies that begin in pregnancy, since pregnancy (even when 
strongly desired) and the first postnatal year are periods of incredible change and inherent stress 
for parents. This point, compounded by the fact that pregnant women frequently have other young 
children at home (55% of participants in this study), has the potential to make subject retention 
even more of a challenge.  
 
Secondly, subjects were drawn from the catchment population of Kings College Hospital and 
South London and Maudsley NHS Trusts. This includes particularly wide-ranging diversity in 
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socio-economic status and ethnicity. Although there were no significant differences in these 
factors between women who participated and those who refused or were not contactable, they 
may not reflect the wider UK population, which would thus limit the generalizability of the results. 
 
Third, the change between ‘pilot’ and ‘main’ protocols meant that there were fewer observations in 
some variables. Furthermore, more researchers participated in assessments and data collection. 
Steps were taken to minimise the impact of this since I personally reviewed all diagnostic 
interviews with the researcher who had performed them and set up a procedure for monitoring 
and reviewing the quality of assessments. 
 
Fourth, although controls were free from lifetime psychiatric disorder, this was not so for cases. In 
order to recruit sufficient numbers of cases, those with a past history of psychiatric disorder (other 
than bipolar affective disorder or psychosis) were included. Clearly this was not ideal but a history 
of other psychiatric disorders in cases of depression is not uncommon and recruitment of a ‘pure’ 
depression group had to be balanced against recruitment of sufficient numbers of cases.  
 
Fifth, although cases were free from antidepressant medication at baseline, a small proportion 
took antidepressants later in pregnancy. The potential effect of antidepressant use in pregnancy 
on obstetric outcome could not be quantified because of the infrequency of this potential 
confounding factor.  
 
Lastly, despite their continued involvement in the study, not all subjects and their infants provided 
usable saliva samples for measurement of cortisol. Other than the saliva samples obtained from 
infants on the day of immunization (when a researcher was present) there was no control on 
adherence to the sampling protocol or accurate recordings of timings. However, steps were taken 
to minimise errors by clear demonstration of the correct procedures including emphasis on the 
importance of the sampling protocol and record of sample timings and the provision of written 
instructions as a reminder. Although samples that were not acquired within our stipulated times 
were not used in the data analyses, this did not guarantee the accuracy of the data which did 
appear to meet the requirements. Measures to control these factors, such as actimetry units (to 
show wake time) and medication event monitoring (MEM) systems to show sampling times, were 
not employed. 
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4.9 Future directions 
 
Since the thesis describes some findings that are first reports, replication is warranted. A larger 
sample size would be required, taking the issue of retention rates into account, to ensure 
adequate power to detect some of the effects, and particularly to test for mediation. Furthermore it 
would be beneficial to include an arm to examine the effects of exposure to antidepressant 
medication in utero on offspring HPA axis. A measure of the quality of postnatal caregiving would 
also be desirable in order to control for offspring postnatal environment (O'Connor et al., 2013a). 
 
A next step would be to study the potential molecular mechanisms of the developmental 
programming effects of depression in pregnancy, for example, epigenetic studies examining 
genes related to the HPA axis and 11β-HSD-2. A small literature now exists although this line of 
research is in its infancy and at the current time is confined to symptoms of, rather than diagnoses 
of depression (Braithwaite et al., 2015, Oberlander et al., 2008).    
 
Clearly further study is required to determine if there is longer term persistence of HPA axis 
change in the offspring; although longer term changes are suggested, at least into adolescence in 
humans (O'Donnell et al., 2013, Vedhara et al., 2012), and in animals, even beyond that to the 
next generation (Schopper et al., 2012). 
 
Furthermore, and related to this issue is to elucidate any associated changes in offspring health 
and behaviour. Contingent on this, the potential for interventions, for example environmental or 





In summary I have demonstrated a novel finding of altered HPA axis function and activity that 
persists over the first year of life in infants who were exposed to major depression in utero 
compared to infants who were not so exposed. Although no evidence of mediation was found, I 
have shown that a relationship exists between antenatal depression, maternal antenatal HPA axis 
and infant HPA axis in the first year of life. This relationship was evidenced by significant 
correlation between some infant and maternal HPA axis measures; and furthermore, that a group 
difference in delta cortisol in 8-week-old infants was only apparent when maternal antenatal 
diurnal cortisol was high (as it was in women with antenatal depression compared with controls).  
Furthermore, I have added to the small body of current literature on major depression in 
pregnancy, maternal antenatal HPA axis and obstetric outcomes, demonstrating an overactive 
maternal HPA axis and shorter length of gestation in women with major depression in pregnancy 
compared to non-depressed pregnant women. Overall, these findings add to the important 
literature on developmental programming and moreover, have potential implications for clinical 
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Appendix A Differences between pilot and main protocol 
Table 47: Comparison of ‘pilot’ and ‘main’ protocols 
 Pilot protocol Main protocol 
Inclusion criteria   
 Maternal age  
 Cases diagnosis 
• 18 to 40 years 
• MDD at baseline 
• 18 to 45 years 
• MDD in pregnancy at or prior to baseline 
Exclusion criteria   
 Medication 
 Diagnosis for cases 
• Regular medication 
• Any axis 1 diagnosis other than anxiety disorders 
• Regular medication was not an exclusion criterion 
• Psychosis or bipolar affective disorder only 
Recruitment process – all subjects 
 • No recruitment script 
• No concise colour pamphlet  
• Recruitment script 
• Concise colour pamphlet 
Recruitment process for controls 
 • Screened for inclusion and exclusion criteria at initial 
approach. 
• Screened for inclusion and exclusion criteria at second 
(telephone) contact. 
Recruitment process for cases 
 • At this time, most referrals for depression were not seen 
in the Perinatal Psychiatry clinic. As a psychiatrist, and 
the only person recruiting subjects throughout the pilot 
study, I made telephone contact with women who were 
potentially eligible to participate as cases. During the 
call, having established that they were currently 
depressed and were happy to have been referred by 
their GP, I invited them to see me for a clinical 
assessment, following which and if they were eligible, I 
invited them to participate. Women who required clinical 
follow-up were referred on to my colleagues within the 
department. In cases where it was not possible to 
contact the woman by telephone, no different 
approaches were pursued. 
• The decision about contacting a woman as a case was 
made at the level of the clinical referrals meeting and 
contact about the study was made by researchers who 
were not part of the clinical team. If it was not possible to 
make telephone contact, a letter was sent to the woman 
and the researcher provided an appointment to discuss 
the research at the woman’s home. If that appointment 
was not attended an invitation to make contact was left 
at the woman’s home. 
280 
Procedures & measures   
   
 Characteristics   
 • Less information was obtained on characteristics of the 
sample, for example paternal characteristics, maternal 
PRN medication. 
• Premorbid IQ was not assessed, although this was done 
subsequently where possible (n= 12). 
• At 8 weeks & 1 year postnatal less information was 
obtained on infant characteristics, e.g. feeding problems, 
medical appointments. 
 
 Psychiatric assessment 
 • Self-rated symptom scores were not obtained at 32/40 • Self-rated symptom scores were obtained at 32/40 
 HPA 1   
 • Serum cortisol was not measured. • Serum cortisol was measured 
 HPA 2   
 • Saliva cortisol was not obtained at baseline  • Saliva cortisol was obtained at baseline. 
 HPA 3   
 • Awakening and evening samples only (not CAR, or 
midday samples) were obtained at 32 weeks gestation, 
8 weeks and one year postnatal 
• Samples for assessment of CAR and midday was 
assessed at each time point. 
 HPA 4   




























































































































































































Appendix N Correlations tables for results – Antenatal 
 
Table 48: Plasma CRH and blood sampling details  
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric analysis. Spearman’s correlation coefficients are presented for 
continuous variables that did not permit parametric analysis.  **p < .01, ***p < .001 
 
    1 2 3 4 5 n 
1 CRH -     76 
2 CRHBP -.07 -    38 
3 Gestational age at sample .31** .06 -   76 
4 Time of sample acquisition -.15 .19 -.21 -  76 
5 Interval between sample acquisition and sample processing .10 .06 .17 -.05 - 75 
6 Interval between collecting sample and analysing CRHBP -.16 .18 -.19 .40*** -.13 76 
335 
Table 49: Plasma CRH and socio-demographic characteristics of the sample at baseline 
  1 2 3 4 5 6 7 8 9 n 
1 CRH -         76 
2 Maternal age at baseline -.13 -        76 
3 Maternal ethnicity white .06 .48*** -       76 
4 Level of qualification ≥ A levels -.17 .49*** -.35** -      76 
5 Not working outside the home .01 -.34** .56*** .36** -     76 
6 Maternal professional or managerial -.10 .47*** -.50*** -.60*** -.47*** -    74 
7 Married -.07 .44*** -.59*** -.40*** -.48*** -.47*** -   76 
8 Paternal status unemployed .06 -.04 -.10 -.07 -.12 .19 -.09 -  37 
9 Paternal professional or managerial -.43* .02 -.35* -.26 -.26 -.38* -.16 .16 - 31 
10 Paternal ethnicity white -.02 .48** -.72*** -.53*** -.50** -.65*** -.57*** .23 -.31 38 
Note. Pearson’s r coefficients are presented for continuous variables. Point-biserial correlation coefficients are reported for associations between a continuous and a 
dichotomous variable. Phi coefficients are presented for associations between two dichotomous variables. *p < .05, **p < .01, ***p < .001. 
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Table 50: Plasma CRH and obstetric history and risk factors at baseline 
   1 2 3 4 5 6 7 8 9 n 
1 CRH -         76 
2 History of preterm birth  -.07 -        76 
3 History of miscarriage .00 .03 -       76 
4 History of termination of pregnancy .00 .11 -.03 -      76 
5 History of intra-uterine death .02 -.03 -.06 -.07 -     75 
6 Parous  -.04 .21 .11 .11 .10 -    76 
7 Age at menarche  -.11 -.14 .22 .09 -.01 -.06 -   40 
8 Gestational age at baseline .40*** .05 -.04 .17 .12 -.14 .14 -  76 
9 Vaginal bleeding in index pregnancy -.07 .30** .13 -.07 .21 .10 .09 .03 - 75 
10 UTI in index pregnancy -.17 -.11 -.03 .01 -.06 -.22 .05 -.19 -.17 74 
Note. Pearson’s r coefficients are presented for continuous variables. Spearman’s correlation coefficients are presented for continuous variables that did not 
permit parametric analysis. Point-biserial correlation coefficients (based on ranked scores) are presented for associations between a continuous and a 
dichotomous variable. Phi coefficients are presented for associations between two dichotomous variables. **p < .01, ***p < .001. 
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Table 51: Plasma CRH and medication, physical health and health behaviours at baseline 
   1 2 3 4 5 6 7 8 n 
1 CRH -        76 
2 Taking regular medication at baseline -.18 -       76 
3 Taking regular or PRN steroids at baseline -.27 .80*** -      45 
4 Chronic medical problem at baseline .06 .24* .50*** -     76 
5 Pre-pregnancy BMI -.10 -.25* -.31 .01 -    72 
6 Coffee use at baseline .05 .06 .01 -.02 -.18 -   75 
7 Tea use at baseline .10 -.01 .03 .09 .09 -.12 -  75 
8 Alcohol >2units/week at baseline .13 -.03 - -.07 -.07 .22 -.14 - 72 
9 Smoking in pregnancy prior to baseline .14 -.10 -.16 .07 .31** -.12 .06 .17 72 
Note. Spearman’s correlation coefficients are presented for continuous variables. Point-biserial correlation coefficients (based on ranked scores for 
continuous variables not permitting parametric analysis) are presented for associations between a continuous and a dichotomous variable. Phi coefficients 
are presented for associations between two dichotomous variables. *p < .05, **p < .01, ***p < .001. 
 
Table 52: Serum cortisol and blood sampling details 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric analysis. Spearman’s correlation coefficients are presented for 
continuous variables that did not permit parametric analysis.  *p < .05 
    1 2 3 n 
1 Serum cortisol -   42 
2 Gestational age at sample -.32* -  42 
3 Time of sample acquisition -.01 -.04 - 42 
4 Interval between sample acquisition and sample processing -.08 .15 -.16 41 
338 
Table 53: Awakening cortisol and saliva sampling details at baseline 
    1 2 3 4 5 n 
1 Awakening cortisol  -     39 
2 Gestational age at date of sample .11 -    38 
3 Time of awakening  -.16 -.01 -   39 
4 Time of awakening sample -.13 -.01 1.0*** -  39 
5 Interval between awakening and sampling  .35* -.07 .03 .08 - 39 
6 Interval between sampling and freezing .05 -.01 -.16 -.15 .16 36 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric analysis; Spearman’s correlation coefficients are presented for 





Table 54: Evening cortisol and saliva sampling details at baseline  
    1 2 3  n 
1 Evening saliva cortisol  -     38 
2 Gestational age at date of sample -.20  -   38 
3 Evening sample time  -.01 -.16 -  38 
4 Interval between sampling and freezing  .08 .01 .19 36 
Note. Spearman’s correlation coefficients are presented 
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Table 55: Diurnal cortisol secretion and saliva sampling details at baseline 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric analysis. Spearman’s correlation coefficients are presented for 





Table 56: CAR and saliva sampling details at baseline  
  1 2 3 4 n 
1 CAR (AUCg)  -       21 
2 CAR (AUCi) .24  -     21 
3 Gestational age at sample acquisition -.00 .27  -   20 
4 Time of awakening -.54* -.27 -.18  - 21 
5 Interval between sampling and freezing .32 .08 -.09 -.60**  19 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric analysis; Spearman’s correlation coefficients are presented for 
continuous variables that did not permit parametric analysis. *p < .05, **p < .01. 
    1 2 3 4 n 
1 Diurnal cortisol secretion -    35 
2 Gestational age at sample -.05 -   32 
3 Time of awakening  -.39* -.09 -  35 
4 Interval between awakening and sampling .29 -.04 .02 - 35 
5 Interval between sampling and freezing .20 .00 -.16 .19 33 
340 
Table 57: Awakening saliva cortisol and saliva sampling details at 32 weeks gestation 
    1 2 3 4 5 n 
1 Awakening cortisol   -         66 
2 Gestational age at date of sample .10  -       65 
3 Time of awakening  -.04 -.02  -     66 
4 Time of awakening sample -.06 -.01 .98***  -   66 
5 Interval between awakening and sampling  -.10 -.30* -.03 .16  - 66 
6 Interval between sampling and freezing -.15 -.17 -.11 -.04 .13 60 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric analysis. Spearman’s correlation coefficients are presented for 
continuous variables that did not permit parametric analysis, *p <.05, ***<.001 
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Table 58: Awakening cortisol at 32 weeks gestation and socio-demographic characteristics of the sample at baseline 
  1 2 3 4 5 6 7 8 9 n 
1 Awakening cortisol  -                 66 
2 Maternal age at baseline .28*  -               66 
3 Maternal ethnicity white .28* .54***  -             66 
4 Level of qualification ≥ A levels .10 -.50*** .47***  -           66 
5 Not working outside the home -.08 -.32** -.48** -.42*** -     66 
6 Maternal professional or managerial .16 .50*** .57*** .63*** -.44** -    66 
7 Married .18 .44*** .53*** .52*** -.32** .51*** -   66 
8 Paternal status unemployed -.13 -.05 .09 .08 -.11 -.22 .09 -  35 
9 Paternal professional or managerial .11 .15 .41* .23 -.22 .42* .23 -.17 - 29 
10 Paternal ethnicity white .22 .58*** .82*** .63*** -.51** .72*** .63*** -.26 .40* 35 
Note. Pearson’s r coefficients are presented for continuous variables. Point-biserial correlation coefficients are reported for associations between a 
continuous and a dichotomous variable. Phi coefficients are presented for associations between two dichotomous variables. *p < .05, **p < .01, ***p < .001. 
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Table 59: Awakening cortisol at 32 weeks gestation and obstetric history and risk factors 
  1 2 3 4 5 6 7 n 
1 Awakening cortisol -       66 
2 History of preterm delivery .16 -      66 
3 History of miscarriage .24 .09 -     66 
4 History of termination of pregnancy .05 .04 -.10 -    66 
5 History of intrauterine death .04 -.03 -.06 -.07 -   65 
6 Parous  .08 .21 .14 .02 .12 -  66 
7 Vaginal bleeding in index pregnancy .29* .40** .12 .09 .23 .16 - 66 
8 UTI in index pregnancy -.18 -.12 .02 .08 -.07 -.26* .05 65 
Note. Point-biserial correlation coefficients are reported for associations between a continuous and a dichotomous variable. Phi coefficients are presented for 
associations between two dichotomous variables. *p < .05, **p < .01. 
343 
Table 60: Awakening cortisol at 32 weeks gestation, medication, physical health and health behaviours 
   1 2 3 4 5 6 7 8 n 
1 Awakening cortisol   -          66 
2 Taking antidepressant at 32 weeks gestation .04  -        64 
3 Taking other regular medication at 32 weeks gestation .01 .22  -      65 
4 Taking regular or PRN steroids at 32 weeks gestation .13 -.06 .35** -     65 
5 Chronic medical problem at baseline .10 -.10 .20 .68*** -    66 
6 Pre-pregnancy BMI -.13 -.21 .06 -.05 -.01 -   62 
7 Coffee use at baseline .08 -.03 -.07 -.06 -.03 .19 -  66 
8 Tea use at baseline .08 -.17 .17 .31* .14 .21 .11 - 66 
9 Smoking in pregnancy prior to baseline .10 .08 .08 .11 .00 .27* .00 .19 62 
Note. Spearman’s correlation coefficients are presented for continuous variables. Point-biserial correlation coefficients (based on ranked scores for 
continuous variables not permitting parametric analysis) are presented for associations between a continuous and a dichotomous variable. Phi coefficients 




Table 61: Evening saliva cortisol and saliva sampling details at 32 weeks gestation  
    1 2 3 n 
1 Evening cortisol  -   61 
2 Gestational age at date of sample .43** -  60 
3 Time of evening sample  .14 .04 - 61 
4 Interval between sampling and freezing -.17 -.16 .10 56 
344 
Note. Spearman’s correlation coefficients are presented, **p <.01. 
Table 62: Evening saliva cortisol at 32 weeks gestation and baseline socio-demographic characteristics of the sample  
    1 2 3 4 5 6 7 8 9 n 
1 Evening cortisol  -                 61 
2 Maternal age at baseline .04  -               61 
3 Maternal ethnicity white -.20 .49***  -             61 
4 Level of qualification ≥ A levels -.18 .44*** .30*  -           61 
5 Not working outside the home .29* -.26* -.52*** -.24  -         61 
6 Maternal professional or managerial -.12 .39** .44*** .59*** -.34**  -       60 
7 Married -.18 .34** .60*** .44*** -.43** .44***  -     61 
8 Paternal status unemployed .01 -.06 -.10 -.07 -.12 -.22 -.10  -   34 
9 Paternal professional or managerial -.34 .15 .32 .19 -.19 .33 .15 -.18  - 29 
10 Paternal ethnicity white -.08 .45** .74*** .54** -.43* .71*** .67*** -.26 .29 34 
Note. Pearson’s correlation coefficients are presented for continuous variables. Point-biserial correlation coefficients are presented for associations between a 
continuous and a dichotomous variable. Phi coefficients are presented for associations between two dichotomous variables. *p <.05, **p < .01, ***p < .001.
345 
Table 63: Evening cortisol at 32 weeks gestation, obstetric history and obstetric risk factors  
    1 2 3 4 5 6 7 n 
1 Evening cortisol -       61 
2 History of preterm delivery .07 -      61 
3 History of miscarriage .35** -.11 -     61 
4 History of termination of pregnancy .20 .08 -.07 -    61 
5 History of intrauterine death -.02 -.02 -.07 -.08 -   60 
6 Parous  -.03 .19 .13 .01 .13 -  61 
7 Vaginal bleeding in index pregnancy .14 .31* .05 .10 .22 .16 - 61 
8 UTI in index pregnancy .01 -.10 .02 .10 -.06 -.19 .05 61 
Note. Point-biserial correlation coefficients are reported for associations between a continuous and a dichotomous variable. Phi coefficients are presented for 
associations between two dichotomous variables. *p < .05, **p < .01. 
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Table 64: Evening saliva cortisol, medications and physical health at 32 weeks gestation  
   1 2 3 4 5 6 7 8 9 n 
1 Evening cortisol   -           61 
2 Taking antidepressant at 32 weeks gestation -.06 -        59 
3 Taking other regular medication at 32 weeks gestation -.12 .21 -       61 
4 Taking regular or PRN steroids at 32 weeks gestation -.07 -.06 .40** -      61 
5 Taking any regular medication or PRN steroids -.04 .55*** .72*** .64*** -     61 
6 Chronic medical problem at baseline -.03 -.10 .19 .60*** .32* -    61 
7 Pre-pregnancy BMI .09 -.23 .03 -.06 -.09 .06 -   58 
8 Coffee use at baseline .24 -.03 -.05 -.04 -.01 -.02 -.21 -  61 
9 Tea use at baseline .17 -.19 .17 .37** .19 .16 .11 -.10 - 61 
10 Smoking in pregnancy prior to baseline .22 -.09 .04 .07 -.05 .08 .24 -.04 -.02 59 
Note. Spearman’s correlation coefficients are presented for continuous variables. Point-biserial correlation coefficients (based on ranked scores for 
continuous variables not permitting parametric analysis) are presented for associations between a continuous and a dichotomous variable. Phi coefficients 




Table 65: Diurnal cortisol secretion (AUC) and saliva sampling details at 32 weeks gestation 
    1 2 3 4 n 
1 Diurnal cortisol (AUC am to pm)  -    53 
2 Gestational age at sample .33* -   52 
3 Time of awakening  -.03 .10 -  53 
4 Interval between awakening and evening samples .25 .11 -.85*** - 53 
5 Interval between sampling and freezing -.13 -.20 -.14 .05 49 
Note. Spearman’s correlation coefficients are presented.  *p < .05, ***p , .001. 
 
 
Table 66: Diurnal cortisol secretion (AUC) at 32 weeks gestation and baseline socio-demographic characteristics of the sample  
    1 2 3 4 5 6 7 8 9 n 
1 Diurnal cortisol (AUC am to pm) -         53 
2 Maternal age at baseline .23 -        53 
3 Maternal ethnicity white .21 .58*** -       53 
4 Level of qualification ≥ A levels -.04 .47*** .39** -      53 
5 Not working outside the home -.01 -.28* -.40** -.27* -     53 
6 Maternal professional or managerial .14 .46*** .49*** .61*** -.32* -    53 
7 Married .05 .38** .54*** .51*** -.30* .49*** -   53 
8 Paternal status unemployed -.09 -.07 .08 .08 -.11 -.24 .09 -  30 
9 Paternal professional or managerial -.02 .08 .36 .20 -.14 .39 .20 -.20 - 25 
10 Paternal ethnicity white .25 .60** .76*** .58** -.36 .65*** .75*** -.30 .35 29 
Note. Pearson’s correlation coefficients are presented for continuous variables. Point-biserial correlation coefficients are presented for associations between a 
continuous and a dichotomous variable. Phi coefficients are presented for associations between two dichotomous variables. *p <.05, **p < .01, ***p < .001.
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Table 67: Diurnal cortisol secretion (AUC) at 32 weeks gestation and obstetric history and obstetric risk factors 
    1 2 3 4 5 6 7 n 
1 Diurnal cortisol  (AUC am to pm) -       53 
2 History of preterm delivery .23 -      53 
3 History of miscarriage .23 -.09 -     53 
4 History of termination of pregnancy -.01 .13 -.24 -    53 
5 History of intrauterine death -.00 -.03 -.06 -.07 -   52 
6 Parous  14 .20 .16 -.08 .14 -  53 
7 Vaginal bleeding in index pregnancy .34* .33* .07 .19 .23 .18 - 53 
8 UTI in index pregnancy -.22 -.11 .00 .14 -.07 -.17 .08 53 
Note. Point-biserial correlation coefficients are reported for associations between a continuous and a dichotomous variable. Phi coefficients are presented for 
associations between two dichotomous variables. *p < .05. 
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Table 68: Diurnal cortisol secretion (AUC) at 32 weeks gestation medication and physical health  
   1 2 3 4 5 6 7 8 9 n 
1 Diurnal cortisol  (AUC am to pm) -         53 
2 Taking antidepressant at 32 weeks gestation .02 -        53 
3 Taking any regular medication at 32 weeks gestation .02 .43* -       53 
4 Taking regular or PRN steroids at 32 weeks gestation .20 -.07 .35* -      53 
5 Taking any regular medication or PRN steroids .14 -.54*** .79*** .63*** -     53 
6 Chronic medical problem at baseline .14 -.11 .16 .63*** .33* -    53 
7 Pre-pregnancy BMI -.11 .18 .09 .04 .07 .04 -   50 
8 Coffee use at baseline .30* .04 .17 .02 .02 .01 -.17 -  53 
9 Tea use at baseline .22 .18 .23 .39** .18 .17 .15 -.10 - 53 
10 Smoking in pregnancy prior to baseline .06 -.09 .06 .12 -.01 .01 .35* .06 .01 51 
Note. Spearman’s correlation coefficients are presented for continuous variables. Point-biserial correlation coefficients (based on ranked scores for 
continuous variables not permitting parametric analysis) are presented for associations between a continuous and a dichotomous variable. Phi coefficients 




Table 69: CAR and saliva sampling details at 32 weeks gestation  
  1 2 3 4 n 
1 CAR (AUCg)  -       28 
2 CAR (AUCi) .66***  -     28 
3 Gestational age at sampling -.15 -.26  -   27 
4 Time of awakening -.12 -.31 .07  - 28 
5 Interval between sampling and freezing .31 .61** -.28 -.18 24 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric analysis. Spearman’s correlation coefficients are presented for 




Table 70: CAR at 32 weeks gestation and baseline socio-demographic characteristics of the sample  
    1 2 3 4 5 6 7 8 9 n 
1 CAR (AUCi)  -                 28 
2 Maternal age at baseline .32  -               28 
3 Maternal ethnicity white .24 .53**  -             28 
4 Level of qualification ≥ A levels .19 .21 .51**  -           28 
5 Not working outside the home .25 -.25 -.48* -.28  -         28 
6 Maternal professional or managerial .30 .17 .43* .63*** -.12  -       28 
7 Married .25 .26 .44* .44* -.20 .34  -     28 
8 Paternal status unemployed -.24 -.11 .08 .08 -.13 -.28 .08  -   26 
9 Paternal professional or managerial .03 .20 .33 .33 -.09 .44* .33 -.18  - 25 
10 Paternal ethnicity white .27 .43* .81*** .59** -.49** .60** .50** -.38 .44* 28 
Note. Pearson’s r coefficients are presented for continuous variables. Point-biserial correlation coefficients are presented for associations between a 
continuous and a dichotomous variable. Phi coefficients are presented for associations between two dichotomous variables. *p <.05*, **p <.01,  ***p <.001. 
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Table 71: CAR at 32 weeks gestation, obstetric history and obstetric risk factors  
  1 2 3 4 5 6 7 n 
1 CAR (AUCi) -       28 
2 History of preterm delivery .10 -      28 
3 History of miscarriage -.02 .19 -     28 
4 History of termination of pregnancy -.14 -.13 -.24 -    28 
5 History of intrauterine death .20 .05 .10 -.09 -   28 
6 Parous  .31 .32 .25 -.03 .22 -  28 
7 Vaginal bleeding in index pregnancy .03 .37 -.03 .24 .26 .26 - 28 
8 UTI in index pregnancy -.31 -.16 .10 -.05 -.11 -.17 .09 28 
Note. Point-biserial correlation coefficients are presented for associations between a continuous and a dichotomous variable. Phi coefficients are presented 
for associations between two dichotomous variables. 
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Table 72: CAR, medication and physical health at 32 weeks gestation  
   1 2 3 4 5 6 7 8 9 n 
1 CAR (AUCi) -         28 
2 Taking antidepressant at 32 weeks gestation -.12 -        27 
3 Taking other regular medication at 32 weeks gestation -.15 .41 -       27 
4 Taking regular or PRN steroids at 32 weeks gestation -.05 -.06 -.59** -      27 
5 Taking any regular medication or PRN steroids -.16 .41* .16 .59** -     27 
6 Chronic medical problem at baseline -.03 -.06 .14 1.0*** .59** -    28 
7 Pre-pregnancy BMI -.29 - .10 .04 .10 .04 -   27 
8 Coffee use at baseline -.01 .17 .15 .04 .15 .03 .05 -  28 
9 Tea use at baseline .03 .23 .26 .46* .26 .42* .19 .11 - 28 
10 Smoking in pregnancy prior to baseline -.27 -.08 .07 .28 .07 .23 .51** .01 .18 28 
Note. Spearman’s correlation coefficients are presented. Point-biserial correlation coefficients (based on ranked scores for continuous variables not permitting 
parametric analysis) are presented for associations between a continuous and a dichotomous variable. Phi coefficients are presented for associations 
between two dichotomous variables. *p <.05*, **p <.01,  ***p <.001. 
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Appendix O Correlations tables for results – Obstetric outcomes 
Table 73: Gestational age at birth and baseline socio-demographic factors 
    1 2 3 4 5 6 7 8 9 n 
1 Gestational age at birth -         58 
2 Maternal age at baseline .26* -        58 
3 Maternal ethnicity white .30* .41** -       58 
4 Level of qualification ≥ A levels .13 .43** .27* -      58 
5 Not working outside the home -.26* -.33** -.57*** -.38** -     58 
6 Maternal professional or managerial .19 .50*** .46*** .59*** -.45*** -    56 
7 Married .29* .39** .56*** .35** -.50*** .46*** -   58 
8 Paternal ethnicity white .08 .47* .67*** .54** -.59** .73*** .59** -  29 
9 Paternal status unemployed  .22 -.04 .13 .10 -.16 -.22 .15 -.25 - 26 
10 Paternal professional or managerial .24 .31 .30 .23 -.32 .39 .17 .24 -.18 22 
Note. Spearman’s correlation coefficients are presented. Point-biserial correlation coefficients (based on ranked scores) are presented for associations 
between a continuous and a dichotomous variable. Phi coefficients are presented for associations between two dichotomous variables. *p <.05, **p <.01,  ***p 
<.001. 
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Table 74: Gestational age at birth and obstetric history and obstetric risk factors 
   1 2 3 4 5 6 7 8 9 n 
1 Gestational age at birth -         58 
2 History of preterm birth  -.17 -        58 
3 History of miscarriage -.19 -.09 -       58 
4 History of termination of pregnancy .02 .28* -.04 -      58 
5 History of intra-uterine death .12 -.03 -.06 -.09 -     58 
6 Parity  -.16 .19 .24 .34* .04 -    58 
7 Age at menarche  .04 -.20 .28 .09 -.03 .09 -   31 
8 Gestational age at baseline .07 -.01 -.21 .26* .13 .03 .08 -  58 
9 Vaginal bleeding in index pregnancy -.12 .15 -.01 .15 .27* .11 -.10 -.08 - 57 
10 UTI in index pregnancy .07 -.09 .00 -.02 -.06 -.16 -.15 -.16 .12 56 
Note. Spearman’s correlation coefficients are presented for continuous variables that did not permit parametric analysis. Point-biserial correlation coefficients 
(based on ranked scores) are presented for associations between a continuous and a dichotomous variable. Phi coefficients are presented for associations 
between two dichotomous variables. *p <.05. 
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Table 75: Gestational age at birth and antenatal physical health 
    1 2 3 4 5 6 7 8 9 10 11 n 
1 Gestational age at birth -           58 
2 Chronic medical problem at baseline .03 -          58 
3 Taking regular medication at baseline -.22 .13 -         58 
4 Taking regular or PRN steroids at baseline -.04 .85*** .21 -        34 
5 Chronic medical problem at 32 weeks gestation .03 .92*** .11 .75*** -       58 
6 Taking antidepressant at 32 weeks gestation -.28* -.08 .24 -.06 -.09 -      50 
7 Taking other regular medication at 32 weeks gestation -.16 -.07 .32* -.09 .22 .38** -     55 
8 Taking regular or PRN steroids at 32 weeks gestation -.04 .58*** .19 .85*** .73*** -.08 .32* -    55 
9 Pre-pregnancy BMI .27* .01 -.16 -.08 .02 -.24 .18 .05 -   54 
10 Coffee use at baseline .19 -.10 .03 .04 -.06 -.06 -.03 .09 -.15 -  57 
11 Tea use at baseline .17 .15 -.18 .21 .23 -.18 .05 .29* .19 -.03 - 57 
12 Any smoking in the index pregnancy  -.05 .05 -.13 -.12 .18 -.11 .16 .08 .27 .03 -.02 55 
Note. Spearman’s correlation coefficients are presented for continuous variables that did not permit parametric analysis. Point-biserial correlation coefficients (based 
on ranked scores for continuous variables not permitting parametric analysis) are presented for associations between a continuous and a dichotomous variable. Phi 
coefficients are presented for associations between two dichotomous variables. *p <.05, **p <.01,  ***p <.001. 
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Appendix P Correlations tables for results – 8 weeks postnatal 
 
Table 76: Infant cortisol and saliva sampling details at immunizations at 8 weeks postnatal 
    1 2 3 4 5 6 n 
1 Cortisol pre-immunization -      54 
2 Cortisol post-immunization .15 -     54 
3 Delta cortisol -.26 .85*** -    54 
4 Baby’s age at immunization .17 -.18 -.22 -   54 
5 Pre-immunisation sample time -.08 -.08 -.13 .18 -  54 
6 Immunisation time  -.10 -.08 -.11 .20 .94*** - 54 
7 Interval between ‘pre’ sample and immunization .12 -.06 -.04 -.03 -.11 .14 54 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric analysis. Spearman’s correlation coefficients are presented for 
continuous variables that did not permit parametric analysis.  ***p < .001. 
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Table 77: Infant cortisol at immunizations at 8 weeks postnatal and potential confounding factors 
    1 2 3 4 5 6 7 8 n 
1 Cortisol before the immunization -        54 
2 Cortisol after the immunization .15 -       54 
3 Delta cortisol -.26 .85*** -      54 
4 Infant taking regular medication .11 .08 .06 -     54 
5 Exposure to smoking in utero -.02 .07 .09 .54** -    53 
6 Exposure to Sx of anxiety in utero .24 .12 .20 .12 .40** -   50 
7 Mother on regular medication at 8 wk PN 25 .12 .08 .35** .23 .48*** -  53 
8 Mother smoking at 8 wk PN -.05 -.17 .05 .52** .88*** .46* .24 - 29 
9 Duration of MDD in the postnatal period .26 .21 .06 .03 -.08 .20 .48*** .59*** 53 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric analysis. Spearman’s correlation coefficients are presented for 
continuous variables that did not permit parametric analysis. Point-biserial correlation coefficients (based on ranked scores for continuous variables not 
permitting parametric analysis) are presented for associations between a continuous and a dichotomous variable. Phi coefficients are presented for 
associations between two dichotomous variables *p <.05, **p <.01,  ***p <.001. 
Sx = symptoms, 8 wk PN = 8 weeks postnatal 
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Table 78: Infant awakening cortisol and saliva sampling details at 8 weeks postnatal  
    1 2 3 4 5 n 
1 Awakening cortisol -     61 
2 Awakening time -.08 -    56 
3 Time of sample acquisition -.01 .91*** -   60 
4 Interval between awakening and sample acquisition .06 -.32* .02 -  56 
5 Interval between end of feed and sample acquisition -.17 .14 -.18 -.57*** - 36 
6 Interval between sample acquisition and storage -.18 -.17 -.23 -.09 -.08 51 





Table 79: Evening saliva cortisol and saliva sampling details at 8 weeks postnatal  
    1 2 3 4 5 n 
1 Evening cortisol -     61 
2 Time of sample acquisition -.06 -    59 
3 Interval between end of feed and sample acquisition .09 .32 -   35 
4 Interval between end of nap and sample acquisition .09 .75*** .23 -  35 
5 Duration of the nap prior to sample acquisition .34 .19 .49** .26 - 31 
6 Interval between sample acquisition and storage -.01 -.02 .13 .25 .21 50 
Note. Spearman’s correlation coefficients are presented. **p < .01,  ***p < .001. 
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Appendix Q Correlations tables for results – 1 year postnatal 
 
Table 80: Infant cortisol response to pain and saliva sampling details at 1 year postnatal 
    1 2 3 4 5 6 n 
1 Cortisol pre-immunization -      43 
2 Cortisol post-immunization .53*** -     43 
3 Delta cortisol -.38* .46** -    43 
4 Baby’s age at immunization .27 .13 -.05 -   43 
5 Pre-immunisation sample time -.22 -.06 .05 -.06 -  43 
6 Immunisation time  -.20 -.11 .00 -.10 .91*** - 43 
7 Interval between ‘pre’ sample and immunization -.02 -.02 -.02 .21 .22 .43** 43 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric analysis. Spearman’s correlation coefficients are presented for 
continuous variables that did not permit parametric analysis. *p < .05, **p < .01, ***p < .001 
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Table 81: Infant cortisol at immunizations at 1 year postnatal and potential confounding factors 
    1 2 3 4 5 6 n 
1 Cortisol before the immunization -      43 
2 Cortisol after the immunization .53*** -     43 
3 Delta cortisol -.38* .46** -    43 
4 Exposure to Sx of anxiety in utero .06 .23 .23 -   41 
5 Duration of MDD between assessments -.03 .09 .21 .46** -  41 
6 Mother on regular medication at 1 year PN -.15 -.06 -.20 .33* .38* - 41 
7 Mother awakening cortisol at 1 year PN .17 -.05 -.17 -.19 .06 -.04 38 
Note. Pearson’s r coefficients are presented for continuous variables that permitted parametric analysis. Spearman’s correlation coefficients are presented for 
continuous variables that did not permit parametric analysis. Point-biserial correlation coefficients (based on ranked scores for continuous variables not 
permitting parametric analysis) are presented for associations between a continuous and a dichotomous variable. *p <.05, **p <.01,  ***p <.001. 
Sx = symptoms, 1 year PN = 1 year postnatal 
 
Table 82: Infant awakening cortisol and saliva sampling details at 1 year postnatal  
    1 2 3 4 5 n 
1 Awakening cortisol -     53 
2 Awakening time -.10 -    50 
3 Time of sample acquisition -.14 .88*** -   50 
4 Interval between awakening and sample acquisition .07 -.19 .16 -  48 
5 Interval between end of feed and sample acquisition -.27 .23 -.18 -.54* - 21 
6 Interval between sample acquisition and storage .10 .09 .09 .12 .14 34 
Note. Spearman’s correlation coefficients are presented. *p < .05, ***p < .001 
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Table 83: Infant evening cortisol and saliva sampling details at 1 year postnatal  
    1 2 3 4 5 n 
1 Evening cortisol -     53 
2 Time of sample acquisition .04 -    49 
3 Interval between end of feed and sample acquisition -.37 .07 -   26 
4 Interval between end of nap and sample acquisition .20 -.36* .16 -  30 
5 Duration of the nap prior to sample acquisition .15 -.35 .13 .37 - 28 
6 Interval between sample acquisition and storage .10 .18 .16 .11 .19 34 
Note. Spearman’s correlation coefficients are presented for continuous variables that did not permit parametric analysis. *p < .05 
	
Table 84: Infant basal cortisol at 1 year postnatal and potential confounding factors 
    1 2 3 4 5 6 n 
1 Infant awakening cortisol -      53 
2 Infant  evening cortisol .11 -     53 
3 Exposure to Sx of anxiety in utero -.04 .23 -    50 
4 Duration of MDD between assessments .02 .26 .53*** -   52 
5 Maternal BDI at 1 year postnatal .04 .23 .50*** .31* -  53 
6 Mother on regular medication at 1 year postnatal -.09 -.14 .12 .38** .29* - 51 
7 Mother awakening cortisol at 1 year postnatal .24 .10 -.12 -.02 .03 -.10 50 
Note. Spearman’s correlation coefficients are presented. Point-biserial correlation coefficients (based on ranked scores for continuous variables not permitting 
parametric analysis) are presented for associations between a continuous and a dichotomous variable. **p <.01,  ***p <.001. 
Sx = symptoms, BDI = Beck Depression Inventory 
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